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The lineage of the lumen of the gastrointestinal (GI) tract from mouth to anus consists of
mucosal cells that separate the inner world of the body from the outer environment. The
functions of these cells are numerous as well as diverse: active uptake of nutritional ele-
ments, passive passage of fluids and electrolytes, secretion of digestive enzymes, defense
from pathogenic bacteria, facilitating stool transportation etcetera. To enhance its perfor-
mance and exchange capacity the mucosal surface is increased by extensive folding on the
macroscopic level: i.e. plicae gastricae of the stomach, Kerckring’s folds in the small bowel,
haustrae of the large bowel and on the microscopic level: i.e. gastric foveolae and colonic
crypts and villi. If spread out, the total surface of the digestive tract would be the size of
approximately two tennis courts. The regenerating capacity of the GI tract lineage is tre-
mendous; i.e. the mucosal layer of the large intestine completely renews itself every 5 days.
The intensive interaction with outer environment and the high rate of cell division may
contribute to the fact that cancers of the gastrointestinal tract are among the most widely
seen in humans. In 2008 in the United States, 271.290 new cases of GI cancer were
diagnosed accounting for 19% of all cancers and GI cancers caused 24% of all cancers
deaths (see table 1)1.  
Causative genetic mutations have been identified in some hereditary forms of GI can-
cers such as Lynch syndrome2-5 (former hereditary non-polyposis colorectal carcinoma,
HNPCC) and familiary adenopolyposis (FAP)6. The exact cause of sporadic cancers of the
GI tract is unknown. Suggested contributive factors in causing gastrointestinal cancers are;
dietary-related (red meat intake7, folic acid8, fiber intake9, 10), alcohol and smoking11, 12.
Another associated factor is obvious but often overlooked and associated with the vast
majority of solid tumors; age. Some macroscopic and microscopic precursor lesions of GI
malignancies are known. In colorectal cancer sessile, serrated or hyperplastic polyps13 or
aberrant crypt foci14 are recognized premalignant abnormalities and in gastric cancer intes-
tinal metaplasia or foveolar hyperproliferation15-17. In premalignant lesions, cell division
activity is disturbed, however, the cells remain within their histological architectural
matrix. At some point, and this is the key step, the cells gain the capacity to invade through
the basal membrane of the mucosa which defines the adenocarcinoma diagnosis. In the
submucosal layer the cells can enter the lymphatic system or the bloodstream causing dis-





New cases Number of deaths New cases Number of deaths
(n in 2000) (n in 2000) (n in 2000) (n in 2000)
Stomach 1938 (2134) 1450 (1719) 21500 (21500) 10880 (13000)
Colorectal 11231 (9236) 4709 (4274) 148810 (130200) 49960 (56300)
Table 1: GI cancer incidence and mortality rates in the Netherlands and United States in 2008.
This thesis aims at the two organs of the digestive system that are most often hit by malig-
nant neoplasia: The stomach and the large bowel. Although over the last decades there has
been an increase in the incidence of esophageal18, gastric cardia19 and pancreatic cancer20
this ranking remains unchanged over the last 20 years. 
Gastric Cancer 
Worldwide, neoplasms of the stomach (figure 1) are second in causing cancer mortality1.
Gastric cancer compared with other GI cancers is known for it’s geographically various inci-
dence and mortality20. In Asian countries such as China, Korea and Japan gastric cancer
has the highest incidence and mortality of all malignancies. In Western countries approxi-
mately 50 years ago gastric cancer was also the most predominant cancer, although inci-
dence rates dropped tremendously over the last decennia. In Portugal, however, gastric can-
cer incidence and mortality is highest and this is exceptional compared with other European
countries21. Dietary factors such as high intake of salted and smoked foods may explain this
geographical variation. Increasing consumption of fresh ingredients in the wealthier Western
world may account for the decline of gastric cancer incidence. Also the various incidences
of gastric infections with Helicobacter Pylori bacteria or Epstein-Barr virus which are con-
sidered precursor stages of gastric cancer may contribute. Clinical symptoms are non-spe-
cific and mimic common diseases like dyspepsia or ulcer disease. Weight-loss or passage
problems are late symptoms and the disease often is incurable at this stage. Five-year sur-
vival rates of gastric cancer in the Western world are deplorable (10-20%) and despite many
efforts this has not markedly improved over the last years22. Scientific interest for gastric
cancer in Western countries has fainted as incidence rates drop. Gastric cancer’s relative
unresponsiveness to the common systemic chemotherapeutics also contributes to this23. 
12
General Introduction
Figure 1: Anatomy of the stomach and its position in the abdomen.
Source: Handatlas der Anatomie des Menschen, Dritter Band, 1909.
The mainstay of gastric cancer treatment is radical surgical removal of the complete or par-
tial stomach with its surrounding lymph node stations. The extend of lymph node removal
has been a subject of study and more extensive nodal dissection (including those surroun-
ding the great vessels) may improve long-term disease survival rates, however, induces rela-
tively high perioperative mortality in a Western study population24-26. Recently, clinical tri-
als have successfully shown the benefit of neoadjuvant therapy over surgery alone27-29.
These important studies now have generated more scientific interest to improve gastric can-
cer treatment. In the Netherlands the CRITICS trial is being conducted that aims to eva-
luate whether postoperative chemo/radiation therapy in addition to preoperative chemo-
therapy further improves survival rates30, 31. 
Colorectal Cancer
The incidence of colorectal cancer in the Netherlands has increased with an average of one
percent per year from 1989 to 2006 (www.ikcnet.nl) and forms a major burden on health
care costs32, 33. It can be concluded that the treatment of colorectal cancer is improving as
despite the increasing incidence, mortality rates have dropped34. The large bowel appears
anatomically and histologically as a continuous tube that is separated from the small bowel
by Bauhin’s valve and ends at the dentate line where the squamous cells of the anal canal
take over from the bowel mucosa epithelial cells. The last 15-20 centimeters distal of the
promontorium or the sigmoid fold is called the rectum and this part of the colonic tube is
fixed in the smaller pelvis between the bladder and the sacrum. The surgical technique for
rectum resection is different from colon surgery due to this close interaction with the ana-
tomical structures within the pelvic cavity. The fixation of the rectum provides opportuni-
ties for external beam radiation therapy. In literature large bowel cancer is often summari-
zed as colorectal cancer while, as pointed out above, from a clinical point of view this
should be separated into colon and rectal cancer.
Colon Cancer
From the cecum throughout the sigmoid the large bowel lies in the abdominal cavity and
is hung up in the great omentum in the hepatic flexure and splenic flexure (figure 2).
Primary tumor removal can be achieved relatively simple in case there is no invasiveness
into surrounding structures (T-stage 1-3). An important indicator of adequate surgery is to
harvest sufficient amounts of lymph nodes for an adequate, complete pathological diagnos-
tic procedure (pTNM-staging). Since nodal status is the most important clinical parameter
to date much effort is put into optimizing nodal harvest and optimizing evaluation of the
retrieved lymph nodes35, 36. Patients with nodal disease spread have shorter survival
chances and have been proven to benefit from adjuvant chemotherapy37. Different admi-
nistration forms and schedules of the current standard FOLFOX-4 (5-FU, leucovorin, oxa-
liplatin) adjuvant treatment regimen are being studied to have added benefit. Addition of
target drugs that specifically inhibit epidermal growth factor receptors (Cetuximab) or vas-
cular endothelial growth factors inhibiting angiogenesis (Bevacuzimab or Avastin®) is
under investigation38-40.  Yet 30 percent of patients without evidence of nodal spread will
develop distant metastasis and this indicates the need for a better classification of this malig-




About 25% of adenocarcinoma in the 150 centimeters long large bowel occurs in the last
15 centimeters of the rectum (figure 2). The surgical treatment of rectal cancer, as indica-
ted, is more challenging compared to colon cancer and can be complicated by specific mor-
bidity. For instance accidental laceration of nerves of the sacral plexus can affect urinary and
fecal continence and in males erectile function. To better protect the nerves and reduce peri-
operative blood loss Heald et al. in 1979 described total mesorectal excision (TME) meaning
sharp dissection of the so–called avascular mesorectal fascia along with the rectum41. TME
has majorly reduced complications and local recurrence rates of rectal cancer42. Many clini-
cal trials have been conducted to further reduce local recurrence rates that test preoperati-
ve or postoperative strategies43-45. Benefit of adjuvant therapy to reduce distant recurrence
rates is currently under investigation in the SCRIPT trial (www.dccg.nl/trials/script). There
are specific prognostic parameters in rectal cancer such as involvement of the circumferen-
tial margin46, 47 and distance from the anal verge48 and these specific parameters should be
included in studies evaluating rectal cancer.   
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Figure 2. Anatomy of the colon and rectum and its position in the abdomen.
Source: Handatlas der Anatomie des Menschen, Dritter Band, 1909.
Molecular Oncology
The significance of the discovery of the molecular structure of DNA for clinical medicine
has been gradually appreciated among physicians since 195349-51. Molecular biology is a
basic element of medical training nowadays. Medical students are taught the fundamental
principles of DNA replication, its transcriptional regulation, the mechanism of protein syn-
thesis and are made familiar with techniques for DNA analysis. Over the next years, mole-
cular medicine will become increasingly integrated into daily medical practice. Oncology is
an important field of research for molecular scientist where many new discoveries on disea-
se mechanisms at the molecular level are being made. Cancer research and molecular onco-
logy in particular will continue to be a field of invention as this disease still puzzles us and
merits a larger portion of our scientific efforts.
Over the last years it has become increasingly clear that genetic alterations majorly con-
tribute to the development of gastrointestinal adenocarcinoma. The nature (mutations,
amplifications, translocations etc.) of genomic instability of GI cancer is being unraveled
fast after the completion of the human genome project (www.genome.gov) and develop-
ment of high resolution techniques that can analyze a individual’s complete genome in only
a few weeks. On the DNA level, cancer cells differ greatly from healthy cells. Early in tumo-
rigenesis genomic stability is affected and results into gene alterations that are key molecu-
lar pathogenic steps52. A current hypothesis is that by acquiring a sufficient number of alte-
rations in tumor suppressor genes and oncogenes a normal bowel mucosa epithelial cell
will transform and promote tumor progression53, 54. Identification of the key molecular
changes of tumorigenesis will allow us to get a grasp on the malignant process and will offer
targets for treatment. As our knowledge of cancer cell molecular biology expands, our
models of disease mechanisms expand and certain dogmatic hypothesis need updating.
Molecular medicine is an evolving field that is gaining importance in daily medical practi-
ce especially for those specialists involved in the treatment of cancer patients.
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Figure 3: detail from the original publication presenting the helical structure of DNA by Watson and Crick
and in Nature journal from 1953
Genetics versus Epigenetics
Alterations in the human genome involving the sequence of the four components of DNA,
the nucleic acids (cytosine, guanine, adenine and thymine), are part of the field of genetics.
Next to the nucleotides that form the double helix (Figure 4) there are many elements that
are crucial for the main function of the human DNA, the process of protein transcription.
These factors, i.e. methyl groups, histone proteins and their tails, chromatin structure remo-
deler complexes (figure 4), are part of the world of epigenetics55, 56. The current definiti-
on of epigenetics is as follows: All heritable traits (over rounds of cell division, even trans-
generationally) that do not involve the DNA nucleotide sequence. This new field is being
more and more appreciated and also plays a key role in carcinogenesis as genetics does57,
58. As genetics is becoming part of our oncology world, epigenetic factors controlling tran-




Figure 4: Representation of DNA unraveling, showing the level at which two important epigenetic regulatory
mechanisms (histon proteins, methyl group placement) take place.   
DNA methylation
The nucleus of each cell in the human body contains the same identical copy of genomic
DNA. Differentiated cells from different organ structures perform specific functions requi-
ring synthesis of specific proteins. Each cell, however, has the necessary information to pro-
duce all proteins encoded by the human genome. One can imagine that most cells have no
need for the whole range of proteins. A large bowel mucosal cell for instance has no need
for genes that encode proteins to form striated muscle. Synthesis of some proteins could
disturb a cell’s homeostasis when produced. How embryonic cells develop into differentia-
ted cells and how differentiated cells suppress transcription of unwanted or unnecessary
proteins is an important question in cellular biology. 
In 1948 it was first observed that a methyl-group was placed on the fifth position of
the cytosine nucleotide (m5Cyt) in calf thymus DNA59, 5 years before the molecular for-
mation structure of DNA was established. Since then it has taken a dedicated group of
scientists several decades to unravel what role this small methylgroup (CH3) has in mole-
cular cell biology. From the start, the hypothesis was postulated that cytosine methylation
had a role in transcriptional regulation, however, there was no experimental evidence to
support this60. Waalwijk et al.´s classic experiments showed differential methylation pat-
terns between various organ tissues in rabbits which was highly suggestive for the role of
methylation in cellular differentiation61. A role in differentiation was likely, as it was known
that specific methylation patterns exist; that methylation was symmetrical in both DNA
strands and that methylation patterns are clonally heritable60. Other hypothesized functi-
ons of methylated DNA were that it would protect DNA from being cut by eukaryotic res-
triction enzymes. It also may play a role in DNA replication as was known that replication
stops when DNA is unmethylated62. A protective role was suggested as it was observed
that unmethylated DNA is more prone to spontaneous mutagenesis63, 64. Also it was found
that methylated sequences are more abundant in centromeric regions of a chromosome that
indicates a role in chromosome structure and possibly folding65. 
Riggs et al. proposed in 1975 a model to explain the initiation and maintenance of
mammalian X chromosome inactivation and certain aspects of other permanent events in
eukaryotic cell differentiation66. A key feature of the model is the proposal of sequence-spe-
cific DNA methylases that methylate unmethylated sites with great difficulty but easily
methylate half-methylated sites. Peter Jones et al. in the late seventies made a key observa-
tion when he incubated mouse fibroblast-like embryonic cell lines with 5-azacytidine, a
chemotherapeutic agent that was tested for treating leukemia67. He noticed after several
rounds of replication that the cells could be characterized as contractile striated muscle
cells, differentiated adipocytes and chondrocytes capable of the biosynthesis of cartilage-
specific proteins68. He realized that this chemical must have activated genes that were silen-
ced. Later on it was demonstrated that 5-aza was a specific inhibitor of DNA methyltrans-
ferase (DNMT) enzymes that are responsible for transferring methylation patterns from
mother to daughter cell during replication69-71. 
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Chemically, due to the open groove in the double helix, placement of a methyl-group is
only possible when cytosine is followed by guanine. An important observation was that the
CpG dinucleotide doublet is found less frequently in the human genome than is statistical-
ly expected72. These doublets are more concentrated in coding regions compared with non-
coding regions and this suggests they have a role in transcription. During the completion
of “the human genome project” it could be more definitely supported that CpG dinucleo-
tides are located predominantly in coding regions. More specifically, they are found in high
concentration in gene promoter regions along with signaling molecules recognition sites
(TATA boxes, helicase binding sites etc.) and those sites were named CpG islands73. About
65% of all human genes have promoter regions that coincide with CpG islands74. It is gene-
rally accepted that the human genome was more CpG rich earlier in evolution and that
over time due to the earlier mentioned susceptibility of CG dinucleotides to spontaneous
mutation/reduction to CT, only the CG´s protected by a methyl-group were conserved.
Heavy methylation or hypermethylation of gene´s promoter region is associated with under-
expression of that gene (see figure 5) 60, 75. This is likely due to the sterical inaccessibility
of the promoter region. In short, the human genome contains CpG dinucleotide rich islands
that coincide with gene promoter regions that are methylated or can undergo de novo
methylation which results into silencing of that gene. 
DNA methylation and cancer
Feinberg and Vogelstein were the first to test whether differences exist in DNA methylati-
on between cancerous and non-cancerous cells of the same patient76. They found that DNA
of a variety of different human cancers was hypomethylated. They could show activation
of some important oncogenes by hypomethylation, i.e. RAS77, MAGE78 and CT79.
Subsequently, many genes thought to be important in cancer were studied for methylation
status and surprisingly some genes were also found to be densely methylated (see table 2)
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Figure 5: Representation of gene silencing by methylation. Boxed areas indicate gene exons. 
• are  methylated CpG dinucleotides, ° are unmethylated CpG sites. 
The arrows indicates the start site of transcription. 
and this was first observed in calcitonin80. Later on, retinoblastoma (Rb), the first tumor
suppressor gene, was found to be silenced by hypermethylation in cancer81, 82. A current
hypothesis adds silencing of tumor related genes by DNA hypermethylation as another form
of a second hit to Knudson’s hypothesis (see figure 6)83. One must look at methylation in
cancer as an example of epigenetic dysregulation, with both hypomethylation and hyper-
methylation having significant roles.  
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Gene abbreviation Gene name Location Gene function
APC Adenomatous 5q21 Signal transduction
polyposis coli
BRCA1 Breast cancer 1 17q2 DNA repair
DAPK Death associated 9q34 Evasion of 
protein kinase programmed cell death
CDH1 E-cadherin 16q22.1 Cell adhesion
ER Estrogen receptor 6q25.1 DNA binding, 
transcription activation
GSTP1 Glutathione 11q13 Cell cycle regulation
S-transferase P1
hMLH1 Human monologue 3p21.3 DNA mismatsch repair
of MutL in bacteria
MGMT O-6- methylguanine-DNA 10q26 DNA repair
methyltransferase
p14 (ARF/CDKN2a) Cyclin dependent 9p21 Cell cycle regulation
kinase inhibitor 2a
p15 (INK4b/CDKN2b) Cyclin dependent 9p21 Cell cycle regulation
kinase inhibitor 2b
p16 (INK4a/CDKN2a) Cyclin dependent 9p21 Cell cycle regulation
kinase inhibitor 2a
RARb2 Retinoic acid 3p24 DNA binding 
receptor beta 2
SOCS Suppressor of 17q25.3 Suppression of 
cytokine signaling cytokine signaling
TIMP3 Tissue inhibitor of 22q12 Tissue invasion 
metalloproteinase 3 and metastasis
Tabel 2: Important tumor-related genes known to be silenced by promoter hypermethylation in solid tumors
(source: Bernal et al., Biol Res41: 303-315, 2008)
Analytical Techniques
The unraveling of the role of DNA methylation in human biology and oncology has been
hampered by technical limitations. Initially, chromatographic- (gas, liquid) or mass-spectro-
metry methods were used. The discovery of methylation-specific restriction enzymes was
a major step forward, but analysis of methylation status of DNA sequences was limited to
the recognition sites of the known enzymes. A major milestone in molecular research in
general was the discovery of the protocol for polymerase chain reaction (PCR) by Kary B.
Mullis described first in 198684-86. Any sequence of the human genome could now be
amplified, with high specificity and reliability to a great amount of template majorly allo-
wing rapid cloning and analysis of DNA. An important improvement in methylation
research was the introduction of sodium metabisulfite treatment of DNA described by
Suzanne Clark et al. first in 199487. The chemical instability of cytosine nucleotides and
their proneness to deamination when unmethylated was utilized. DNA was incubated with
a mild reductor (sodium metabisulfite) and showed specific conversion of cytosine nucleo-
tides to thymine but not when methylated. Followed by direct sequencing analysis it can
be detected if the DNA was methylated or not. Herman et al. then introduced DNA bisul-
fite treatment followed by PCR amplification with primers specific for methylated or unme-
thylated sequences88. This protocol was highly sensitive and applicable in many laboratory
settings and most importantly required only small amounts of sample DNA. When this the-
sis’ studies were initiated the most widely used technique for DNA methylation assessment
was DNA bisulfite modification followed by methylation specific PCR (MSP) followed by
gel electrophoresis of PCR products. 
20
General Introduction
Figure 6: Adjustment of Knudson’s hypothesis on gene inactivation
Micro Satellite Instability
In about fifteen percent of all cases of large bowel cancer there is positive family history.
The most frequent form of hereditary colorectal cancer is Lynch Syndrome (former HNPCC).
On the molecular level this cancer is hallmarked by mutations affecting DNA repair genes
and thus impairing the proof reading mechanism after DNA replication in cell division89.
Mismatch repair (MMR) genes affected by mutations in Lynch Syndrome are MLH1, PMS2,
MSH2 and MSH6. MMR deficiency can be detected by comparing the length of non-coding
DNA repeat sequences, called microsatellites, of cancer cells with those of healthy cells that
become shorter due to the defectiveness to repair these missing nucleotides after cell divi-
sion4, 5, 90, 91. This so-called microsatellite instability (MSI) is also found in about 15% of
colorectal patients without a positive family history and in whom no mutation in MMR
genes is detected. Colorectal tumors with sporadic MSI show specific histologic features
such as mucin excretion, poor differentiation, lymphocytic infiltration and clinical features
such as location in the proximal colon and female sex92, 93. It has now been firmly esta-
blished that in these patients shutdown of the hMLH1 mismatch repair gene by promoter
region methylation is causative for sporadic MSI94, 95. This interesting interaction between
genetics and epigenetics is further looked into in this thesis´s studies.
CpG Island Methylator Phenotype
The epigenetic silencing of tumor suppressor genes appealed to many researchers as a key
causative mechanism of carcinogenesis and lead to a hunt for densely methylated CpG
islands in human cancers. Issa et al. developed a screening method that compared human
CRC cell line DNA to that of healthy donor lymphocytes96. Differentially methylated
sequences were located on the human genome, confirmed to adhere to the CpG island defi-
nition and this lead to 33 so-called methylated-in-tumor (MINT) loci. The MINT loci did
not relate to any coding sequence or promoter region and some could be verified by methy-
lation specific PCR to be specifically methylated in colorectal tumor tissue97, 98. It was
observed that methylation of several MINT loci often occurred simultaneously and in con-
currence with methylation of important tumor related genes such p16 and hMLH1. Also,
tumors with increased methylation showed MSI and a CpG island Methylator Phenotype
(CIMP) colorectal cancer was proposed. Later, CIMP was further established as correlati-
ons were shown with KRAS, BRAF and p53 mutational status99. The phenotype character
of CIMP was challenged as this group of tumors could also constitute the far end of a con-
tinuous spectrum of methylation in tumor and not a distinct, clearly separable group100, 101.
CIMP currently is still not clearly defined and different research groups use different mar-
ker-sets and techniques and show different clinical correlations. There are some consistent
findings on clinical parameters associated with CIMP+ colorectal tumors: Older age, proxi-
mal location in colon, female sex, however, not surprisingly these all match MSI positive
CRCs. Whether CIMP will be as significant in CRC as MSI is still under investigation. 
Biomarkers
In daily medical practice, biomarkers are highly important tools for physicians in diagno-
sing diseases, estimating disease severity, follow-up of disease progression, exclusion of
pathology etc. Next to diagnostics, markers are also used to help clinical decisions to start,
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stop, adjust, switch or postpone treatment. Some biomarkers are direct reflectors of condi-
tions (i.e. serum hemoglobin levels for anemia, however, indirect, surrogate markers are
also frequently used that are reflective of conditions (i.e. C-reactive protein or CRP for infec-
tion). In GI cancer, the TNM-staging system is currently the best tool we have for making
treatment decisions. There are indications, however, that there is room for improvement.
First it is first important to realize that our treatment for GI cancer is empiric and non-spe-
cific. Aggressive surgery and chemo- and radiotherapy come with considerable morbidity
and mortality. Better subclassification of GI tumors is needed to prevent undertreatment in
some cases as well as overtreatment in others. The TNM system only includes surrogate
parameters of disease progression. Primary tumor cell features, especially in GI cancers, cur-
rently have a limited role in clinical decision making. Molecular biomarkers assessed in the
primary GI tumor form a new area of cancer diagnostics and are currently under investiga-
tion for their use. The use of epigenetic biomarkers in GI cancers is a relatively new field
compared with genetic biomarkers. The single, most important objective of this thesis’ stu-
dies was to test whether epigenetic biomarkers have potential to subclassify GI cancer
patients into clinically relevant groups. The role of this novel category of biomarkers in pre-
diction of gastrointestinal cancer disease outcome was evaluated. Subsequently we conti-
nued to assess whether these markers merit further evaluation to make decisions tailoring




1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2):71-96.
2. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of
two large midwestern kindreds. Arch Intern Med 1966; 117(2):206-212.
3. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple
repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363(6429):558-
561.
4. Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue
hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368(6468):258-261.
5. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its association
with hereditary nonpolyposis colon cancer. Cell 1993; 75(5):1027-1038.
6. Herrera L, Kakati S, Gibas L, Pietrzak E, Sandberg AA. Gardner syndrome in a man with an intersti-
tial deletion of 5q. Am J Med Genet 1986; 25(3):473-476.
7. Chao A, Thun MJ, Connell CJ et al. Meat consumption and risk of colorectal cancer. JAMA 2005;
293(2):172-182.
8. Hubner RA, Houlston RS. Folate and colorectal cancer prevention. Br J Cancer 2009; 100(2):233-
239.
9. Park Y, Hunter DJ, Spiegelman D et al. Dietary fiber intake and risk of colorectal cancer: a pooled
analysis of prospective cohort studies. JAMA 2005; 294(22):2849-2857.
10. Peters U, Sinha R, Chatterjee N et al. Dietary fibre and colorectal adenoma in a colorectal cancer
early detection programme. Lancet 2003; 361(9368):1491-1495.
11. Breslow L. Risk factor intervention for health maintenance. Science 1978; 200(4344):908-912.
12. Coyle YM. Lifestyle, genes, and cancer. Methods Mol Biol 2009; 472:25-56.:25-56.
13. Peipins LA, Sandler RS. Epidemiology of colorectal adenomas. Epidemiol Rev 1994; 16(2):273-297.
14. McLellan EA, Medline A, Bird RP. Sequential analyses of the growth and morphological characteris-
tics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res 1991; 51(19):5270-5274.
15. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48(13):3554-3560.
16. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiolo-
gy. Lancet 1975; 2(7924):58-60.
17. Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinoge-
nesis. J Gastroenterol Hepatol 2009; 24(2):193-201.
18. Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res 2009; 3(2
Suppl):S2-S5.
19. El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma
of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002; 50(3):368-372.
20. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74-
108.
21. Quina MG, Guerreiro AS. Gastric cancer (carcinoma) and Helicobacter pylori: situation in Portugal.
Hepatogastroenterology 2001; 48(42):1565-1568.
22. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review
and considerations for future directions. Ann Surg 2005; 241(1):27-39.
23. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric can-
cer: meta-analysis of randomized trials. J Clin Oncol 1993; 11(8):1441-1447.
23
General Introduction
24. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric cancer. N Engl
J Med 1999; 340(12):908-914.
25. Hartgrink HH, van d, V, Putter H et al. Extended lymph node dissection for gastric cancer: who may
benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;
22(11):2069-2077.
26. Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with para-aortic nodal dissecti-
on for gastric cancer. N Engl J Med 2008; 359(5):453-462.
27. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric
cancer. N Engl J Med 2008; 358(1):36-46.
28. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for
resectable gastroesophageal cancer. N Engl J Med 2006; 355(1):11-20.
29. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surge-
ry alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;
345(10):725-730.
30. van d, V, Benson AB. Accomplishments in 2007 in the management of localized gastric cancer.
Gastrointest Cancer Res 2008; 2(3 Suppl):S42-S46.
31. Ng K, Meyerhardt JA, Fuchs CS. Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J
2007; 13(3):168-174.
32. Koopmanschap MA, van RL, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J
Cancer 1994; 30A(1):60-65.
33. van den Hout WB, van den BM, Stiggelbout AM, van d, V, Kievit J. Cost-effectiveness analysis of colo-
rectal cancer treatments. Eur J Cancer 2002; 38(7):953-963.
34. van Steenbergen LN, Lemmens VE, Louwman MJ, Straathof JW, Coebergh JW. Increasing incidence
and decreasing mortality of colorectal cancer due to marked cohort effects in southern Netherlands.
Eur J Cancer Prev 2009; 18(2):145-152.
35. Wong SL, Ji H, Hollenbeck BK, Morris AM, Baser O, Birkmeyer JD. Hospital lymph node examinati-
on rates and survival after resection for colon cancer. JAMA 2007; 298(18):2149-2154.
36. Simunovic M, Baxter NN. Lymph node counts in colon cancer surgery: lessons for users of quality
indicators. JAMA 2007; 298(18):2194-2195.
37. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant tre-
atment for colon cancer. N Engl J Med 2004; 350(23):2343-2351.
38. Taieb J, Puig PL, Bedenne L. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scien-
tific background and the ongoing PETACC-8 trial. Expert Rev Anticancer Ther 2008; 8(2):183-189.
39. Saltz LB, Clarke S, az-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemothe-
rapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol
2008; %20;26(12):2013-2019.
40. Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/foli-
nic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a rando-
mized phase III noninferiority study. Ann Oncol 2008; 19(10):1720-1726.
41. Heald RJ. A new approach to rectal cancer. Br J Hosp Med 1979; 22(3):277-281.
42. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total meso-
rectal excision for resectable rectal cancer. N Engl J Med 2001; 345(9):638-646.
43. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer.
N Engl J Med 2006; 355(11):1114-1123.
24
General Introduction
44. Quasar Collaborative Group, Gray R, Barnwell J et al. Adjuvant chemotherapy versus observation in
patients with colorectal cancer: a randomised study. Lancet 2007; 370(9604):2020-2029.
45. Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postope-
rative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a mul-
ticentre, randomised trial. Lancet 2009; 373(9666):811-820.
46. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of
rectal cancer? J Clin Oncol 2008; 26(2):303-312.
47. Quirke P, Steele R, Monson J et al. Effect of the plane of surgery achieved on local recurrence in
patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-
CTG CO16 randomised clinical trial. Lancet 2009; 373(9666):821-828.
48. West NP, Finan PJ, Anderin C, Lindholm J, Holm T, Quirke P. Evidence of the oncologic superiority
of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol 2008; %20;26(21):3517-
3522.
49. WATSON JD, CRICK FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic
acid. Nature 1953; 171(4356):737-738.
50. Olby R. Quiet debut for the double helix. Nature 2003; 421(6921):402-405.
51. Alberts B. DNA replication and recombination. Nature 2003; 421(6921):431-435.
52. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development.
N Engl J Med 1988; 319(9):525-532.
53. Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002;
3(2):83-88.
54. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia.
Gastroenterology 2002; 123(3):862-876.
55. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic
therapy. Nature 2004; 429(6990):457-463.
56. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999; 286(5439):481-
486.
57. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental
aspect of neoplasia. Adv Cancer Res 1998; 72:141-96.:141-196.
58. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;
3(6):415-428.
59. HOTCHKISS RD. The quantitative separation of purines, pyrimidines, and nucleosides by paper chro-
matography. J Biol Chem 1948; 175(1):315-332.
60. Razin A, Riggs AD. DNA methylation and gene function. Science 1980; 210(4470):604-610.
61. Waalwijk C, Flavell RA. DNA methylation at a CCGG sequence in the large intron of the rabbit beta-
globin gene: tissue-specific variations. Nucleic Acids Res 1978; 5(12):4631-4634.
62. Billen D. Methylation of the bacterial chromosome: an event at the "replication point"? J Mol Biol
1968; 31(3):477-486.
63. Marinus MG, Morris NR. Pleiotropic effects of a DNA adenine methylation mutation (dam-3) in
Escherichia coli K12. Mutat Res 1975; 28(1):15-26.
64. Coulondre C, Miller JH, Farabaugh PJ, Gilbert W. Molecular basis of base substitution hotspots in
Escherichia coli. Nature 1978; 274(5673):775-780.




66. Riggs AD. X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet 1975; 14(1):9-
25.
67. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;
20(1):85-93.
68. Jones PA. DNA methylation and cancer. Cancer Res 1986; 46(2):461-466.
69. Wigler M, Levy D, Perucho M. The somatic replication of DNA methylation. Cell 1981; 24(1):33-
40.
70. Doerfler W. In pursuit of the first recognized epigenetic signal--DNA methylation: a 1976 to 2008
synopsis. Epigenetics 2008; 3(3):125-133.
71. Doerfler W. DNA methylation and gene activity. Annu Rev Biochem 1983; 52:93-124.:93-124
72. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321(6067):209-213.
73. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;
%20;196(2):261-282.
74. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N
Engl J Med 2003; %20;349(21):2042-2054.
75. Brown DD. Gene expression in eukaryotes. Science 1981; 211(4483):667-674.
76. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their
normal counterparts. Nature 1983; 301(5895):89-92.
77. Feinberg AP, Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem
Biophys Res Commun 1983; 111(1):47-54.
78. De SC, De BO, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in
tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 1996;
93(14):7149-7153.
79. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4(2):143-153.
80. Baylin SB, Hoppener JW, de BA, Steenbergh PH, Lips CJ, Nelkin BD. DNA methylation patterns of
the calcitonin gene in human lung cancers and lymphomas. Cancer Res 1986; 46(6):2917-2922.
81. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylati-
on of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991; 48(5):880-888.
82. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to
the formation and spontaneous regression of retinoblastoma. Hum Genet 1989; 83(2):155-158.
83. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A
1971; 68(4):820-823.
84. Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of DNA in
vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol 1986; 51 Pt 1:263-73.:263-
273.
85. Saiki RK, Scharf S, Faloona F et al. Enzymatic amplification of beta-globin genomic sequences and
restriction site analysis for diagnosis of sickle cell anemia. Science 1985; %20;230(4732):1350-1354.
86. Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich HA. Analysis of enzymatically amplified beta-glo-
bin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 1986; 324(6093):163-
166.
87. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic
Acids Res 1994; 22(15):2990-2997.
88. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR
assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93(18):9821-9826.
26
General Introduction
89. de la CA. Microsatellite instability. N Engl J Med 2003; 349(3):209-210.
90. Leach FS, Nicolaides NC, Papadopoulos N et al. Mutations of a mutS homolog in hereditary nonpo-
lyposis colorectal cancer. Cell 1993; 75(6):1215-1225.
91. Papadopoulos N, Nicolaides NC, Wei YF et al. Mutation of a mutL homolog in hereditary colon can-
cer. Science 1994; 263(5153):1625-1629.
92. Jass JR. Pathology of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci 2000; 910:62-73;
discussion 73-4.:62-73.
93. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colo-
rectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96(4):261-268.
94. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies spo-
radic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat
Genet 2006; 38(7):787-793.
95. Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter
hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95(12):6870-6875.
96. Toyota M, Ho C, Ahuja N et al. Identification of differentially methylated sequences in colorectal can-
cer by methylated CpG island amplification. Cancer Res 1999; 59(10):2307-2312.
97. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenoty-
pe in colorectal cancer. Proc Natl Acad Sci U S A 1999; %20;96(15):8681-8686.
98. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999;
9(5):349-357.
99. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or wit-
hout the CpG island methylator phenotype. Proc Natl Acad Sci U S A 2000; 97(2):710-715.
100. Suzuki K, Suzuki I, Leodolter A et al. Global DNA demethylation in gastrointestinal cancer is age
dependent and precedes genomic damage. Cancer Cell 2006; 9(3):199-207.
101. Yamashita K, Dai T, Dai Y, Yamamoto F, Perucho M. Genetics supersedes epigenetics in colon cancer









This dissertation is divided into two sections. The first section introduces four studies that
were performed to further develop and validate techniques for DNA methylation analysis.
The second section shows application of the developed techniques and intends to demon-
strate that the relatively new field of epigenetics can be utilized for better subclassification
of gastrointestinal malignancies to aid their surgical treatment. The studies demonstrate
DNA methylation analysis on primary GI tumor tissue to potentially hold value in clinical
decision making. The four chapters of the second section focus on gastric cancer, colorec-
tal cancer and on rectal cancer specifically. 
Section One
The first chapter introduces a method that allows to control methylation-specific PCR
reactions better, a technique widely used in DNA methylation analysis. In the study a pro-
tocol is described for synthesis of completely unmethylated whole genomic DNA that can
be used as a negative control to include in MSP experiment set-ups. The sample DNA is
cheaply and quickly synthesized and quantities of DNA are obtained. The introduced so-
called universal unmethylated control (UUC) can be used as a standard negative, unmethy-
lated reference sample for any human gene.
The second chapter reports on a protocol that dramatically reduces the number of
steps needed to obtain sodium bisulfite modified sample DNA from formalin-fixed paraffin-
embedded (FFPE) tissue DNA ready for PCR amplification. This protocol eliminates many
purification and washing steps used in classic DNA isolation techniques and classic bisulfi-
te treatment methods. The procedure was named on-slide sodium bisulfate modification
(SBM) since the formalin fixed paraffin embedded (FFPE) tissue section on the glass slide
is incubated directly into sodium bisulfite solution. The DNA is modified in situ, still being
in the nucleus. Performance of DNA conversion efficiency is tested and compared with the
classic SBM methods. Application is shown in that on-slide SBM enables methylation-spe-
cific PCR (MSP) experiments on small tissue areas (1-2 mm2) that previously were difficult
to perform. For instance, direct comparison of specific gene promoter methylation status of
tumor cells with adjacent adenoma cells to adjacent normal epithelial cells on the same tis-
sue section is now possible. 
The PCR technique used in the first two chapters was semi-quantitative and we wis-
hed to combine the on-slide protocol with a fully quantitative PCR technique for better
detailed DNA methylation assessment. The third chapter introduces Absolute Quantitative
Analysis of Methylated Alleles (AQAMA). The experiments show that AQAMA can be com-
bined with on-slide SBM and constitutes a robust assay that enables new opportunities to
study cancer progression in a better quantitative detail. 
The fourth chapter describes a protocol that aims to further improve the detailed analyti-
cal capabilities of the in-situ DNA modification concept. We integrated in-situ modification with
the existing laser capture microdissection (LCM) system. LCM can select and isolate and pick
up individual cells or groups of cells from a paraffin tissue section. The developed so-called “on-
cap SBM” technique can compare isolated cells from histologically different tissue areas. The
studies show feasibility of performing on-cap SBM combined with AQAMA assessment of the
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LINE-1 DNA repeat-sequence. Application is shown that LINE-1 methylation levels of primary
tumor tissue can discern presence of lymph node metastasis or distant disease spread.
Section 2
After optimizing our analytical approaches for DNA methylation assessment we formulated
translational research questions. Gastro-intestinal primary tumor FFPE tissue was available
as patient study material from gastric, colon and rectal cancer. The TNM-staging system
accurately predicts disease outcome and is used for most treatment decisions for patients
with gastro-intestinal tumors. Further subclassification to assess disease aggressiveness,
however, is needed to further improve tailoring (neo)adjuvant treatment to radical surgery.
Therefore as a central objective of Section 2 DNA methylation analysis was evaluated for
its potential to subgroup GI cancer patients and analyze prognostic .
In gastric cancer protein expression of cyclo-oxygenase-2 (COX-2) enzyme has been
tested to provide additional prognostic information independent from TNM staging.
Methods for protein expression assessment, however, are still difficult to standardize and
allow for inter observer variation. In chapter 5 we looked into whether epigenetic status
of the COX-2 gene promoter region in gastric cancer patients controls COX-2 expression
and whether it can be utilized as a prognostic marker in gastric cancer. Identification of
novel biomarkers with good diagnostic performance qualities for gastric cancer has beco-
me increasingly important especially since recent studies are showing effectiveness of che-
moradiation regimens in addition to surgery where this was unsuccessful in the past.  
The next three chapters test clinical utility of methylated-in-tumor loci (MINT) in rec-
tal and colon cancer. MINT loci have been repeatedly shown to be aberrantly methylated in
colorectal and gastric cancer, however, their prognostic utility has not been explored wide-
ly to date.
In chapters 6 and 7 we test quantitative MINT locus methylation for its ability to sub-
classify rectal large bowel adenocarcinomas specifically and whether they can serve as bio-
markers to aid treatment decisions in the multimodality treatment approach of rectal can-
cer. Clearly separate subgroups of rectal cancer patients based on MINT locus methylation
levels could be identified. Chapter 6 focuses on predictive value on the potential of early
rectal cancer to distantly metastasize. Chapter 7 evaluates the ability of predicting rectal
cancer local recurrence probability. The data provide evidence for MINT markers to be of
potential help in indicating patients towards specific adjuvant treatment regimens aimed to
reduce either local or distant recurrence. 
In chapter 8 we test changes in MINT locus methylation quantitatively during CRC
progression using our developed techniques AQAMA and on-slide SBM. We study these
methylation changes in relation to microsatellite instability and DNA mismatch repair sys-
tem sufficiency which is an important hallmark of genomic instability of a subgroup of
CRCs. The relation between DNA methylation is used to epigenetically subgroup large
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Abstract
Optimization of highly sensitive methods to detect methylation of CpG islands in gene pro-
moter regions requires adequate methylated and unmethylated control DNA. Whereas uni-
versal methylated control DNA is available, universal unmethylated control (UUC) DNA
has not been made because demethylase is not available to remove methyl groups from all
methylated cytosines. On the basis that DNA synthesized by DNA polymerase does not con-
tain methylated cytosines, we developed a method to create UUC DNA by nested whole
genome amplification (WGA) with Φ29 DNA polymerase. Contamination of the template
genomic DNA in UUC was only 3.1*107, below the detection limit of sensitive methods
used for methylation studies such as methylation-specific PCR. Assessment of microsatelli-
te markers demonstrated that even nested Φ29 WGA achieves highly accurate and homo-
geneous amplification with very low amounts of genomic DNA as an initial template. The




Cytosines of CpG dinucleotides in DNA of higher order eukaryotes are partially methyla-
ted 1, and this modification has important regulatory effects on gene expression, especially
when it involves CpG-rich areas (CpG islands) in the promoter region2,3. Epigenetic gene
silencing by promoter hypermethylation is as significant as deletions or mutations for inac-
tivation of tumor suppressor genes4-6. Because these events play a significant role in malig-
nant transformation and immortalization of cells, assessment of gene promoter hyperme-
thylation has become important to understand tumor progression. Among the available
methods for detecting specific methylation status of genes, methylation-specific PCR (MSP)
and its derivatives are currently the most widely used techniques because they have high
sensitivity for virtually any block of CpG sites in CpG islands7. Because the MSP results are
highly dependent on the specificity of primer annealing, the annealing temperature of ther-
mal cycling and other PCR conditions must be optimized carefully with proper methylated
and unmethylated control DNA to avoid nonspecific amplification which causes false-posi-
tives or false-negatives. However, universal unmethylated control (UUC) DNA is not avai-
lable whereas universal methylated control (UMC) DNA can be made from normal geno-
mic DNA with a CpG methylase SssI8. Therefore, DNA from peripheral blood leukocytes
(PBL), sperm, or other tissues is usually utilized as an unmethylated control, depending on
the methylation status of the target site. However, it is labor consuming and sometimes very
difficult to verify the absence of CpG methylation at the target site of the template DNA
used as an unmethylated control. In addition, it is impossible to find an unmethylated con-
trol for global methylation analysis because there is no completely unmethylated genome
in humans. Therefore, artificially synthesized UUC DNA would be highly valuable in any
methylation analyses such as global methylation analysis or assessment of promoter hyper-
methylation of tumor-related genes in tumors and serum. On the basis that DNA synthesi-
zed by DNA polymerase does not contain methylated cytosines, we aimed to create UUC
by whole genome amplification (WGA), but the conventional thermal cycling WGA
methods were not adequate because they inefficiently amplified GC-rich areas9, the targets
of methylation studies. Recently, a WGA technique by Φ29 DNA polymerase, which is from
the bacteriophage Φ29, has been developed10,11. The Φ29 polymerase continuously ampli-
fies single- or double-stranded circular- or linear-DNA by strong strand displacement activi-
ty. Therefore, after an initial heat-melting step, the Φ29 polymerase does not require furt-
her thermocycling to initiate nascent strand synthesis and can amplify highly GC-rich
sequences. In addition, Φ29WGA has been shown to have high fidelity and near comple-
te genome representation12. However, because the amplification power of this method is
only 103–104, we designed a protocol using nested Φ29 WGA to make a UUC and confir-
med its utility for practical methylation studies. 
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Materials and Methods
Template genomic DNA
The genomic DNA of PBL obtained from healthy donor volunteers was used as the templa-
te DNA for WGA. Peripheral blood was centrifuged and the PBL fraction was isolated. DNA
was extracted using DNAzol reagent (Molecular Research Center, Cincinnati, OH) and
quantified with an UV absorption spectrophotometer.
Creation of UUC by nested WGA with Φ29 DNA polymerase
GenomiPhi DNA Amplification Kit (Amersham Biosystems, Piscataway, NJ) utilizing Φ29
DNA polymerase was used to create UUC from genomic DNA. For primary WGA, 1.0 ng
of genomic DNA prepared in 1 µl was amplified in a total volume of 20 µl following the
instruction provided by the kit manufacturer. DNA was diluted with 9 µl sample buffer con-
taining random primers, heat-denatured at 95 °C for 3 min, cooled to 4 °C, and then mixed
with 9 µl reaction buffer and 1 µl enzyme mix containing Φ29 DNA polymerase. All the
buffers used were provided as premixed in the kit. The mixture was incubated at 30 °C for
18 h, and then the enzyme was deactivated by heating at 65 °C for 10 min. For nested
WGA, 0.1 µl of the product of primary WGA was amplified in a total volume of 20 µl with
the same protocol as the primary reaction. DNA products synthesized by primary and nes-
ted WGA were quantified with UV absorption spectrophotometer after purification by
QIAquick PCR purification kit (Qiagen, Valencia, CA). The nested WGA product was elec-
trophoresed on 2% agarose gel, and the DNA length was analyzed.
Creation of UMC by SssI methylase
SssI methylase (New England Biolabs, Beverly, MA), which methylates all cytosine residu-
es within the double-stranded dinucleotide recognition sequence 5’. . .CG. . .3’, was used
to create UMC in accordance with the manufacturer’s protocol8.
Microsatellite analysis of UUC
To ensure the fidelity and representation of nested WGA, allelic ratios at 34 microsatellite
markers (mononucleotide repeat markers BAT25 and BAT26; dinucleotide repeat markers
TGFbR2, TP53, D1S228, D2S123, D5S229, D5S346, D6S1678, D6S1700, D6S286,
D8S261, D8S262, D8S321, D9S171, D10S197, D10S393, D10S591, D12S1657,
D12S1706, D12S327, D12S346, D12S393, D14S51, D14S62, D16S421, D16S422,
D17S1832, D17S849, D17S855, D18S61, and D18S70, and tetranucleotide markers
D12S1059 and D12S296)13-15 of the genomic DNA (template) and UUC (nested WGA pro-
duct) were compared. Primer sequences were obtained from the National Cancer for
Biotechnology Information (NCBI) database. Forward primers were labeled with WellRED
dye-labeled phosphoramidites (Beckman Coulter, Fullerton, CA). PCR was performed with
10 ng of genomic DNA or nested Φ29 WGA product, 2.5 mM Mg2+, and 0.2 µM of each
primer in a 10-µl reaction volume for 36 cycles: 30 s at 94 °C, 30 s at suitable annealing
temperature for each primer set, 30 s at 72 °C, and 7-min final extension at 72 °C. The
amount and size of the PCR amplicon were determined by capillary array electrophoresis
(CAE) with the CEQ 8000XL system (Beckman Coulter). Allelic ratio deviation of nested
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WGA products on each heterozygous marker was calculated using the following formula:
Max (RG, RU)/Min (RG, RU) - 1.0, where RG, RU are the CAE intensity ratios of two alleles
in genomic DNA and in UUC, respectively.
SBM on UUC and UMC
SBM was applied on UUC and UMC as previously described16. A 5 µg DNA sample in 46.7
µl was denatured by the addition of 3.3 µl of 3M NaOH and incubated at 37 °C for 15
min. After addition of 520 µl of 2.5M sodium metabisulfite at pH 5.0 and 30 µl of 10 mM
hydroquinone, DNA was incubated at 60 °C for 4 h in the dark. The bisulfite-treated DNA
was desalted using the Wizard DNA cleanup system (Promega, Madison, WI) and eluted
in 50 µl H2O. DNA was then desulfonated by 5.6 µl of 3M NaOH at 37 °C for 15 min and
neutralized by 14 µl of 3M sodium acetate. After ethanol precipitation, the DNA pellet was
resuspended in 50 µl of 10 mM Tris–HCl, 0.1 mM EDTA, pH 8.0.
Detection of methylation of promoter region of genes
To test the UUC, we demonstrated the methylation status of p16 (INK4a) gene promoter
region by SBM direct sequencing and MSP. This gene is one of the most intensely studied
tumor suppressor genes in malignant tumors5,17. DNA sequence of p16 gene isoform-1 promo-
ter region with indication of the primers is shown in Fig. 1. We also demonstrated the methy-
lation of promoter regions of seven other genes (RASSF1A (ras association domain family pro-
tein 1), hMLH1 (mutL homologue 1), TWIST, ID4 (inhibitor of DNA binding 4), ESR1
(estrogen receptor 1), 14-3-3σ, and MGMT (methylguanine-DNA methyltransferase)) by MSP.
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Fig. 1. DNA sequence of p16 gene isoform 1 promoter region with indication of the primers for methy-
lation detection analyses. Lowercase: upstream of 50’ untranslated region; uppercase: exon 1.
Open boxes: SBM sequencing primers; solid underlines: methylated-specific MSP primers; and
dotted underlines: unmethylated-specific MSP primers. CpG sites are indicated in bold.
For SBM direct sequencing, 1 µl of SBM UUC was amplified by PCR with the SBM sequen-
cing primers and 2.5 mM of Mg2+ in a 50-µl reaction volume for 36 cycles: 30 s at 94 °C,
30 s at 60 °C, and 30 s at 72 °C, and a 7 min final extension at 72 °C. Purified PCR pro-
ducts were bidirectionally direct-sequenced by CAE using CEQ DYE Terminator Cycle
Sequencing kit (Beckman Coulter). The cycling program included 30 cycles: 20 s at 95 °C,
40 s at 55 °C, and 4 min at 60 °C.
For MSP, each primer was designed to cover two or more CpG sites. Unmethylated-
specific and methylated-specific PCR was performed on 1 µl SBM UUC with 0.2 lM of each
primer and 2.5 mM Mg2+ in a 10-µl reaction volume for 36 cycles: 30 s at 94 °C, 30 s at
optimized annealing temperature for each primer set, and a 7-min final extension at 72 °C.
Forward primers were labeled with WellRED dyelabeled phosphoramidites (Beckman
Coulter). PCR products were detected and analyzed by CAE.
Results
Nested WGA product
The amount of UUC created by nested WGA in 20 µl of reaction volume was 15.9 ± 1.1 µg
(mean ± SEM, n = 4), which included only 5 pg of template genomic DNA (1/200 amount
of the initial template DNA). The total amplification ratio was 3.2*106, and the contaminati-
on ratio of genomic DNA was 3.1*107. When 100 ng of nested WGA product was used as
a template for subsequent analysis, estimated contamination of the genomic DNA was as low
as 0.02 copies per reaction, below the minimum detection level of a highly sensitive method
such as MSP. When the nested WGA product was electrophoresed on 2% agarose gel, the
DNA fragment length was widely distributed but >5 kb fragments were dominant, indicating
wide coverage of the genes and their promoter regions (Fig. 2A). 
Microsatellite analysis
All 34 microsatellite markers were sufficiently amplified on UUC. When amplicon length
and distribution were compared for each marker, all the peaks shown by CAE were equi-
valent and no aberrant bands were observed. No significant amplification error occurred
on the nucleotide repeats, and the amplicon size was completely preserved after nested
WGA reactions (Fig. 2B). In 16 heterozygous markers, allelic ratios were highly maintai-
ned in all markers; the deviations caused by nested WGA were only 5.9 ± 0.8% (mean ±
SEM) with a maximum value of 11% in D12S327 (Figs. 2B and C). Thus, the two alleles
were equally amplified by nested WGA, and it was demonstrated that Φ29 WGA achieves
highly accurate and homogeneous amplification, even on nested reactions with very low
amounts of genomic DNA as a template. 
Methylation status of gene promoter regions in UUC
As a demonstration, SBM direct sequencing and MSP at p16 promoter region on the UUC
were performed. Sequencing showed that all cytosines of CpG dinucleotides were conver-
ted to uracils; thus, there was no methylation on CpG dinucleotides (Fig. 3A). In MSP, only
the unmethylated-specific peak was observed (Fig. 3B). Restriction enzymatic digestion
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study using methylation-specific restriction endonuclease HpaII confirmed that the CpG
within the recognition site was not methylated in UUC (data not shown). COBRA analysis
using restriction endonuclease HpyCH4 IV further confirmed that specific CpG site in p16
promoter region had no methylation (data not shown). Similarly, MSP analysis of the pro-
moter regions of RASSF1A, hMLH1, TWIST, ID4, ESR, 14-3-3σ, and MGMT showed only
unmethylated-specific peaks (Fig. 3B). In all primer sets, the PCR amplicon length and the
shape of the peaks were identical for UUC and PBL DNA. Thus, nested Φ29 WGA did not
affect promoter sequence. 
43
Synthesis of universal unmethylated control DNA by nested whole genome amplification with...
Fig. 2. (A) Nested /29 WGA product elec-
trophoresed on 2% agarosegel
along with molecular size marker.
DNA fragment lengths were wide-
ly distributed, but >5 kb fragments
were dominant. (B) CAE results of
16 microsatellite markers showing
heterozygosity on genomic DNA
among 34 tested markers. Upper
figure (U) in each marker is of UUC
and lower figure (G) is of genomic
DNA used as a template. The ver-
tical axis represents the fluores-
cent intensity indicating the
amount of PCR amplicon and the
horizontal axis represents the PCR
amplicon size. All the peaks shown
by CAE were equivalent and no
aberrant bands were observed.
Allelic ratios were highly maintai-
ned in all markers. (C) Histogram
of allelic ratio deviation of UUC;
the allelic ratio deviation was 5.9
± 0.8% (mean ± SEM).
Discussion
There are two major types of WGA: thermal cycle amplification using thermostable DNA
polymerase and continuous amplification at a stable temperature using DNA polymerase
such as Φ29. To make a UUC DNA, the entire genome including GC-rich sequence must
be equally amplified. However, thermal cycling methods amplify the genome unequally
depending on the distribution of primer annealing sites, and the length of products is rela-
tively short. In addition, because GC-rich sequences are not efficiently amplified9, thermal
cycling methods may not be adequate for the CpG islands, which are the usual targets of
interest for methylation studies. In contrast, a continuous amplification method using Φ29
DNA polymerase, which synthesizes the DNA strand displacing the bound complementa-
ry DNA, has demonstrated that genome representation was comprehensive and estimated
to be 99.8% complete, there was no degradation in the accuracy of single nucleotide poly-
morphism (SNP) genotyping, and the estimated error rate (9.5 · 10 6) was equivalent to
that for unamplified samples12. In our results of microsatellite markers, it was demonstra-
ted that Φ29 WGA achieves highly accurate and homogeneous amplification, even on nes-
ted reaction with very low amounts of genomic DNA as a template. Contamination of
methylated CpG dinucleotides of the template genomic DNA must be minimized in UUC.
However, amplification ratio of Φ29 WGA is only 103–104, and it is insufficient because
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Figure 3. (A) SBM direct sequencing result at p16 promoter region on UUC in reverse direction. It is shown
that all the cytosines of CpG dinucleotides in UUC were converted to uracils (shown as A in rever-
se sequence with *), representing that there was no methylation on CpG dinucleotides. (B)
Methylated- and unmethylated-specific MSP for p16, RASSF1A, hMLH1, TWIST, ID4, ESR1, 14-3-
3d, and MGMT on SBM UUC. Unmethylatedspecific peaks were observed in unmethylated-speci-
fic MSP in upper figures (U), but no peaks were observed in methylated-specific MSP in lower figu-
res (M). The vertical axis represents the fluorescent intensity indicating the amount of PCR
amplicon and the horizontal axis represents the PCR amplicon size.
the subsequent method such as MSP can detect as low as 104 level of contaminated methy-
lated DNA7. Nested amplification can reduce the percentage of the contaminating genomic
DNA used as the template. In this study, a nested Φ29 WGA amplified the template DNA
by a factor of 3.2*106. The final concentration of contaminant was only 0.02 copies for the
subsequent reactions, a negligible amount. Nested Φ29 WGA maintained the allelic ratio
and the size of microsatellites, representing the high fidelity of the amplification. As shown
in gel electrophoresis, the fragment of DNA synthesized by nested Φ29 WGA had sufficient
length to cover promoter regions, and the CpG islands in the promoter regions were ade-
quately amplified. In addition, results of MSP and SBM direct sequencing demonstrated
that the promoter regions were maintained in the nested Φ29 WGA products. For highly
sensitive methods, both negative and positive controls are essential to optimize conditions.
UUC is very useful and necessary for methylation studies, especially MSP, which is a sen-
sitive and powerful technique but critical for condition settings. Inappropriate settings easi-
ly cause false-positive and/or false-negative results. The designing of MSP primer sets can
have difficulties because of restrictions such as limited annealing sites. Optimization of the
PCR is essential but can be difficult without adequate controls. In conclusion, the UUC
DNA created by nested Φ29 WGA is practically very useful and highly essential for ade-
quate methylation analyses such as evaluations of promoter methylation status of tumor-
related genes in tumor tissues. Contamination ratio of the template genomic DNA in UUC
was below the detection limit of MSP or other sensitive methods. Because the UUC con-
tains near complete whole genome sequence and does not contain methylated cytosines,
it can be utilized as a standard control material for various genomic methylation analyses.
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Abstract
Accurate assessment of gene methylation in formalin-fixed, paraffin-embedded archived tis-
sue (FF-PEAT) by microdissection remains challenging because the tissue volume is small
and DNA is damaged. In addition, methods for methylation assessment, such as methyla-
tion-specific PCR (MSP), require sodium bisulfite modification (SBM) on purified DNA,
which causes major loss of DNA. On-slide SBM, in which DNA is modified in situ before
isolation of tumor cells, eliminates DNA purification steps and allows histology-oriented
assessment of gene methylation. This study describes a protocol and use of on-slide SBM
using 20 FF-PEAT of colorectal cancers with intratumoral adenoma components to detect
accumulation of gene methylation during colorectal malignant transformation.
Deparaffinized tissue sections were incubated in sodium bisulfite solution for 8 hours at
60°C, stained with hematoxylin, and then microdissected. Proteinase K lysate was direct-
ly used as a template in subsequent PCR. Using on-slide SBM, 282-bp-long bisulfite direct
sequencing was possible. Yield of modified DNA was 2.6-fold greater than standard SBM
on average. The mean conversion rate was 97%, and false-positive or false-negative results
were not observed in subsequent MSP. Intratumoral heterogeneity by accumulation of p16
and Ras association domain family protein 1a methylation during malignant transformati-
on were shown by MSP comparing cancer with adenoma parts within a single section. On-
slide SBM is applicable in most methylation studies using FF-PEAT. It allows detailed, intra-
tumoral analysis of methylation heterogeneity within solid tumors. On-slide SBM will
significantly improve our approach and understanding of epigenetic events in minimal




In the mammalian genome, 5% of cytosines are modified to 5-methylcytosine1, and this
modification has important regulatory effects on gene expression especially when it invol-
ves cytosine-guanine dinucleotide (CpG) rich areas (CpG islands) in promoter regions2,3.
Epigenetic gene silencing by promoter hypermethylation of tumor suppressor genes is as
significant as deletions or mutations4-6, and it can play a significant role in malignant trans-
formation and immortalization of cells. Therefore, assessment of promoter hypermethylati-
on has become important for understanding the mechanisms of malignant transformati-
on7,8. Sodium bisulfite modification (SBM) of genomic DNA is commonly used to detect
methylation of CpG islands in promoter regions. Sodium bisulfite converts cytosines but
not 5-methylcytosines to uracils9. Therefore, the methylation status reflects the changes in
the sequence of the DNA after modification. The modified DNA can be analyzed by sequen-
cing10, methylation-specific PCR (MSP)11, combined bisulfite restriction analysis12, high-
throughput quantitative methylation assay (MethyLight)13, quantitative analysis of methy-
lated alleles14, and other methods. The most widely available starting material for
assessment of solid tumors is formalin-fixed, paraffin-embedded archived tissue (FF-PEAT)
used for pathologic diagnosis after surgical removal of the tumor or after tumor biopsy. Use
of FF-PEAT for epigenetic analysis, such as MSP, would have significant use to evaluate
patients’ specimens. As described in a previous report, there are critical issues with SBM
of FF-PEAT15,16, formalin fixation causes fragmentation and cross-linking of the DNA that
is dependent on the acidity of the formalin and soaking time. In addition, 84% to 96% of
the source DNA may be lost during conventional SBM17. This significant loss of template
DNA hampers assessment of methylation; a previous study reported that 50 cycles of ther-
mal cycling in MSP were needed for SBM DNA extracted from a small area of FF-PEAT by
microdissection18. This high number of PCR cycles would detect only a single copy of
DNA, which increases the risk of false-positive results due to incomplete SBM, and may
not be reproducible. Extracting DNA from a larger tumor area or whole-tumor sections inc-
rease yields of DNA would result in more reproducible results, but it increases the risk of
contamination with DNA from non-cancer cells. On-slide SBM, in which DNA is modified
in the tissues, was initially developed for MSP in situ hybridization19, but its application
has been very limited to date. However, on-slide SBM should minimize loss of DNA becau-
se it eliminates DNA purification steps. We have developed and optimized a protocol for
on-slide SBM that can be easily adapted in laboratories to do histology-oriented methylati-
on analyses. We validated the use of on-slide SBM using primary colorectal cancers with
intratumoral adenoma component. Specificity was assessed by estrogen receptor 1 (ESR1)
and thymine-DNA glycosylase (TDG) promoter methylation status. Intratumoral heteroge-
neity of p16 and Ras association domain family protein 1a (RASSF1a) promoter methylati-
on status was also assessed. The feasibility of direct sequencing of a relatively long PCR pro-
duct was tested to show that DNA modified by the on-slide SBM technique is degraded to
a lesser extent compared with conventional SBM.
To evaluate the yield and conversion rate (i.e., percentage of modified DNA) of on-slide
SBM, we have newly developed a highly sensitive quantitative real-time PCR (qPCR) assay
for bisulfite-modified and unmodified DNA (i.e., genomic DNA). Alu, which is the most
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abundant repeat sequence in the human genome with a copy number of f1.4 106 in a
cell20, was used as a target of qPCR to maximize sensitivity. It allowed accurate quantifica-
tion and precise evaluation for samples having very low amount of modified DNA. Bisulfite-
modified DNA and the remaining unmodified DNA were separately quantified by Alu-qPCR
with specifically designed primer sets. 
Materials and Methods
Tissue Specimens
FF-PEAT of colorectal cancers were obtained from 20 patients who underwent colectomy
or proctectomy between 1995 and 1998 at Saint John’s Health Center (Santa Monica, CA)
and consented for research use of their tissue specimens according to the guidelines of Saint
John’s Health Center/John Wayne Cancer Institute’s (Santa Monica, CA) review board.
Cases were selected in which the pathologic report described presence of intratumoral ade-
noma component. All tissue specimens had been fixed in 10% buffered formalin for 24
hours and paraffin embedded. A set of eight colorectal cancer specimens was used to eva-
luate yield, conversion rate, and a set of three colorectal cancer specimens was used to
show feasibility of relatively long sequencing of on-slide SBM DNA. Sections (10 µm) were
cut with a microtome from each FF-PEAT block.
On-Slide SBM and Subsequent Microdissection
To evaluate the yield and conversion rate of on-slide SBM, deparaffinized and rehydrated
tissue sections were incubated in 0.2mol/L NaOH at room temperature for 15 minutes and
then incubated in 3 mol/L sodium bisulfite solution with 0.5 mmol/l hydroquinone (pH
5) in the dark. We tested four incubation settings (60°C for 4 hours, 60°C for 8 hours,
70°C for 4 hours, and 70°C for 8 hours) for three colorectal cancer specimens in the ini-
tial evaluation set. Eight colorectal cancer specimens were used with two incubation set-
tings (60°C for 4 hours and 60°C for 8 hours) to compare conversion rate and yield of modi-
fied DNA between on-slide SBM and conventional SBM methods. After incubation, sections
were rinsed with distilled water, soaked in 0.3 mol/l NaOH for 15 minutes to desulfonate
the modified cytosines, and then desalted in distilled water at 60°C for 2hours. After light
staining with hematoxylin, 25-mm2 cancer tissue was microdissected under a microscope
from each section. The microdissected areas of each section were identical for each incu-
bation setting. Microdissected tissues were digested in 50 µl lysis buffer containing 4 µg
proteinase K, 2.5% Tween 20, 50 mmol/l Tris, and 1 mmol/l EDTA at 50°C for 5 hours
followed by heat deactivation of proteinase K at 95°C for 10 minutes. In each subsequent
qPCR, 2 µl lysate was used as a template without DNA purification.
To validate the use of on-slide SBM to study intratumoral heterogeneity in methylati-
on status, paired cancer and adenoma tissues were microdissected from each on-slide SBM
section treated at the conditions that were found to be optimal. From each specimen, ~1
mm2 tissue was microdissected and consisted of ~2 to 10 ducts of cancer or adenoma tis-
sue. Each specimen was digested in 10 µl lysis buffer; 1 µl lysate was used as a template
in subsequent MSP or direct sequencing without DNA purification.
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Standard SBM on Purified DNA from Microdissected Tissue
For comparison of standard SBM with on-slide SBM DNA, purified DNA from microdissec-
ted FF-PEAT sections was bisulfite modified with standard SBM method as described pre-
viously23. DNA was extracted from the same area (25 mm2) of each tissue section as on-
slide SBM. DNA was purified with phenol-chloroform-isoamylalcohol from proteinase
K–digested tissues microdissected from deparaffinized sections and modified by sodium
bisulfite 60°C for 3 hours with 1 µg salmon sperm DNA as a carrier using the same bisul-
fite solution as described above. Modified DNA was recovered using the Wizard DNA
Clean-Up System (Promega, Madison, WI), desulfonated with 0.3 mol/l NaOH, and resu-
spended in 50 µL Tris-EDTA buffer; 2 µl of the solution were used as a template in subse-
quent qPCR.
Agarose-Bead SBM on Microdissected Tissue 
Bisulfite modification of DNA in digested tissues trapped in agarose beads24 does not requi-
re the DNA purification steps and therefore allows a relatively high recovery rate of DNA
from FF-PEAT samples. Same area (25 mm2) of each tissue section was microdissected and
treated. For bisulfite modification, digested tissues trapped in 2% agarose beads containing
0.2mol/l NaOH were incubated in bisulfite solution, same as for on-slide and standard
SBM, at 50°C for 14 hours. After modification, beads were desalted as described previou-
sly (24) and heat diluted up to 50 µl with Tris-EDTA buffer; 2 µl of the diluted agarose gel
were directly used as a template in subsequent qPCR without DNA purification.
Quantification of Bisulfite-Modified and Unmodified DNA
To determine the yield and conversion rate of SBM DNA, bisulfite-modified and unmodi-
fied DNA was separately quantified by Alu-qPCR. Primers specific for bisulfite-modified Alu
sequence independent to the methylation status were 5’-TTGTAATTTTAGTATTTTGGGAG
GT-‘3 (forward) and 5’-TCACCATATTAACCAAACTAATCTC-‘3 (reverse); their amplicon
size was 83 bp. Primers specific for unmodified Alu sequence were 5’-CCTGAGGT CAG-
GAGTTCGAG-‘3 (forward) and 5’-CCCGAGTAGCTGGGATTACA-‘3 (reverse); their ampli-
con size was 115 bp. The reaction mixture for each Alu-qPCR consisted of SBM DNA tem-
plate, 0.2 µmol/l forward and reverse primers, 1 unit iTaq DNA polymerase (Bio-Rad
Laboratories, Hercules, CA), 0.02 µl fluoresceïn calibration dye (Bio-Rad Laboratories), and
1x concentration of SYBR Gold (Molecular Probes, Eugene, OR) in a total reaction volume
of 20 µl with 5 mmol/l Mg2+. Real-time PCR amplification was done with a precycling heat
activation of DNA polymerase at 95°C for 10 minutes followed by 35 cycles of denatura-
tion at 95°C for 30 seconds, annealing at 59°C (primer set for modified Alu) or 64°C (pri-
mer set for unmodified Alu) for 30 seconds, and extension at 72°C for 30 seconds using
iCycler iQ Real-time PCR Detection System (Bio-Rad Laboratories). The absolute copy num-
bers of modified and unmodified Alu sequence in each sample were determined from the
threshold cycle numbers with a standard curve done by serial dilutions of bisulfite-modi-
fied or unmodified Alu fragment, which was purified from PCR product and quantified by
UV-absorption. Triplicate reactions of qPCR were done, and each reaction plate included a
negative control (no template). PCR products were electrophoresed on 2% agarose gels to
confirm product size and specificity of the PCR. The relative yield was calculated as Qos /
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Qstd for on-slide SBM and Qag / Qstd for agarose-bead SBM, where Qstd, Qos, and Qag are
the absolute copy numbers of modified Alu of standard, on-slide, and agarose-bead SBM,
respectively. The conversion ratio was calculated as Qmod / (Qmod + Qunmod), where Qmod
and Qunmod are the absolute copy numbers of modified and unmodified Alu, respectively.
Cross-reaction of Alu primers on the salmon sperm DNA used as a carrier in the standard
SBM was assessed using a blank sample prepared without tissue DNA.
Bisulfite Direct Sequencing for p16 Gene Promoter Region
To show the feasibility of on-slide SBM for bisulfite direct sequencing of relatively long tar-
get, we sequenced 282 bp of the modified p16 gene promoter, which is usually difficult for
DNA from FF-PEAT modified by standard SBM. Bisulfite direct sequencing was done as des-
cribed previously25. The primers were 5’-GGGTAGGTGGGGAGGAGTTTAGTTT-‘3 (for-
ward) and 5’-AATAACCAACCAACCCCTCCTCTTT-‘3 (reverse). PCR amplification was
done in a 50-µl reaction volume using 1-µl template with a precycling heat activation of
DNA polymerase at 95°C for 10 minutes followed by 36 cycles of denaturation at 95°C for
30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds fol-
lowed by final extension at 72°C for 7 minutes with 2.5 mmol/l concentration of Mg2+
and 0.2 µmol/l of each primer concentration. After PCR products were run on agarose gels
and purified, they were directly sequenced using CEQ Dye Terminator Cycle Sequencing
kit (Beckman Coulter, Inc., Fullerton, CA) according to the manufacturer’s instructions.
Cycling program includes 30 cycles of denaturation at 95°C for 20 seconds, annealing at
55°C for 40 seconds, and extension at 60°C for 4 minutes. Sequences were read by CEQ
8000XL CAE System (Beckman Coulter).
MSP for ESR1, TDG, p16, and RASSF1a
Methylation status of CpG islands in ESR1, TDG, p16, and RASSF1a gene promoter regions
of paired cancer and adenoma tissues was assessed by MSP. Forward primers of MSP were
labeled with D2, D3, or D4 WellRED dye-labeled phosphoramidites (Beckman Coulter).
The methylation-specific primers for ESR1 were 5’-D4-TAAATAGAGATATATCG-
GAGTTTGG TACG-‘3 (forward) and 5’-AACTTAAAATAAACGCGAAAAACGA-‘3 (reverse);
the unmethylation-specific primers for ESR1 were 5’-D3-TAAATAGAGATATATTGGAGTTT
GGTATGG-‘3 (forward) and 5’-AACTTAAAATAAACACAAAAAACAAA-‘3 (reverse). The
methylation-specific primers for TDG were 5’-D4-TGAGCGTGATTGGGTTGTTTTAT
ATTAC-‘3 (forward) and 5’-TTCTACCGTCCCCCACGA-‘3 (reverse); the unmethylation-
specific primers for TDG were 5’-D3-AGTGTGATTGGGTTGTTTTATATTATGT-‘3 (for-
ward) and 5’-CTTCTACCATCCCCCACAAA-‘3 (reverse). The methylation-specific primers
for p16 were 5’-D4-TTATTAGAGGGTGGGGCGGATCGC-‘3 (forward) and 5’-CG
ATTTCGGGTCGCGG TCGTGG-‘3 (reverse); the unmethylation-specific primers for p16
were 5’-D2-TATTAGAGGGTGGGGTGGATTGT-‘3 (forward) and 5’-TGATTTTGGGTTG
TGGTTGTGG-‘3 (reverse). PCR conditions were optimized to achieve highest sensitivity
without false-positive results using universal methylated control DNA and universal unme-
thylated control DNA as described previously25. The optimized annealing temperatures for
methylated-specific primers for ESR1, unmethylated-specific primers for ESR1, methylated-
specific primers for TDG, and unmethylated-specific primers for TDG, methylated specific
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primers for p16, and unmethylated-specific primers for p16 were 61°C, 58°C, 62°C, 61°C,
62°C, and 61°C, respectively. Primers and PCR settings used for amplification of the
RASSF1a promoter region were published previously23. PCR amplification was done in a
10-µl reaction volume using 1-µl template with a precycling heat activation of DNA poly-
merase at 95°C for 10 minutes followed by 36 cycles of denaturation at 95°C for 30
seconds, annealing at optimized annealing temperature for 30 seconds, and extension at
72°C for 30 seconds followed by final extension at 72°C for 7 minutes with 2.5 mmol/l
concentration of Mg2+ and 0.2 µmol/l of each primer concentration. PCR products were
detected and analyzed by CEQ 8000XL CAE system as described previously26.
Results
Effect of On-Slide SBM on Microscopic Histology of Tissue Sections
Because on-slide SBM uses alkaline pretreatment for denaturation of DNA, potent acid tre-
atment for modification of cytosines at relatively high temperatures for long durations, and
alkaline treatment for desulfonation of cytosines, we expected some deterioration of
microscopic tissue architectures. However, as shown in Fig. 1, tissue architecture was main-
tained after on-slide SBM at optimal conditions of 60°C for 8 hours, and there was no
impairment of pathologic assessment after hematoxylin staining. Consequently, microdis-
section could be precisely done without difficulty. H&E and methyl green staining was also
done on post on-slide SBM slides and showed similar quality (data not shown).
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Figure 1. Microscopic photographs
of three tissue sections
after on-slide SBM treat-
ment and hematoxylin
staining. Magnification,
100 (A1, B1, and C1) and
200 (A2, B2, and C2).
Bisulfite Direct Sequencing of p16 Gene Promoter Region
Bisulfite direct sequencing of a 282-bp amplicon in the p16 gene promoter region was done
in an initial evaluation set of three colorectal cancer specimens comparing two incubation
temperatures of on-slide SBM. Sequencing of on-slide SBM samples incubated at 70°C for
4 or 8 hours was unsuccessful. This suggests that template DNA may be damaged and trun-
cated during incubation at 70°C, thus not suitable for assessment. In contrast, on-slide SBM
samples incubated at 60°C for 4 or 8 hours were successfully sequenced (Fig. 2). All cyto-
sines in the sequencing results were correctly converted to uracil with incubation at 60°C
for 8 hours. Therefore, incubation at 60°C was used for on-slide SBM in the subsequent
assessments. Direct sequencing of DNA after standard SBM or agarosebead SBM was
unsuccessful with the same sequencing protocol.
The Yield and Conversion Rate of Modification
The yield and conversion rate of modification was evaluated using eight tissue samples for
on-slide, standard, and agarosebead SBM by assessing the copy numbers of modified and
unmodified Alu repeat sequences. Each sample was assessed in triplicate, and the median
intersample coefficient of variance for modified and unmodified DNA was 6.8% and 11.2%,
respectively. The yield of modified DNA increased with the duration of incubation of on-
slide SBM. When modified Alu copy numbers of on-slide and standard SBM were compa-
red, the relative yield of modified DNA by on-slide SBM was higher by a mean factor of 1.3
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Figure 2. Representative standard sequencing diagram for bisulfite direct sequencing of p16 gene promoter
region after on-slide SBM DNA with incubation at 60jC for 8 hours depicting the high quality of
modified DNA. Bisulfite direct sequencing of a 282-bp amplicon was made possible by on-slide
SBM from 1-mm2 microdissected tissue of 10-Am FF-PEAT section of a colorectal cancer. All cyto-
sines in this sequence (*) were converted to uracil, shown as ‘‘A’’ in reverse strand. Signals of false
conversion were not observed. CpGs are underlined. The p16 gene promoter region of this colo-
rectal cancer is not methylated. 
± 0.8 and 2.6 ± 1.0 (mean ± SD) at incubation settings of 60°C for 4 hours and 60°C for
8 hours, respectively (Fig. 3). The relative yield of modified DNA by agarose-bead SBM was
only 0.9± F 1.0 (mean ± SD) after 14 hours of incubation at 50°C. The conversion rates
of modified DNAby on-slide SBM were 75.4 ± 15.2% and 97.1 ± 2.7% (mean ± SD) at
incubation settings of 60°C for 4 hours and 60°C for 8 hours, respectively (Fig. 4).
Conversion rates increased with increasing duration of incubation. The conversion rate of
on-slide SBM with 4 hours of incubation was obviously low for specific assessment of
methylation status, but it was satisfactory and similar to the standard SBM method with 8
hours of incubation. The conversion rate of standard SBM was 97.6 ± 1.3% after 3 hours
of incubation at 60°C. Assessment of cross-reaction of Alu primers on the salmon sperm
DNA used as a carrier in the standard SBM revealed that it contributed only <0.1% of the
total copy numbers. The agarose-bead SBM method had a conversion rate of 99.4 ± 0.5%
after 14 hours of incubation at 50°C. 
MSP for ESR1, TDG, p16, and RASSF1a
To evaluate the possibility of false-positive or false-negative MSP results after on-slide SBM,
we assessed the methylation status of CpG islands in ESR1 and TDG gene promoter of 16
pairs of cancer and adenoma tissues. All showed methylation of ESR1 (Fig. 5A), and none
showed methylation of TDG (Fig. 5B). These results indicate that on-slide SBM did not
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Figure 3. Relative yield of modified DNA of on-
slide and agarosebead SBM over stan-
dard SBM, calculated as the ratio of abso-
lute copy numbers of modified Alu.
On-slide SBM at incubation settings of
60°C for 8 hours had the highest relati-
ve yield, which was 2.6 ± 1.0-fold (mean
± SD) greater than the yield of standard
SBM. 
Figure 4. Conversion rates of standard, on-slide,
and agarose-bead SBM, calculated as the
ratio of absolute copy numbers of bisul-
fite-modified Alu over total absolute copy
numbers of modified and unmodified
Alu . On-slide SBM at incubation set-
tings of 60°C for 8 hours had similar
conversion rate as standard SBM. 
cause false-positive or false-negative results by MSP. Methylation status of the CpG island
in the p16 and RASSF1a gene promoter region was assessed to show the use of on-slide
SBM for assessment of intratumoral heterogeneity of epigenetic alterations. MSP results
from cancer and adenoma parts within the same tissue section were compared. Among the
16 evaluated pairs, 4 showed methylation of the p16 promoter in both the cancer and the
adenoma parts, and 3 showed methylation only in cancer part (Fig. 5C). These results show
that certain colorectal cancers arisen from adenoma acquire p16 promoter hypermethyla-
tion during malignant transformation, and others acquire it at an earlier stage. Methylation
of RASSF1a promoter was assessed for a total of 20 pairs of colorectal cancers and adeno-
mas. One sample showed methylation of RASSF1a promoter in both the cancer and the
adenoma parts, and two showed methylation only in cancer part among the 19 informati-
ve pairs. Specific involvement of RASSF1a in malignant transformation of certain colorec-
tal cancers was shown. On-slide SBM was proved to be a powerful tool for precise assess-
ments of gene methylation status, such as intratumoral heterogeneity. 
Optimization on Glass Slides
Because tissue sections did not adhere consistently enough to noncoated glass slides during
on-slide SBM treatment, we initially tested the adhesive-coated, positive-charged slides
(Superfrost Plus microscope slides, Fisher Scientific, Pittsburgh, PA) that are commonly
used for immunohistochemistry. However, long incubation periods at increased temperatu-
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Figure 5. Representative MSP results for promoter regions of ESR1 (A), TDG (B), and p16 (C) genes after
on-slide SBM of 16 pairs of cancer and adenoma tissues. For each MSP, 1-mm
2
tissue from 10-µm
FF-PEAT section was microdissected and 1 of 10 tissue lysate was used as a template. X axis, ampli-
con size; Y axis, relative amounts of the PCR amplicons. 
res in acidic or alkaline solutions sometimes caused tumor tissue sections to detach, and
experiments had to be repeated. Therefore, we tested silane coated slides (Tekdon, Inc.,
Myakka City, FL) to improve the robustness of the protocol on 20 colorectal cancer tissue
samples. Consequently, none of the tissue sections detached during the on-slide SBM pro-
cess. The yield of modified DNA and conversion rate was equivalent to the other kinds of
glass slides (data not shown). Because of the improvement of robustness of the protocol,
we advocate use of silane coated slides for on-slide SBM.
Discussion
As shown by our results, we were able to study malignant tumor progression by assessing
intratumoral heterogeneity in silencing by hypermethylation using a single section of FF-
PEAT. On-slide SBM technique is widely applicable because FF-PEAT is the most abundant
tissue source for cancer-related studies or any other disease-related studies. The use of on-
slide SBM could greatly enhance our knowledge of the relation between histopathologic
observations and epigenetic events. To date, to study such phenomena in vivo has been dif-
ficult because of technical limitations of conventional SBM methods. By simply applying
the SBM step in situ previous to DNA isolation from the cells of interest, we were able to
obtain sufficient amounts of DNA to do PCR analyses. Consequently, we could provide evi-
dence that epigenetic changes of p16 and RASSF1a might be involved in a multistep man-
ner in the progression of the adenomas to colorectal cancers similar to the structural DNA
changes21. 
The success of methylation analysis depends on yield of modified DNA and complete-
ness of conversion. When the yield of modified DNA is low, it becomes difficult to detect
the methylation status of small amounts of tissue. If the conversion rate is low, false-positi-
ve results for methylation can be observed in unmethylated DNA by PCR-based nonquan-
titative methods because of misgenerated DNA coincidentally having the similar sequence
of methylated DNA. Our results showed that TDG, which was unmethylated by standard
SBM in a pilot study using 26 colorectal cancer tissues and six colorectal cancer cell lines,
was unmethylated by on-slide SBM in all 16 pairs of cancer and adenoma tissues. In addi-
tion, ESR1, which is reportedly methylated in all colorectal cancers22, was methylated by
on-slide SBM in all 16 pairs. Therefore, on-slide SBM is accurate enough for highly-sensiti-
ve methods, such as MSP, and does not cause false-negative or false-positive results. After
incubation at 60°C for 8 hours, the conversion rate of on-slide SBM was similar to that of
standard SBM. Furthermore, the yield was greater than that of agarose-bead SBM, which
is commonly used for specimens containing minimal DNA, such as microdissected FF-PEAT
tissue or blood serum. 
We did not pretreat the tissue samples with a digestive enzyme, such as pepsin or pro-
teinase K, that elevates permeability of reaction solution routinely done in a previous MSP
in situ hybridization report19, because predigestion can damage the microscopic tissue
structure. Moreover, in our preliminary assessment, predigestion did not significantly inc-
rease the conversion rate or the yield of modified DNA (data not shown). Eliminating the
predigestion step maintains the microscopic morphology of the tissue during SBM and
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allows subsequent hematoxylin staining and microdissection. 
We initially planned to use a SBM direct sequencing technique to evaluate the conver-
sion rates between three SBM methods. Assessment of 282 bp of the p16 promoter region
of samples treated with the on-slide SBM protocol showed a complete, 100% conversion.
Therefore, doing sequencing on modified DNA of a limited number of samples to evaluate
the conversion rate was considered not fit to assess subtle differences among the three SBM
methods. In addition, our preliminary assessment of SBM DNA revealed that unmodified
cytosines are not randomly scattered but exist as clusters in the genome (data not shown)
probably because of regional protection from bisulfite, such as fixed double helix. Therefore,
we aimed to develop an assay to quantify bisulfite-modified and unmodified DNA using Alu-
qPCR for evaluation of yield and conversion rate of SBM DNA. This assay can be widely
used as a tool for preevaluation of quality of SBM DNA. In addition, it can be widely used
to standardize the amount of template SBM DNA in each reaction of methylation assess-
ment. Using this technique, we showed that on-slide SBM yielded 2.6 times more modi-
fied DNA than standard SBM. This is likely caused by loss of DNA in purification steps befo-
re and during the standard SBM. The high yield of on-slide SBM is a great advantage when
the target tissue is small. In addition, on-slide SBM allowed 282-bp bisulfite direct sequen-
cing from a very small amount of FF-PEAT, reflecting the high quality of modified DNA. 
Total reagent cost and labor cost for on-slide SBM were relatively low because it does
not require DNA purification. This is particularly advantageous when multiple areas of a
tissue section are assessed simultaneously because DNA modification is completed before
microdissection. Another advantage of on-slide SBM is consistency of modification conditi-
ons, such as incubation temperature, incubation duration, and concentration of bisulfite
within a slide. Therefore, on-slide SBM should be especially suitable for assessments of
intratumoral heterogeneity. 
In conclusion, tissue architecture was maintained during onslide SBM treatment with
8-hours of incubation at 60°C in 3 mol/L sodium bisulfite solution without predigestion.
Yield of modified DNA was 2.6-fold greater than that of standard SBM. Bisulfite direct
sequencing of a 282-bp amplicon was possible. Conversion rate was 97.1%, and no false-
positive or false-negative results in the subsequent MSP for ESR1 and TDG were observed.
Intratumoral heterogeneity of p16 and RASSF1a gene methylation representing pathologic
malignant transformation was shown. On-slide SBM should be applicable in most methy-
lation studies using FF-PEAT especially in assessments of intratumoral heterogeneity in solid
tumors. The approach provides a unique opportunity to assess retrospective archived pro-
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Abstract
To date, the epigenetic events involved in the progression of colorectal cancer (CRC) are
not well-described. To study, in detail, methylation during CRC development in high risk
adenomas, we developed an assay combining in situ (on-slide) sodium bisulfite modification
(SBM) of paraffin-embedded archival tissue (PEAT) sections with absolute quantitative
assessment of methylated alleles (AQAMA). We tested the performance of the assay to
detect methylation level differences between paired pre-malignant and malignant CRC sta-
ges. AQAMA assays were used to measure methylation levels at MINT (methylated in
tumor) loci 1, 2, 12, and 31. Assay performance was verified on cell line DNA and stan-
dard cDNA. On-slide SBM, allowing DNA methylation assessment of 1-2 mm2 of PEAT was
employed. Methylation levels of adenomatous and cancerous components within a single
tissue section in 72 CRC cancer patients were analyzed. AQAMA was verified to accurate-
ly assess CpG island methylation status in cell lines. The correlation between expected and
measured cDNA methylation levels was high for all four MINT AQAMA assays (R≥0.966,
P<0.0001). Total methylation levels at the 4 loci increased in 11% and decreased in 36%
of specimens comparing paired adenoma and cancer tissues (P<0.0001 by Kolmogorov-
Smirnov test). Single-PCR AQAMA provided accurate methylation level measurement.
Variable MINT locus methylation level changes occur during malignant progression of colo-
rectal adenoma. Combining AQAMA with on-slide SBM provides a sensitive assay that
allows detailed histology-oriented analysis of DNA methylation levels, and may give new,





Cytosine-5 of CpG dinucleotides is the unique target of methyl-group placement in mamm-
als1. CpG methylation is a heritable mechanism to assist in silencing of noncoding DNA in
mammals2. In cancer, dense methylation of a gene’s promoter region, or the region in the vici-
nity of the 5’ region of a gene’s open reading frame, can silence expression of genes involved
in cancer-related processes3-5. Tumor-specific DNA methylation events have been demonstra-
ted in a great variety of human cancers and can encompass both loss and gains in methylati-
on6. Currently, the clinical utility of detecting CpG methylation status in primary tumors for
the management of cancer patient treatment is being evaluated as a useful surrogate marker
for disease parameters. Some studies have successfully shown clinical correlates and/or prog-
nostic value7-9. Epigenetic changes may be important as signatures of tumor progression or
prognosis, and they may become potential therapeutic targets. Studying epigenetic changes
during malignant tumor development would provide valuable additive information on tumor
specificity and genesis of key methylation aberrancies.
Recently, studies in colorectal cancer (CRC) have shed new light on the macro- and
microscopic pathways involved in the transition from normal epithelium to adenomatous
polyps to invasive cancer10, 11. Novel subgroups of colorectal adenomas were identified, indi-
cating differential pathways of CRC development. On the molecular level, Vogelstein et al.12
reported specific genomic mutations associated with CRC carcinogenesis. On the epigenetic
level, it is known that aberrant DNA methylation is present at the earliest dysplastic stages,
as well as in malignant tumors13. How levels of methylation develop during CRC formation
remains uncertain. In general, the molecular events involved in CRC development and pro-
gression are still not clearly validated. To investigate this, CRC specimens harboring adeno-
matous cell components belonging to the precursor lesion would provide an attractive study
model. This direct comparison of the pre-malignant lesion with the associated cancer would
enable paired analysis of specific events during malignant progression. The adenomatous cells
analyzed would represent relevant, high risk cancer precursors, while most studies use ran-
domly selected colorectal adenomas with an unknown likelihood to develop into cancer. We
have previously described an approach that enables this direct comparison in CRC paraffin-
embedded archival tissue (PEAT) sections by employing in situ sodium bisulfite modification
(on-slide SBM) of the DNA14. Adding a quantitative method to evaluate PEAT sections would
allow accurate analysis of epigenetic events related to tumor histopathologic changes. To date,
such detailed studies have been challenging, as reported studies often fail to microscopically
confirm the selection of tumor cells for nucleic acid isolation. On-slide SBM enables DNA
methylation assessment of tissue areas of 1-2 mm2 in size with DNA yields 2.5 to 4 times hig-
her, and similar efficiency of SBM, compared to standard SBM protocols. Assessment of small
areas of tissue allows for more homogenous tumor sample DNA by reducing the risk of selec-
ting uninvolved tissue areas, such as bowel musculature or serosa, especially compared to
DNA isolated from whole tissue sections. Using on-slide SBM with absolute quantitative PCR
methods would, therefore, give a more reliable representation of methylation levels in speci-
fically defined small areas of tissue.
Advances in sequence detection technology have been made with the addition of
minor groove binder (MGB) molecules to Taqman® probes. MGB probes have been tested
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to be more sequence-specific than standard DNA probes, especially for single base pair mis-
matches at elevated PCR extension temperatures15, 16. Zeschnigk et al. 17 applied these
improved probe qualities to design a fully quantitative, real-time PCR assay for methylati-
on level measurement, QAMA (quantitative assessment of methylated alleles, figure 1).
This method was designed as a relative quantification containing a mathematical derivati-
on using the methylated and unmethylated fluorescent signal threshold value as input. In
this study, we used an absolute quantitative version of QAMA (AQAMA) with cDNA stan-
dard curves to provide better internal assay control. As methylation biomarkers, we selec-
ted four MINT (methylated in tumor) loci, CpG-rich regions1, 2, 12 and 31, as they have been
previously demonstrated to become methylated in a tumor-specific and, recently, in a ade-
noma-specific manner in CRC18. We demonstrated the accuracy of methylation level assess-
ment of AQAMA alone in evaluating the combination of AQAMA and on-slide SBM to
detect changes in methylation levels between paired pre-malignant and malignant CRC cells.
Materials and Methods
Cancer cell lines and patient specimens 
For assay validation, DNA was isolated from 8 cancer cell lines obtained from the American
Type Culture Collection (ATCC, Manassas, VA); gastric cancer (AGS, SNU-1 and KATO-III),
CRC (SW480, SW620, DLD-1, HT-29, Colo320DM and LoVo). All cell lines were cultu-
red and maintained according to the ATCC recommendations. Additionally, we obtained
DNA from 2 gastric cancer cell lines (RL-0380 and FN-0028) from the John Wayne Cancer
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Figure 1. Schematic representation of the AQAMA assay. A universal primer set amplifies a target sequen-
ce. A. A methylation-specific probe with FAM-labeled reporter, BHQ, and MGB molecule recogni-
zes sample DNA showing hypermethylation. B. An unmethylated-specific probe with VIC-labeled
reporter, BHQ, and MGB molecule recognizes unmethylated sample DNA. 
Institute (JWCI) cell line bank. Seventy-two CRC PEAT blocks were obtained from the sur-
gical pathology department of Saint John’s Health Center (SJHC). All human specimens
were collected under research protocols reviewed and approved by the combined institu-
tional review board of SJHC/JWCI. 
DNA preparation, quantitation and SBM
Genomic DNA from cell lines was isolated as previously described32 with DNAzol
(Molecular Research Center, Cincinnati, OH), and quantified and assessed for purity with
UV-spectrophotometry. DNA from PEAT was modified according to our previously publis-
hed protocol14. Briefly, from each tissue block, a single 4µm section was cut and stained by
hematoxylin and eosin (HE). Seven  µm PEAT sections were cut consecutively and moun-
ted on adhesive silane-coated slides for DNA studies. Adenomatous and cancer tissue com-
ponents were identified and marked on the HE stained section by an expert surgical patho-
logist (R.R.T.). Sections for DNA studies were deparaffinized, soaked in 0.2 M NaOH for
15 min at room temperature, incubated for 8 hr in sodium bisulfite solution at 60°C, rin-
sed twice with H2O, soaked in 0.3 M NaOH for 10 min, and desalted in ddH2O for 2 hr
at 60°C. Subsequently, sections were lightly stained with hematoxylin and specific tissue
areas were carefully isolated by manual dissection under an inverted light microscope. The
isolated tissue was digested in 30 µl lysis buffer containing proteinase K and tween-20 at
50°C for 16 hr. The proteinase K enzyme was than denatured at 95°C for 15 min and the
lysate was stored at -30°C. For cell line DNA, SBM was performed on 1 µg of DNA as des-
cribed previously (33). 
AQAMA assay design
Four sets of PCR primers and probes were designed for SBM converted sequences. For a
single marker, the assay contains four oligonucleotides. One forward (5’) and one reverse
(3’) primer will amplify the target sequence independent from the markers methylation sta-
tus, as they do not anneal to any CpG’s. The methylation status is assessed by two minor
groove binder (MGB)-molecule containing probes (Applied Biosystems, Foster City, CA),
one methylation-specific and one unmethylated-specific. Forward and reverse primer sets
were designed using Primer 3 software (online at http://frodo.wi.mit.edu/cgi-bin/pri-
mer3/primer3_www.cgi). The MGB probes were designed with Primer Express software
(version 2.0, Applied Biosystems) with the MGB probe test document according to the
recommendations. Probe length was as short as possible (≥13bp’s) while keeping the anne-
aling temperature and GC-percentage of both the methylated and unmethylated probe as
similar as possible. Methylated probes were FAM(6-carboxyfluorescein)-labeled, and unme-
thylated probes were VICtm-labelled for optimal discrimination of the two fluorescent sig-
nals by the detection system. Black hole quenchers (BHQ) were used to silence the probe
fluorescent signal when not hybridized. Selected markers were “methylated in tumor” loci
MINT1, 2, 12 and 31. The 5’ primer, 3’ primer, methylation-specific probe and unmethy-
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TTT- MGB-BHQ, VIC-5’-TTTTTTTGTTGAATTTTAG-MGB-BHQ), MINT12(GGGTTTTAG-
TTTTGAGGATTAGG, CAAAACCATATCTAAATCACTAACCTT, FAM-5’-AACGACCG-




One  µl of modified DNA from cell lines or 1 µl of digested tumor tissue DNA was ampli-
fied in a total volume of 10 µl on a 384-well plate using fluorescence-based, real-time PCR
with the ABI prism 7900HT Sequence Detection System (Applied Biosystems) and SDS
software version 2.2.2. The reaction mixture for each AQAMA PCR consisted of DNA tem-
plate, 0.4  µM each of forward primer and reverse primer, 1.4 U of iTaq DNA polymerase
(Bio-Rad Laboratories, Hercules, CA), 350  µM of each dNTP, and 0.025 pmol of each
MGB-probe with 5 mM Mg2+. The master mix contained ROX(6-carboxy-X- rhodamine)-
dye for passive reference fluorescence. Samples were amplified with a pre-cycling hold at
95°C for 10 min to heat-activate DNA polymerase, followed by 40 cycles of denaturation
at 95°C for 15 sec, and annealing and extension at 60°C for 1 min for all MINT loci. The
final value of data analysis is expressed as a sample’s methylation index [MI = methylated
copy number / (methylated copy number + unmethylated copy number)]. Sample DNA
was added to each reaction plate as controls for specificity of the methylation-specific (AGS
and Raji DNA) and unmethylated-specific probe (RL-0380, FN-0028 DNA and donor PBL
DNA). PCR and bisulfite reagent controls for non-specific amplification are also included in
each plate. Equal PCR efficiency of the methylated and unmethylated reactions was con-
trolled by a duplicated sample that contained equal amounts of methylated and unmethy-
lated cDNA standard. 
AQAMA DNA standard construction
The standard curve for quantifying methylated and unmethylated copy numbers was esta-
blished by amplifying five-aliquot duplicates of templates with known copy numbers (105
to 101 copies). To obtain high-quality, homogeneous, and consistent DNA standards, we
synthesized DNA constructs as follows. We selected cell lines that were confirmed by MSP
or bisulfite sequencing to be methylated or unmethylated at the target MINT locus. Regular
PCR with only the AQAMA forward and reverse primer on the selected cell line DNA as a
template was performed in a 50 µl reaction volume for 35 cycles, and the product was run
on a 2% agarose gel. Specific amplification was confirmed by visualization of a single band.
The band was cut out and DNA was extracted using the QIAquick gel extraction method
(Qiagen, Valencia, CA) according to the manufacturer’s instructions. The completely
methylated and unmethylated PCR product was ligated into a pCR 2.1-TOPO cloning vec-
tor (Invitrogen, San Diego, CA), the clones were transformed into Escherichia coli DH5- 
cells, and cultures were expanded as described previously34. Plasmids containing the tar-
get gene were purified and quantified by UV-spectophotometry. 
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MINT locus CpG methylation status confirmation
To assess, non-quantitatively, the CpG methylation status of the MINT loci we employed
CAE-MSP as described7, 35. The MINT locus methylation-specific forward (MF), methylati-
on-specific reverse (MR), unmethylated -specific forward (UF) and unmethylated-specific
reverse (UR), primers are listed here, respectively; 
MINT1, 5’-TTGTTAGCGTTTGTATTTTTTACGT-‘3 (MF), 5’-AATTACCTCGATAACTTATT-
TA CTACGAT-‘3 (MR), 5’-AGGTTTTTTGTTAGTGTTTGTATTTTTTAT-‘3 (UF) and 5’-AA
AATTACCTCAATAACTTATTTACTACAA-‘3 (UR); 
MINT2, 5’-CGTCGAATTTTAGTA TTTAAGTTCGT-‘3 (MF), 5’-AATAATAACGAC-
GATTCCGTACG-‘3 (MR), 5’-TTTTGTTGAATTTTAGTATTTAAGTTTGT-‘3 (UF) and 5’-
AATAATAACAACAATTCCATACACC-‘3 (UR); 
MINT12, 5’-GTTTTTTCGTAGATTGTGTTTGC- ‘3 (MF), 5’-CGTTTTATTTAATTTAA-
AATCCGAA-‘3 (MR), 5’-GGTTTTTTTGTAGATTGTGTTTGTG-‘3 (UF) and 5’-AAAAC-
ATTTTATTTAATTTAAAATCCAA A-‘3;
MINT31, 5’-ATATAATTTTGTGTATGGATTCGGC-‘3 (MF), 5’-AATTAAAATCGTCT-
CAATTCCCG-‘3 (MR), 5’-ATAA TTTTGTGTATGGATTTGGTGA-‘3 (UF) and 5’-TTAAAAT-
CATCTCAATTCCCACC-‘3 (UR). Primers were dye-labeled with different labels for methy-
lation- and unmethylated-specific sets so that PCR products of the predicted base-pair size
could be detected by the CEQ 8000XL capillary array electrophoresis (CAE) system
(Beckman Coulter, Inc., Fullerton, CA) with CEQ 8000 software version 6.0 (Beckman
Coulter). A methylation index was calculated from the detected PCR product signal inten-
sities at the predicted base-pairs size as [MI = signal intensity methylated PCR product /
(signal intensity methylated PCR product + signal intensity unmethylated PCR product)].
Methylation status of the samples was assigned unmethylated (U) if MI<0.1, mixed (M/U)
if 0.1<MI<0.9 or methylated (M) if MI>0.9.  
Additionally, bisulfite sequencing was also performed to further confirm, non-quantita-
tively, methylation of the AQAMA target sequences for MINT2 and MINT12, as described
previously7, 36. Briefly, the sequencing primer sets were designed to flank the region ampli-
fied by the AQAMA assay. When it was not possible to design flanking primer sets, either
the forward or the reverse AQAMA assay primer was used. The primer sets used for sequen-
cing were: MINT2, 5’-TTTTAGTTTTAGTAGTTGTTTTTAATGGAA -3’ (forward) and 5’-
TCAACACTTTAACAAAATCCAAAATC-3’ (reverse), MINT12, 5’- GGGTTTTAGTTTT-
GAGGATTAGG-3’ (forward) and 5’-CAAAACCATATCTAAATCCTAACCTT-3’ (reverse).
The amplified PCR product was run on a 2% agarose gel and the single band was confir-
med and cut out. DNA was purified from the gel and sequenced with the dye terminator
cycle sequencing (DTCS) quick start kit (Beckman Coulter) according to the manufactu-
rer’s instructions. Sequencing fragments were analyzed by CAE (Beckman Coulter) and
analyzed by the instrument software. 
Statistical Analyses
AQAMA assay performance was tested by comparing the linearity of input and measured
MI by Pearson’s correlation coefficient. We evaluated whether AQAMA can identify mar-
ked differences between methylation levels of MINT loci in paired CRC adenoma and can-
cer cells diverging from normal variance. We calculated Kurtosis of the data distribution. A
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positive (>0) Kurtosis denotes that fewer observations cluster near the average and more
observations populate the extremes either far above or far below the average compared to
the bell curve shape of the normal distribution. To identify outlier values of the measured
methylation differences, we performed the Kolmogorov-Smirnov test (KS test). The one-
sample KS test compares the empirical distribution function with the cumulative distribu-
tion function specified by the null hypothesis (a normal distribution). A significant P-value
here indicates that the tested data-set does not adhere to the null hypothesis. Positive and
negative extreme differences at which the tested data-set exceeds the normal distribution
were calculated.
Results
AQAMA Specificity and Performance
First we evaluated, non-quantitatively, the CpG island methylation status of the MINT loci
selected for this study in cancer cell lines. To this end we performed capillary array electro-
phoresis methylation specific PCR (CAE-MSP) to assess the CpG island methylation status
for all 4 selected MINT loci in 5 colorectal and 5 gastric cancer cell lines. These results
(table 1) were used to identify cell lines that were fully methylated or unmethylated and
therefore suitable as template for cloning into vectors, cultured and expanded to be used
as template for the AQAMA standards. Before doing so, we further corroborated the methy-
lation status of the CpG islands of two of the MINT loci2 (MINT2 and MINT12) in two of
the cell lines used for cloning (AGS and FN-0028) by direct bisulfite sequencing. Sequencing
confirmed the methylation status as reported by CAE-MSP (see figure 2a-c for the sequen-
cing and CAE-MSP results for the MINT12 locus). To gauge the accuracy of AQAMA in
assessing various levels of methylation, mixtures of methylated and unmethylated standard
cDNA, synthesized from template of which the methylation status was confirmed by at
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Cell line MINT1 MINT2 MINT12 MINT31
AQAMA CAE-MSP AQAMA CAE-MSP AQAMA CAE-MSP AQAMA CAE-MSP
SW480 0.49 M/U 0.47 M/U 0.51 M/U 0.46 M/U
SW620 0.51 M/U 0.53 M/U 0.49 M/U 0.45 M/U
DLD-1 0.49 M/U 1 M 0.48 M/U 0.44 M/U
HT-29 0.50 M/U 1 M 0.48 M/U 0.47 M/U
LoVo 0 U 0.51 M/U 0.50 M/U 0.47 M/U
AGS 0.54 M/U 1 M 1 M 1 M
KATO-III 0.53 M/U 0.49 M/U 1 M 0.48 M/U
SNU-1 0.49 M/U 0.50 M/U 0 U 1 M 
RL-0380 0 U 0 U 0 U 0 U
FN-0028 0 U 0 U 0 U 0 U
TABLE 1. Comparison of MI Assessment by AQAMA and CAE-MSP in Cell Lines
least one technique, were prepared and measured as unknown samples. The mixtures were
prepared from the methylated and unmethylated diluted 1x103 copy number DNA stan-
dard. The AQAMA assay performance for all four MINT loci was assessed. In figure 3, the
results of two representative independent experiments for each MINT locus assay are
shown. Pearson’s correlation coefficient for linearity of the methylation percentage of the
known mixture with the AQAMA assay outcome MI-value was not lower than 0.966
(P<0.001). SD of all measured MI levels between the two independent experiments did
not exceed 0.08 for the four MINT locus assays. We subsequently quantitatively assessed
the ten cell lines analyzed with CAE-MSP by AQAMA. The results showed that there was
100% agreement between the methylation categories of CAE-MSP and the quantitative
result of AQAMA (table 1). The AQAMA result could be compared with the results from
the direct bisulfite sequencing and here was good agreement as well. Strikingly, the quanti-
tative results of the cell lines returned by the AQAMA assay appeared to be categorical. Of
the 40 datapoints, 10 were MI=0, 7 were MI=1 and 23 had 0.44<MI<0.54 with an aver-
age MI of 0.49. These results suggest that methylation of MINT loci in the studied cell lines
is homogenous. An explanation for this observation is that MINT locus methylation occurs
at a single or both alleles in cell lines.
CRC tumor-adenoma methylation level differences 
To demonstrate the value of assessing primary CRC tissue methylation levels by AQAMA,
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Figure 2. Methylation assessment results for MINT12. Representative direct bisulfite sequencing (forward
direction) for FN-0028 (A) and AGS (B). Arrows, CpG sites. Boxed site, hemi-methylation. C.
Representative results of CAE detection of labeled (left, methylated; right, unmethylated) products
after MSP for FN-0028 and AGS, respectively.
we investigated application of the technique and its utility when combined with on-slide
SBM. We tested whether the AQAMA assay has the ability to detect differences in methy-
lation levels between pre-malignant and malignant CRC stages. A schematic overview of
combining AQAMA with on-slide SBM is given in figure 4. Seventy-two cases were selec-
ted based on review of histopathology indicating that, along with invasive cancer cells, the
specimen also had an area of tissue containing the precursor adenomatous lesion. Each sam-
ple was measured in triplicate and the SDs were 0.04, 0.04, 0.05, and 0.06 for MINT1,
MINT2, MINT12, and MINT31, respectively. The boxplots of the measured MI values in
adenoma and cancer tissue (figure 5) clearly show that the MI values are not normally dis-
tributed and that samples showing methylation are outliers The experiments testing the
linearity of AQAMA’s quantitative qualities showed that AQAMA is able to reliably discri-
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Figure 3. A to D. Graphs representing the correlation between result of two independently assessed
AQAMA assay MI levels (Y -axis) and input DNA methylation percentage (X-axis). c and s, results
of the two experiments. u, expected MI. 
minate a minimum difference of 5% from MI=0 or amongst samples. An MI≥0.05 was
detected in 12% versus 11% (MINT1), 35% versus 29% (MINT2), 22% versus 22%
(MINT12), and 22% versus 15% (MINT31) in adenoma versus cancer cells, respectively,
and none of the proportions differed significantly. It suggests that CRCs with methylation
at the MINT loci form subgroups as the majority of CRCs is unmethylated. The total num-
ber of MINT loci with MI≥0.05 per sample did not differ significantly either between ade-
nomas and cancer samples (P=0.27). No significant differences in MI value were present
between adenomas and cancers with MI≥0.05 for individual MINT loci. We also analyzed
if MI levels differed significantly when methylation at all MINT loci was added up. For this
analysis we first included all samples and subsequently only samples with MI≥0.2 as
AQAMA was tested to discriminate 5% difference from zero at a single locus and subse-
quently 20% from zero at 4 loci. No significant overall event of gain or loss of methylation
could be demonstrated in both analyses (P=0.11 for all samples, P=0.20 for samples with
MI≥0.20) at the combined MINT loci between pre-malignant and malignant CRC lesions.
Likely, this is due to the fact that increases as well as decreases in methylation were mea-
sured as becomes clear from Figure 5 that shows the measured change in MI level between
the 72 adenoma-cancer pairs. Therefore, we also analyzed the distributions of the measu-
red MI changes at individual and at the four combined loci to see whether substantial inc-
reases or decreases were measured by AQAMA. Kurtosis is based on the size of a distribu-
tion tail. Distributions with relatively large tails are referred to as "leptokurtic" and a
distribution with the same kurtosis as the normal distribution is referred to as "mesokurtic"
(Figure 6). Kurtosis of the data distributions of the methylation level differences between
adenoma and tumor cells was high except for MINT2 (table 2). However, this was still
greater than zero and therefore leptokurtic. This suggests that methylation levels in some
CRCs change considerably at individual MINT loci and that a global event at multiple loci
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Figure 4. Schematic representation of histology-oriented tissue isolation followed by AQAMA. Left, AQAMA
PCR plot. The adenomatous tissue component (bottom marked area) shows only unmethylated
fluorescent signal (triplicate results), whereas the cancerous component (top marked area) shows
both unmethylated and methylated fluorescent signal. Both signals are visualized here; however,
in the raw data analysis, the CT is analyzed separately. 
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Figure 5. A. Boxplots showing the distribution of the measured MI values for each individual MINT locus in
adenoma and cancer tissue. B. Scatter plot of the measured MI changes detected by the AQAMA
assay between adenoma and cancer tissue areas in the same colorectal cancer tissue section for
all individual MINT loci. Y -axis, change in MI level calculated as MIcancer -MIadenoma.
A
B
may occur. To identify how many tumors increase or decrease their methylation, we per-
formed one-sample Kolmogorov-Smirnov (KS) analysis on the data distribution of individu-
al MINT loci and overall MINT methylation (table 2). The strong significance in KS ana-
lysis for individual and total MINT loci shows a clear deviation from the null-hypothesis
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Figure 6. Explanatory representation of leptokurtic and mesokurtic distribution. Vertical bars, cutoff value
calculated by Kolmogorov-Smirnov analysis to identify extreme differences between assumed
mesokurtic and measured leptokurtic distributions. 
Marker Outlier values* 
Kurtosis Median SD Negative Positive P 
MINT1 11.2 -0.006 0.13 -0.36 0.34 <0.001
MINT2 1.9 -0.03 0.16 -0.27 0.24 <0.001 
MINT12 17.5 -0.01 0.14 -0.25 0.34 <0.001 
MINT31 18.5 -0.001 0.17 -0.25 0.35 <0.001 
Total methylation level difference at four MINT loci 15.4 -0.02 0.46 -0.12 0.27 <0.001
TABLE 2. Distribution Characteristics of Individual MINT Locus MI Differences between Paired
ColorectalCarcinoma Adenoma and Cancer Cells 
*Kolmogorov-Smirnov analysis was used to calculate extreme outlier values of the largest positive and negative
points of divergence from the tested normal distribution. 
(normal distribution), implying that the found positive and negative outlier values do not
result from variance by chance. The KS test can calculate the most extreme differences as
the largest positive and negative points of divergence between the tested dataset and nor-
mal distribution. For total methylation, twenty-six (36%) cases were identified with a dec-
rease in methylation (MI difference <0.12), and 8 (11%) cases were identified with increa-
ses (MI difference >0.27). Fifty-three percent of cases had change in methylation levels that
did not exceed the tested normal distribution (figure 7).
Currently, there is no established technique to adequately confirm the measured diffe-
rences in MI value between the small areas of paraffin tissue by AQAMA. It has been con-
sistently reported that CRCs with increased methylation are found in the right colon 21-23.
As an external validation, we therefore analyzed whether the positive MI change category
identified by the KS-analysis correlated to the location of the tumors in the large bowel
(table 3). Tumor location did significantly correlate to MI change category (P=0.03).
Seven of the eight identified cases with an increase in MI were in the right colon. The sin-
gle positive MI change case that was identified in the rectum was from a 48 year old fema-
le with an undifferentiated tumor. Cases with extreme negative MI change were equally
distributed over the right and left colon. Sixty-four percent of cases with no change were
in the left colon. Additionally we analyzed whether the MI change categories were corre-
lated to age, sex, or tumor differentiation. No associations were seen between the assigned
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Figure 7. Di st r i but i on of val ues of summed up MINT methylation level differences (Y -axis) between
adenoma and cancer tissue from the same patient at MINT1, MINT2, MINT12, and MINT31
assessed by AQAMA. X -axis, different cases (dimensionless). Horizontal reference lines, cutoff
values as calculated by Kolmogorov-Smirnov analysis from Table 3. Vertical bars, dividing lines 
grouping into cases with extreme positive methylation differences, no differences, and extreme
negative differences. 
MI change categories and these parameters.
The results indicate that AQAMA can identify CRCs with gains and losses of DNA
methylation levels at individual and combined multiple MINT loci between adenomatous
dysplastic epithelial cells and invasively growing adenocarcinoma cells. MINT loci 1, 2, 12,
and 31 were originally identified to be methylated in CRC and not in normal colorectal epi-
thelial cells. Our study analyzed adenomatous components of existing CRCs with common
histopathology, and therefore focuses on sporadic pre-malignant lesions that will develop
into cancer. This novel approach quantitatively shows that divergent MINT methylation
changes accompany the malignant turning point of CRC subsets. 
Discussion
Hypermethylation of CpG islands is an early event in the development of CRC24-26. Better
identification of methylation changes when adenomatous epithelial cells manifest invasive
growth could greatly enhance our knowledge of the malignant turning point. To date, the
assessment of confined areas with specific histopathology in PEAT specimens by PCR tech-
niques for methylation status has not been efficient. Relatively large amounts of DNA are
required to compensate for the inevitable loss of DNA during the standard protocol for
SBM. We have previously employed a model of comparing, by MSP, the methylation sta-
tus of CRC cells within the same tissue section showing invasion with cells from the ade-
nomatous precursor lesion14. In this study, we applied an informative, quantitative techni-
que, providing more detailed information about the methylation status than the
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Site* Kolmogorov-Smirnov analysis assigned categories 
Negative No change Positive Total 
outliers outliers 
Right colon 
Cecum 2 7 4 13 
Ascending colon 4 2 2 8 
Hepatic flexure 4 2 0 6 
Transverse colon 4 4 1 9 
Left colon 
Splenic flexure 0 0 0 0 
Descending colon 1 2 0 3 
Sigmoid colon 5 4 0 9 
Rectosigmoid 1 5 0 6 
Rectum 5 12 1 18 
Total 26 38 8 72 
TABLE 3. Association between MI Change Category and Tumor Location 
*Tumor location significantly associated with MI change category: P = 0.03 
(Kruskal-Wallis test). 
dichotomous results of MSP. The absolute quantitative aspect of AQAMA is well suitable
to be used in combination with on-slide SBM. The use of a standard curve from serial dilu-
tions of DNA construct allows precise assessment of copy numbers in the sample DNA over
a wide range of input concentrations. The original report of QAMA describes that input
DNA before sodium bisulfite treatment was standardized to 1 µg. The amount of input
DNA in the AQAMA assay isolated from 1-2 mm2 of tissue of a 7 µm section is difficult to
standardize. Therefore the control on the linearity of the PCR reaction that the standard
curve provides over a wide range of input concentrations complies well with on-slide SBM.
Also, standardization allows comparison of results amongst different PCR runs. We demon-
strated that levels of MINT locus methylation in CRCs can accumulate at multiple geno-
mic CpG island loci (predominantly in the right colon), but can also decrease during malig-
nant change in CRC. It is interesting to note that there seems to be no uniform event that
most CRCs undergo during malignant transformation for the methylation at MINT loci. In
addition, the data indicate that subgroups of CRCs may exist that can lose, stabilize or gain
methylation in the gene promoter region. Considering the silencing effect of methylation,
the divergent development of methylation patterns could lead to differential gene expres-
sion signatures proven to be clinically relevant in CRC27, 28.
The capacity of AQAMA to discern differences in methylation levels was excellent as
it was measured in a range of MI = 0.05 through MI=0.6 with increments of 0.1. However,
it was noted that the accuracy decreases at methylation levels containing a MI < 0.05.
Single reaction AQAMA, therefore, is likely to have less value in picking up the so-called
“needle in a hay stack” from a large population of normal cells, as in micrometastatic tumor
cells of CRC in lymph nodes. To use AQAMA for such purposes of detection, PCR reacti-
ons with methylated and unmethylated probes may be run separately. 
On-slide SBM reduces the risk of non-cancer cell contamination compared to DNA iso-
lated from whole PEAT sections, where normal colon tissue areas, such as muscle layers
and serosal layers, are usually present. Because the studied tissue area can be confined to
a specific 1-2 mm2 tumor sample, the DNA source is usually more homogeneous, resulting
in a more reliable representation of the amount of methylated alleles in the tumor. Another
important aspect in measurement of DNA methylation levels is that human error and inter-
assay variability is kept to a minimum. The control that the single reaction AQAMA assay
provides is that results can be analyzed directly without the need to compensate for the
variability of two or three separate PCR reactions with different settings and reaction kine-
tics29, 30. 
In summary, AQAMA is a very sensitive assay that can reliably detect 10% differences
in methylation between samples. It utilizes a real-time PCR technique with reported robust-
ness and reproducibility31. The single-reaction assay makes AQAMA suitable for the assess-
ment of large clinical sample sizes, as required in biomarker studies. The technique can be
applied to widely accessible PEAT specimens, and uses a minimal amount of tissue (one
single 7 µm section), making it suitable for retrospective analysis. We demonstrated that,
when combined with on-slide SBM, AQAMA forms a useful assay that can give new
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Background: Methylation levels of DNA repeats such as long interspersed nucleotide ele-
ments (LINE-1) are representative of global methylation status and play an important role
in maintenance of genomic stability. LINE-1 methylation is known to be disrupted in many
types of cancer. In this study we report on high detail analyses of LINE-1 methylation levels
at different stages of colorectal cancer (CRC) development and at different stage of CRC
disease.  
Material and Methods: Sample DNA was collected by laser-capture microdissection
(LCM) treated by a newly introduced protocol of on-cap (in situ) DNA sodium bisulfite
modification (SBM). LINE-1 hypomethylation index (LHI), a higher index indicates more
hypomethylation, was measured by absolute quantitative analysis of methylated alleles
(AQAMA). 
Results: LHI was significantly higher in adenoma tissue (n=25) compared to normal epi-
thelium (n=23, P=0.0003) and cancer mesenchymal tissue (n=22, P<0.0001). LHI did not
differ significantly between adenoma and cancer tissue (n=24, P=0.20). No significant dif-
ferences were found in LHI between normal epithelium from non-cancer (n=13), adeno-
ma (n=18) and cancer patients. Tumor heterogeneity was tested and LHI did not differ sig-
nificantly comparing cells collected from a tumor’s luminal side compared with cells from
the invasive margin. LHI increased with higher T-stage (P<0.04) and was significantly hig-
her in node-positive versus node-negative disease (P=0.03) and was significantly higher in
stage IV versus all other disease stages (P<0.05). 
Conclusion: By using quantitative LINE-1 analysis with on-cap SBM microdissection tech-
niques this is the first study to demonstrate hypomethylation of LINE-1 to increase with




LINE-1 stands for long interspersed nucleotide elements and constitutes about 17-18% of
the human genome. Roughly 500,000 truncated and 3000 to 5000 full length LINE-1s are
dispersed throughout the human genome1. LINE-1 sequences are moderately CpG rich and
most CpG’s locate in the 5’ region that can behave as a internal promoter2. In normal soma-
tic cells, LINE-1s are heavily methylated restricting activities of retrotransposal elements
and genomic instability2, 3. 
Numerous studies have been reported identifying colorectal cancer (CRC) cancer-asso-
ciated epigenetic aberrations such as promoter region hypermethylation of tumor suppres-
sor genes4. Another characteristic alteration in CRC regarding DNA methylation in cancer
is global hypomethylation5, 6. LINE-1 methylation status is thought to represent the geno-
me-wide DNA methylation status such as global hypomethylation, since LINE-1 sequences
are highly repeated and widely interspersed human retrotransposons. The role of global
DNA hypomethylation in cancer is unclear, although it may cause genomic instability and
correlates with tumor progression and invasiveness in several types of cancer including
colon cancer. Regarding colon cancer, Bariol et al. revealed that the global DNA methylati-
on level was higher in neoplastic lesions (including hyperplastic polyps and adenoma) than
in normal mucosa7. Ogino et al. suggests that LINE-1 hypomethylation status of colon can-
cer associates with poor prognosis8. The progression of LINE-1 hypomethylation level
according to the sequence of colorectal tumor disease stage remains unclear to date. 
Cancer tissue is highly heterogeneous and contains various cells, such as normal (i.e.
stromal cells and infiltrating lymphocytes) and malignant cells and their distribution differs
in each cancer patient. This heterogeneous nature of cancer tissue may confound molecular
analysis, especially in case of a molecular target such as LINE-1 methylation analysis, becau-
se unmethylated LINE-1 is non-cancer-specific. In this study we therefore utilize automated
laser–capture microdissection (LCM) to harvest the cells of interest directly without conta-
mination of non-cancer cells. A precise quantification method for analysis of methylation sta-
tus is further necessary to evaluate the degree of LINE-1 methylation. Absolute quantitative
assessment of methylated alleles (AQAMA) assays was used for this purpose in this study. As
previously demonstrated, the capacity of AQAMA to discern differences in methylation level
was excellent9. The single reaction AQAMA assay provides good control because results can
be analyzed without the need to compensate for the variability of two or three separate PCR
reactions with different setting and reaction kinetics. The approach allows accurate derived
analysis of histopathology microdissected cells from PE tissue sections. 
Sodium bisulfite modification (SBM) of genomic DNA is commonly used method to
discern methylation status of CpG islands10. Sodium bisulfite converts cytosines but not 5-
methylcytosines to uracil and the changes in sequence of the DNA after SBM can be ana-
lyzed by many kinds of methylation assays including AQAMA assay. Conventional SBM
results into 84% to 96% loss of sample DNA11. This significant loss of template DNA cau-
ses the necessity for a high volume of start material tissue samples and high number of
cycles for PCR. To reduce the loss of sample DNA from cell collected by LCM we develo-
ped on-cap SBM. On-cap SBM was designed to minimize DNA loss by eliminating DNA
purification steps. In the process of on-cap SBM, DNA is modified in-situ while the cells are
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still attached on the cap which is used for LCM. DNA is collected afterwards and proces-
sed for AQAMA. We have developed and optimized a protocol for on-cap SBM in this study
by which sufficient DNA conversion rates can be achieved and relatively low volumes of
tissue sample are needed for the subsequent AQAMA LINE-1 hypomethylation assay. 
LCM, on-cap SBM and AQAMA was combined and used in samples from patients with
adenomas containing invasive adenocarcinoma and patients with advanced colon cancer.
This allowed to analyze the development of LINE-1 hypomethylation levels during tumor
progression and differences of LINE-1 hypomethylation levels between node positive and
node negative colon cancer patients. Our results indicate that LINE-1 hypomethylation
occurs in the early stage of colorectal tumorigenesis such as adenoma and proceeds accor-
ding to the tumor stage such as depth of invasion and establishment of lymph node metas-
tasis.
Materials and Methods
Measurement of LINE1 hypomethylation
The methylation status of LINE1 was evaluated by absolute quantitative assessment of
methylation alleles (AQAMA) assay to make accurate assessment of CpG island methylati-
on levels9. Before performing the AQAMA assay of LINE1 methylation status, sodium bisul-
fite modification (SBM) was applied on each DNA sample as previously described12.
AQAMA requires one forward and one reverse primer which will amplify the target sequen-
ce independent from the methylation status, as those forward and reverse primer set does
not contain any CpG. The methylation status is assessed by two minor-groove-binding
(MGB) molecule containing probes (Applied Biosystems): one methylation specific and one
unmethylation specific. The 5’ primer, 3’ primer, methylation-specific probe and unmethy-
lation-specific probe are listed as follows: 5’-GGGTTTATTTTATTAGGGAGTGTTAGA-3’
(forward), 5’-TCACCCCTTTCTTTAACTCAAA-3’ (reverse), FAM-5’-TGCGCGAGTC-
GAAGT-3’-MGB-BHQ and VIC-5’-TGTGTGAGTTGAAGTAGGG-3’-MGB-BHQ. The reacti-
on mixture for each AQAMA PCR consisted of DNA template, 0.4 µmol/L of the forward
and reverse primer, 1.4 unit of iTaq DNA polymerase (Bio-Rad, Hercules, CA, USA), 350
µmol/L of each deoxynucleotide triphosphate and 0.025 pmol of each MGB probe with 5
mmol/L Mg2+. PCR amplification was performed with pre-cycle heat activation of DNA
polymerase at 95° C for 10 minutes, followed by 40 cycles of denaturation at 95° C for 15
seconds, annealing and extension at 60° C for 60 seconds. The absolute copy number in
each sample was determined using a standard curve established by amplifying six aliquot
duplicates of templates with known copy numbers (10*6 to 10*1 copies). All quantitative
PCR assays were performed in a blinded fashion without knowledge of specimen identity.
Mean values were calculated from triplicate reactions. LINE1 hypomethylation index (LHI)
of each sample was calculated as follows: LINE1 LHI = unmethylated copy number /
(methylated copy number + unmethylated copy number). 
On-cap SBM assay optimization
To measure LINE1 hypomethylation index after micro-dissection using LCM, we develo-
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ped the on-cap SBM procedure based on previously introduced on-slide SBM technique.
On-cap SBM was designed to analyze methylation status of genes in small amount of DNA
obtained from formalin fixed paraffin embedded archival tissue (FF-PEAT). On-cap SBM
aims to eliminate DNA isolation and purification steps that are performed before the actu-
al SBM in the classic procedure which is the main cause of DNA loss. On-cap SBM con-
tains three steps; denaturing of DNA, SBM and collection of modified DNA. First, the cells
micro-dissected from deparaffinized and rehydrated tissue sections that stick on the cap
used in LCM are incubated in 0.2 mol/L NaOH at room temperature for 15 min. Then the
samples on the cap are incubated in 3 mol/L sodium bisulfite solution with 0.5 mmol/L
hydroquinone (pH 5) in the dark. Three incubation setting were tested regarding the con-
version rates (the rate of modification of cytosine to uracil) and yields of modified DNA and
incubation setting of 60 degrees for 8 hours was chosen as optimal (see results section).
After incubation, samples on the cap were rinsed with distilled water, soaked in 0.3 mol/L
NaOH for 15 minutes to desulfonate the modified cytosines, and then desalted in distilled
water at 60°C for 2 hours. Finaly, 50 µL lysis buffer containing 4  µg proteinase K, 2.5%
Tween 20, 50 mmol/L Tris, and 1 mmol/L EDTA were added on the cap and incubated
at 50°C for 24 hours followed by heat deactivation of proteinase K at 95°C for 10 minu-
tes. In each subsequent AQAMA reaction, 1-2  µL lysate was used as a template without
DNA purification.
FF-PEAT colorectal tumor samples
FF-PEAT samples of colorectal cancers were obtained from patients who underwent colec-
tomy or proctectomy between 1995 and 1998 at Saint John's Health Center (Santa Monica,
CA) and consented for research use of their tissue specimens according to the guidelines
of Saint John's Health Center/John Wayne Cancer Institute's (Santa Monica, CA) review
board. All tissue specimens had been fixed in 10% buffered formalin for 24 hours and paraf-
fin embedded. For LCM followed by on-cap SBM and LINE1 methylation analysis by
AQAMA, sections (4  µm) were cut with a microtome from each FF-PEAT block.
To assess the differences of LINE-1 methylation status between normal mucosa, ade-
noma, cancer and cancer mesenchymal connective tissue, 25 samples of early CRC in ade-
noma were selected by a pathologist specialized in colorectal cancer that contained all of
these four tissue categories. To study malignant alteration, 92 surgically resected specimen
CRC were collected to investigate the alteration of LINE1 methylation status in accordance
with cancer progression. The correlation between clinico-pathological stage such as T stage,
nodal status and dukes stage and LINE-1 methylation index were analyzed.        . 
Statitical analysis
All data are expressed as mean+/-S.D., and percentages as appropriate. Mean value of LHI
between two groups such as adenoma and early cancer, node negative and node positive
were compared using Student’s t-test. All statistical analysis including receiver operating
characteristic (ROC) curve analysis were performed using JMP 8 (SAS Institute, Cary, NC)
and a P-value less than 0.05 (two-sided) was considered significant.
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Results
AQAMA linearity for LINE-1 methylation level assessment
First, we evaluated the accuracy of AQAMA in assessing various levels of LINE-1 methyla-
tion. For this study we prepared stepwise mixtures of the methylated and unmethylated
cDNA standard and measured them as samples with unknown methylation level. The line-
arity of AQAMA assay for LINE-1 methylation level (figure 1) was evaluated by Pearson’s
coefficient of linearity: 0.9897 (P<0.001). This results shows that the AQAMA LINE-1
assay can discern 10% methylation level differences adequately. 
Optimization of on-cap SBM settings
Automated LCM was performed to harvest cells of interest (figure 2a) to establish how
many cells are needed for successful AQAMA measurements. Three different sample volu-
mes from tissue areas of 104, 105 and 106 µm2 harvested from 7µm thickness formalin fixed
paraffin embedded archived tissue (FF-PEAT) were tested. AQAMA measures copy num-
bers and we established that 2x105µm2 of 7µm thickness FF-PEAT results in about 1x105
copy numbers of modified LINE-1 DNA and this provides clearly detectable fluorescent
probe amplification signals for the LINE-1 methylation assay. After LCM, on-cap SBM was
optimized in a similar manner as was performed in the reported studies introducing on-
slide SBM13. The conversion rate and yield were evaluated using eight tissue samples by
assessing the copy number of modified and unmodified ALU repeat sequences, as previou-
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Figure 1. Graph showing linearity of the AQAMA LINE-1 methylation assay to measure 10% differences in
sample hypomethylation levels.
sly published13. The conversion rates of modified DNA by on-cap SBM were 18.4±14.9%,
87.8±7.8% and 94.4±2.1% at incubation setting of 60º C for 2, 4 and 8 hrs, respectively
(figure 2b). The conversion rates increased with increasing duration of incubation and
after 8 hours it reached about 95%. The yield of total DNA (modified and unmodified DNA)
did not decrease with increasing incubation time up to 8 (figure 2c). From these results,
incubation setting of 60 for 8 hrs was chosen as optimal for on-cap SBM.
LINE-1 hypomethylation levels in colorectal tumor progression and cancer 
mesenchyme.
We have selected 25 patients with colorectal cancer in adenoma. Using LCM, four diffe-
rent tissue samples (normal mucosa, adenoma, cancer and cancer mesenchymal tissue)
were collected from each patient. On-cap SBM and LINE-1 AQAMA assay was performed
on each sample. Level of LINE-1 hypomethylation (LHI) were calculated as Qunmeth /
(Qunmeth + Qmeth), where Qunmeth and Qmeth are the absolute copy numbers of unmethyla-
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Figure 2. Representations of LCM combined with on-cap SBM optimization studies. In A, showing specific pick-
up of target cells by automated LCM. In B and C, showing results for DNA conversion rate (%) and for DNA
content (x10
4
copy numbers), respectively, in 8 different samples at 3 different incubation periods. 
Sample CR; 2hour CR; 4hour CR; 8hour
1 0,045 0,704 0,944
2 0,371 0,953 0,963
3 0,144 0,856 0,954
4 0,060 0,909 0,908
5 0,226 0,931 0,955
6 0,442 0,845 0,946
7 0,092 0,914 0,915
8 0,092 0,910 0,965
Average CR 0,184 0,878 0,944
On Cap SBM optimization; conversion ratio (CR)
Sample 2hour 4hour 8hour
1 24,87 34,29 32,40
2 21,60 39,87 27,74
3 19,55 25,54 28,97
4 22,88 24,98 23,65
5 18,17 29,07 34,85
6 21,14 31,58 28,25
7 22,47 21,96 26,10
8 28,66 24,41 48,92
Average CN 22,42 28,96 31,36
On Cap SBM optimization; yield of converted DNA copy
number (CN*104)
ted and methylated LINE-1, respectively. In normal mucosa adjacent to tumor lesions and
cancer mesenchyme, the average LHI was 0.382 and 0.366, respectively. There was no dif-
ference of LHI between cancer mesenchyme and normal mucosa adjacent to tumor. LHI
was significantly higher in adenoma part and cancer part than in normal mucosa (mean
LHI=0.486, 0.523 and 0.382, respectively) (figure 3). From this we concluded that LINE-
1 hypomethylation occurs in the early period of colorectal tumorigenesis. Further, these
experiments demonstrated the necessity of using detailed procedures for sample DNA col-
lection when analyzing LINE-1 methylation as methylation levels of cancer mesenchyme
varied widely and are therefore likely to influence results when LCM is not used.     
LINE-1 hypomethylation tissue heterogeneity
To test whether there is heterogeneity of LINE-1 hypomethylation within a tumor, twenty
T3N0 tumors were selected. Sample DNA was collected from the luminal surface and the
deepest invasional site of each tumor. LHI of those two loci were compared (figure 4). The
mean LHI was 0.58 in the surface and 0.54 in the deepest loci, respectively. LHIs were
similar in the surface and in the deepest loci and tumor heterogeneity of LINE-1 hypome-
thylation could not be observed. 
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Figure 3. LHI assessment in normal large bowel epithelium, adenomatous cells, cancer cells and CRC
mesenchymal cells.
LINE-1 hypomethylation and CRC stage 
To assess the alteration of LINE-1 hypomethylation level according to tumor progression,
the correlation between Dukes stage and LHI was analyzed. Duke A samples (n=38),
Dukes B (n=18) and Dukes C (n=29) samples were selected (figure 5a). The mean LHI in
Dukes A, B and C was 0.533, 0.607 and 0.621, respectively. Dukes B and C tumors show-
ed significantly higher levels of LINE-1 hypomethylation than Dukes A tumors. T1 (n=24),
T2 (n=21), T3 (n=21) and T4 (n=26) cases were assessed, in which 35 positive lymph node
cases were included. The increase of the LINE-1 hypomethylation level according to tumor
invasion (figure 5b) and the difference of LINE-1 hypomethylation between lymph node
positive and negative cases were assessed (figure 5c). The mean LHI of T1, T2, T3 and T4
was 0.50, 0.58, 0.60 and 0.65, respectively. Cases with positive lymph nodes showed sig-
nificantly (P=0.03) more LINE-1 hypomethylation (LHI=0.64)  than cases with negative
lymph nodes (LHI=0.54). T stage advancement correlated significantly with increasing LHI
(p=0.01). LINE-1 hypomethylation levels differed significantly between node positive and
node negative cancers and the AUC was 0.69 to predict node positive cancer from whole
samples according to ROC curve analysis (figure 5d).     
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Figure 4. Measured LHI values in T3N0 CRC tumors comparing cells obtained from the surface luminal
tumor area to the deep invasional tumor area. 
Discussion
The alteration of DNA methylation patterns has been studied in many types of cancer14.
Neoplasia is now epigenetically characterized by hypermethylation of specific cancer asso-
ciated gene promoter regions and global DNA hypomethylation15, 16. LINE-1 constitutes
about 17-18% of the human genome and about 500,000 truncated and 3000-5000 full
length LINE-1s are dispersed throughout the human genome1, 17. LINE-1 sequences are
moderately CpG rich and most CpG locate in the 5’ region that can behave as an internal
promoter. Therefore LINE-1 hypomethylation has been used as a surrogate for global DNA
hypomethylation. LINE-1 hypomethylation in colorectal cancer has been described in sever-
al aspects; hypomethylation in cancer and adjacent normal mucosa, inverse association
with microsatellite instability and association with poor prognosis8, 18-20.
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Figure 5. Measured LHI values comparisons between clinical disease stage classifications. In A, B and C dif-
ferences are shown between Duke stage, T-stage and N-stage, respectively. In D, a receiver-opera-
tor-curve (ROC) analysis is given for prediction of lymph node status by primary tumor LINE-1
hypomethylation analysis with an area under the curve (AUC) of 0.69). 
LINE-1 hypomethylation is not specific for cancer cells and about one third of LINE-1 is
unmethylated in normal mucosa and cancer mesenchymal cells21, 22. The possible conta-
mination of sample DNA considered to be cancer with mesenchymal cells such as fibro-
blasts or lymphocytes may therefore cause inaccurate assessment. For this reason, especi-
ally regarding LINE-1 methylation analysis, isolation of target cells is necessary. To minimize
the contamination and obtain to cells of interest only, we successfully integrated automa-
ted LCM in LINE-1 methylation analyses this study which has not been reported to date.
We introduce on-cap SBM as a novel approach which makes DNA methylation assay effi-
cient and enables evaluation of cells from small areas of target regions. 
On-cap SBM was designed based on on-slide SBM13. On-slide SBM is a powerful pro-
cedure for the methylation analysis using FF-PEAT, however, after on-slide SBM the speci-
men becomes too adhesive to the glass slide making efficient LCM to capture target cells
difficult at times. On-cap SBM eliminates the numerous DNA isolation and purification
steps of classic SBM which are the main cause of DNA loss dealing with small amounts of
DNA such as isolated by LCM or from serum. We performed optimization studies and an
8 hour incubation showed excellent DNA conversion rates of approximately 95% was
achieved and this relatively long incubation duration did not result into loss of converted
DNA. 
Combining automated LCM, on-cap SBM and AQAMA assay, LINE-1 hypomethylati-
on was demonstrated in adenoma, an early stage of colorectal tumorigenesis, which is in
agreement with previous studies8, 20. Furthermore, the level of hypomethylation increased
according to tumor stage. In previous studies, no correlation between tumor stage in colo-
rectal cancer and LINE-1 hypomethylation level has been reported. One of the reasons for
those differences may be the degree of mesenchymal cell DNA contamination to the sam-
ple DNA. Our results demonstrate that not only adjacent normal mucosa but also mesen-
chymal cells in cancer shows about one third loss of LINE-1 hypomethylation compared to
normal epithelium. Sample DNA contamination with those cells causes decrease of LINE-
1 hypomethylation level and may result in failure to detect the differences between early
and advanced cancer. 
Our method enabled methylation analysis of sample DNA from small areas about
2x105 µm2 and this enabled to analyze heterogeneity of LINE-1 methylation status within
the tumor. The comparison between the deepest part and the surface of the tumor revea-
led that tumor heterogeneity of LINE-1 methylation status is relatively subtle. The results
suggest that colorectal tumor biopsy specimens collected during colonoscopy are represen-
tative can be used for a tumor’s LINE-1 methylation status analysis. LINE-1 hypomethyla-
tion levels differed significantly between node positive and node negative cancers and the
AUC was 0.69 to predict node positive cancer from whole samples according to the ROC
curve analyses. The LINE-1 unmethylation index of colorectal tumor biopsy sample may
therefore be useful to preoperatively predict lymph node status of colon cancer. Prospective
studies are needed to confirm our study’s findings.
In conclusion our study demonstrated that LINE-1 methylation status correlates with
clinical stage of colon cancer and its accurate analysis with LCM or equivalent techniques
is mandatory. The combination of LCM, on-cap SBM and AQAMA is a powerful method
for such accurate analysis.
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Abstract
Purpose: Overexpression of cyclooxygenase-2 (COX-2) in gastric cancer has been shown
to enhance tumor progression. We investigated whether silencing by promoter region
hypermethylation of the COX-2 gene contributes to disease outcome in gastric cancer.
Materials and Methods: COX-2 methylation status was initially assessed by capillary
array electrophoresis methylation-specific PCR (CAE-MSP) and COX-2 protein expression
by immunohistochemistry (IHC) in 40 primary gastric cancer tissues in a pilot study.
Prognostic endpoints of correlative studies of COX-2 methylation status were time to recur-
rence, overall survival, and standard clinicopathologic features. CAE-MSP analysis was then
validated in a second independent gastric cancer population (n=137). 
Results: COX-2 methylation was detected in 23% and 28% of the pilot and validation
patient groups, respectively. COX-2 expression (IHC) in gastric tumors inversely correlated
with COX-2 gene methylation status in the pilot study (P=0.02). COX-2 methylation in
tumors was significantly associated with lower T-, N-, and TNM-stage in the validation
patient group (P=0.02, P=0.006 and P=0.008, respectively). Patients with COX-2 methy-
lated tumors had significantly longer time to recurrence (TTR) and improved overall survi-
val (OS) in a multivariate analysis in the smaller (HR=0.08; 95%CI, 0.01-0.65 and HR=0.37;
95%CI, 0.14-1.00, respectively) and larger patient groups (HR=0.49; 95%CI, 0.24-0.99
and HR=0.62; 95%CI, 0.38-0.99, respectively). 
Conclusion: Hypermethylation of COX-2 gene promoter was identified as an independent
prognostic factor in gastric cancer patients. The results suggest promoter hypermethylation
to be an important regulatory mechanism of COX-2 expression in gastric cancer and show





Despite its decreased incidence, gastric cancer remains the second most common cause of
cancer death and the third most common cancer worldwide1. Recently, gastric cancer the-
rapy has received more attention, since neoadjuvant modalities have shown to improve out-
come for resectable tumors2-4. Molecular surrogate marker(s) of disease outcome could be
of benefit in the management of gastric cancer patient treatment. 
About 60% of human genes are associated with clusters of CpG dinucleotides, refer-
red to as CpG islands5. Clustered methylation of CpG islands at a gene promoter or tran-
scription start site is associated with gene silencing. This epigenetic event has been obser-
ved in many genes of different cancers6. Hypermethylation of tumor-related regulatory
genes may play a significant role in tumor transformation and progression, impacting the
clinical course of disease. Recent studies focus on hypermethylation of specific tumor-rela-
ted genes with suppressing capacities on growth and proliferation of gastric cancer7-11.
Genes regulated by methylation status can have tumor suppressor functions, as well as
tumor-inducing capacities, significantly altered. Therefore, gene inactivation by hyperme-
thylation may have dual effects on tumorigenesis and tumor progression. Epigenetic inac-
tivation of genes related with tumor progression has not been well studied in gastric can-
cer as related to disease outcome.
COX-2 (cyclooxygenase-2/PTGS2, prostaglandin-endoperoxide synthetase-2) expressi-
on is upregulated in gastrointestinal cancers12-15. In gastric cancer, COX-2 expression is
involved in several important tumor progression-related mechanisms, such as angiogene-
sis16, inhibition of apoptosis17, and invasiveness18. Song et al. demonstrated regulation of
COX-2 mRNA and protein expression by hypermethylation of the COX-2 promoter region
in gastric cancer lines19. Most gastric cancers overexpress COX-2, and, recently, COX-2
expression assessed by immunohistochemistry (IHC) was identified to impact disease sur-
vival20. Because of the reported epigenetic regulation and predictive value of COX-2 expres-
sion, we hypothesized a role for COX-2 promoter hypermethylation status in the clinical
outcome of patients with gastric cancer. To study this, we first assessed COX-2 promoter
methylation status by quantitative methylation-specific PCR (MSP), as well as its relation
to COX-2 protein expression in paraffin-embedded archival tumor (PEAT) specimens of
gastric cancer patients with known disease outcome in a pilot study. All patients were enrol-
led in a randomized, multi-center trial for primary gastric cancer comparing preoperative
chemotherapy versus surgery alone21,22. The clinical impact of COX-2 methylation in the
cancer trial patients was studied by correlating disease outcome to tumor COX-2 methyla-
tion status. The MSP findings were then confirmed in a larger, independent validation
patient group, selected from another multi-center randomized trial comparing primary
tumor resection with limited versus extended nodal dissection23,24.
Materials and Methods
Tumor specimens 
The pilot study group contained patients (n=59) accrued in the FAMTX (5-fluorouracil,
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doxorubicin, and methotrexate) trial conducted by the Dutch Gastric Cancer Group
(DGCC)21,22 evaluating preoperative chemotherapy with FAMTX for gastric cancer. As a
validation set, patients were used from the D1D2 trial by the DGCC23,24. The trial evalua-
ted (sub)total gastrectomy for gastric cancer with D1 to D2 lymph node dissection of which
the latter, included partial removal of spleen and pancreas. All tumors were classified and
staged according to the revised guidelines set by the International Union Against Cancer
(UICC). PEAT specimens of the primary tumor were collected from patients from both tri-
als. PEAT specimens from gastric tissue biopsies for benign conditions as controls were also
collected from 18 patients without a history of malignancy. The protocol for this study was
approved by the Human Subjects Institutional Review Boards of both participating institu-
tions (Saint John’s Health Center / JWCI; Leiden University Medical Center).
Tissue and DNA preparation
Serial sections from each PEAT specimen were cut. One section (4 µm) was stained by
hematoxylin and eosin and a tumor representative tissue was marked by an expert surgi-
cal pathologist for gastric cancer (G.A.M.). The next section (7 µm) was deparaffinized, and
lightly stained with hematoxylin. Tumor tissue was precisely isolated by manual microdis-
section under an inverted microscope using the marked HE section for target tissue identi-
fication. Isolated tissue was digested by 50 µl of proteinase K (Qiagen Inc, Valencia, CA)
containing lysis buffer at 50°C for 16hrs. Subsequently, DNA was purified with phenol-
chloroform-isoamyl alcohol (Fisher Chemicals, Fairlawn, NJ) and precipitated by ethanol.
Subsequent tissue sections (4 µm) were prepared on aminopropylethoxysilane (APES) coat-
ed slides for IHC.
Analysis of CpG island methylation status
Sodium bisulfite modification (SBM) was performed on 20 µl of sample PEAT DNA plus
1 µg of salmon sperm DNA as a carrier. Sample concentrations of double-stranded DNA
were quantified by the PicoGreen assay (Molecular Probes, Eugene, OR) prior to bisulfite
treatment and were between 10 and 100 ng/µl. We allowed for 90% sample loss during
desalting and further clean-up steps. DNA isolation was repeated if concentrations were
lower than 10 ng/µl. If insufficient DNA could be detected the sample was not further eva-
luated. SBM was carried out as previously described25; sulphonation incubation time was
3hrs at 60°C. Capillary array electrophoresis analysis was used after methylation-specific
PCR for analysis of CpG island methylation status as previously described. Methylation-spe-
cific and unmethylated-specific primer sets were designed around the COX-2 transcription
start site (-14bp/+110bp). The primers were dye-labeled for detection using capillary array
electrophoresis (CAE). Forward and reverse sequences for the methylation-specific primer
set were: 5’-TTTCGGTTAGCGATTAATTGTTATAC-3’ and 5’-CGAAAATAAACTTTAC-
TATCTAAAAACGTC-3’, respectively. Forward and reverse sequences for the non-methyla-
ted-specific primer set were: 5’-TTTGGTTAGTGATTAATTGTTATATGA-3’ and 5’-CAAAA-
ATAAACTTTACTATCTAAAAACATC-3’, respectively. Two positive (sssI methyltransferase
treated donor lymphocyte DNA and the RL-0380 cell line DNA), and two negative (phi-29
DNA polypmerase amplified donor lymphocyte DNA26 and the FN-0028 cell line DNA)
controls were included in each assay. Relative amounts of PCR products were quantified
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by CAE (CEQ 8000XL, Beckman Coulter, CA) using CEQ 8000XL software version 6.0
(Beckman Coulter), as described previously27. A methylation index (MI) was calculated;
MI = [(methylated peak intensity) / (methylated peak intensity + unmethylated peak inten-
sity)]28. 
Immunohistochemistry
Tissue sections were deparaffinized and endogenous peroxidase was blocked by hydrogen
peroxidase-methanol for 20min. Antigen retrieval was performed by boiling the sections in
10mM citrate buffer for 10min. Sections were incubated overnight at room temperature
with a monoclonal antibody against human COX-2 (Cayman Chemical, MI) at a dilution
of 1:200 (2.5 µg/mL) in phosphate-buffered saline (pH 7.4) with 1% BSA (PBS/BSA).
Sections were then incubated for 30min with biotin (1:400; DAKO, Glustrup, Denmark),
washed, and incubated for 30min with Streptavidin-Biotin-Complex (SABC) (1:100; DAKO,
Denmark). The sections were washed in PBS for 15min, rinsed in Tris/HCl-buffer (pH 7.6)
for 5 min, and developed in 3.3 diaminobenzidine tetrahydrochloride (DAB) with hydro-
gen-peroxide for 10min. The sections were counterstained with hematoxylin and moun-
ted. COX-2 IHC staining intensity of tumor cell cytoplasm was scored independently in a
blinded manner by two expert gastric cancer pathologists (GAM and NCvG) using the fol-
lowing scoring criteria: absent staining; weak diffuse cytoplasmic staining (may contain
stronger intensity in <10% of the cancer cells); moderate granular cytoplasmic staining in
10%-90% of the cancer cells; and strong granular staining in more than 90% of the tumor
cells according to the method of Buskens et al29. In case of disagreement, a third indepen-
dent staining assessment (by PdH) was used to designate tumor staining-intensity.
MSP assay validation
Methylation status of the COX-2 promoter region was confirmed in gastric cancer lines,
KATO-III (ATCC, Manassas, VA) and FN-0028 (JWCI), by direct bisulfite sequencing, as
described previously28. Forward and reverse sequencing primers were 5’-TAAGGGGA-
GAGGAGGGAAAA-3’ and 5’-CACCTATATAACTAAACYCCAAAACC-3’, respectively, with
Y=A or G. Both cell lines were treated with 5-azacytidine (5-aza) and trichostatin-A (TSA)
for verification of epigenetic regulation of COX-2 mRNA expression, as described previou-
sly28,30. COX-2/GAPDH mRNA expression ratio was assessed by using quantitative
RealTime PCR31. Sequences for forward and reverse primers and fluorescent labeled probe
for COX-2 mRNA were 5’-CATTTGAAGAACTTACAGG-3’, 5’-CCAAAGATGGCATCTG-
3’, and 5’-FAM-CTCCACAGCATCGATGTCACCATA-BHQ-3’, respectively.   
Study design and statistical analyses
This was a retrospective study and all assays were performed in a blinded manner to the
trial clinical outcome parameters. We first established tumor-specific MI by assessment of
non-neoplastic gastric tissue controls. A cut-off MI to allocate tumors to the methylated or
unmethylated category was set at the 95th percentile of the measured MI values in normal
controls. This cut-off was uniformly and consistently used to study the clinical value of
COX-2 methylation status initially in the pilot study and then in the validation D1D2 trial
specimens. D1D2 trial patients that received resection with curative intent were selected,
105
Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer
satisfying the following criteria: complete surgical resection (R0) and no postoperative mor-
tality. Required sample size of the validation patient group was calculated based on recur-
rence-percentages in patients with COX-2 methylated and unmethylated tumors after 10
years of follow up of in the pilot study. Correlation between methylation status of the COX-
2 gene and clinicopathological features was analyzed by Fisher’s exact test or Pearson’s c2
test. Student’s t-test evaluated differences in age between groups. The Mann-Whitney U-
test was used for ordinal variables. Survival length was determined from the day of prima-
ry tumor surgery to the date of death or last clinical follow-up. The Kaplan-Meier method
was used for survival analysis grouping with COX-2 methylation status. Differences between
curves were analyzed using the log-rank test. Cox’s proportional hazard regression model
was used in a backward stepwise method for variable selection in multivariate analyses. T-
stage, N-stage, TNM-stage, trial randomization, Lauren classification, and complete resec-
tion were included in the model. Kruskal-Wallis test was used to assess the relation between
COX-2 MI and the different staining-intensity categories. The statistical package SPSS ver-




Regulation of COX-2 expression by promoter region methylation has previously been
shown in gastric cancer lines19. We first verified whether the CAE-MSP assay on COX-2
methylation status associated with regulation of COX-2 mRNA expression. Two represen-
tative gastric cancer lines assessed by the CAE-MSP assay as completely methylated (KATO-
III, MI=1.0) and completely unmethylated (FN-0028, MI=0). The individual CpG-dinucle-
otide methylation status of the target region of the promoter transcription site was confirmed
by bisulfite sequencing in RL-0380 and FN-0028 to be, respectively, completely methyla-
ted and unmethylated. This established these cell lines as suitable positive and negative con-
trols for the CAE-MSP assay. RL-0380 and FN-0028 cell lines were than treated by 5-aza
and TSA to evaluate COX-2 mRNA re-expression. The combination of 5-aza and TSA was
used because epigenetic silencing can involve both methylation of CpG islands and deace-
tylation. In KATO-III, the demethylating effect was confirmed by CAE-MSP, and expressi-
on of COX-2 mRNA was induced (COX-2/GAPDH ratio was 0 versus 4.46E-02, respecti-
vely, before and after treatment). In FN-0028, COX-2 mRNA was present before treatment
and did not significantly change after treatment (COX-2/GAPDH ratio was 1.69E-04 ver-
sus 3.45E-04, respectively). Results confirmed that promoter region methylation affects
COX-2 expression, and validated the CAE-MSP assay for detecting methylation at the COX-
2 promoter region transcription site.
Primary tumor COX-2 methylation status 
Increased COX-2 methylation has been shown to be a tumor-related event in gastric can-
cer32,33. Using the COX-2 CAE-MSP assay, we verified tumor-related COX-2 levels.
Methylation status was assessed in FAMTX patients’ primary tumors, as well as 18 non-
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cancerous gastric biopsies in patients with benign conditions as controls. Forty-four of the
59 patients enrolled in the trial finally underwent resection. Three of the 44 primaries could
not be evaluated because of insufficient DNA, and in one patient the paraffin-embedded
block had an insufficient amount of cells, leaving 40 patients available for analysis. Relatively
low levels of COX-2 methylation were detected in control samples compared to tumors
(figure 1). The 95th percentile of the MI values in non-neoplastic gastric tissues was calcu-
lated (MI=0.24) and used as a cut-off to establish tumor-related methylation. COX-2 methy-
lation was detected by the CAE-MSP assay in 9 of 40 (23%) tumors using the predetermi-
ned cut-off level standard. 
Primary tumor COX-2 methylation status and COX-2 IHC
The regulatory effect of COX-2 promoter methylation in tumors was assessed by correla-
ting COX-2 gene MI values to intratumoral COX-2 protein expression in FAMTX trial pri-
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Figure 1. Scatter plot indicating distribution of measured methylation index (MI) values in normal gastric
epithelium and primary gastric tumor. Horizontal bar indicates the cutoff level for increased tumor-
related methylation (MI, 0.24).
maries. PEAT specimens were assessed by IHC for COX-2 expression of tumor cells. Of the
39 evaluated cases, 3 (8%), 9 (23%), and 27 (69%) patients showed weak diffuse, modera-
te, and strong COX-2 expression, respectively. figure 2 shows representative results of
COX-2 expression with the corresponding CAE-MSP signal intensity peaks. The relation of
COX-2 gene methylation status to respective protein expression in tumor cells is shown in
figure 3. Mean MI values were 0.46, 0.32, and 0.13 for tumors with weak diffuse, mode-
rate granular, and strong granular staining, respectively. The gradual decrease of methylati-
on levels along COX-2 IHC categories increasing in staining intensity was significant
(P=0.02 by Kruskal-Wallis test), and suggests a direct regulatory effect of COX-2 methyla-
tion on COX-2 protein expression in gastric tumors.
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Figure 2. Representative cyclooxygenase-2 (COX-2) immunohistochemistry (IHC) results of primary gastric
tumors with respective capillary array electrophoresis methylation–specific polymerase chain reac-
tion (CAE-MSP) outcomes. x-axis of the CAE-MSP represents the fluorescent intensity (M, methy-
lated product; U, nonmethylated product) indicating polymerase chain reaction amplicon. y-axis
represents the product base pairs. (A, C) Nonmethylated primary gastric tumor. Strong cytoplas-
mic COX-2 protein staining in tumor cells. (B, D) Methylated primary gastric tumors show weak
diffuse IHC staining. 
COX-2 methylation and clinical outcome 
We evaluated gastric cancer patients’ clinical prognostic factors between COX-2 methylated
and non-methylated FAMTX trial tumors in a pilot study. COX-2 methylation status showed
no relation to sex, age, Lauren type, T-, N- or TNM-stage, or resectability in this patient group
(table 1). Univariate analysis of Kaplan Meier survival curves (figure 4A-B) demonstrated
that COX-2 methylation status gave significant differences in time to recurrence (TTR) and
overall survival (OS). Five patients that did not receive a curative (R0) resection were exclu-
ded for the analysis of TTR. Multivariate analysis (table 2) showed that methylation of the
COX-2 gene was a favorable independent prognostic factor for TTR and OS. Nodal status
showed the strongest predictive value, as expected. The multivariate analysis also showed
predictive value for the FAMTX trial randomization arm, indicating improved outcome for
patients that received surgery alone. 
109
Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer
Figure 3. Boxplots showing gastric primary tumor cyclooxygenase-2 (COX-2) methylation index (y-axis) in
relation to COX-2 protein expression categories (x-axis) as assessed by immunohistochemistry in
gastric tumor cells.
Based on the above pilot studies, we validated the utility of COX-2 methylation status
in an independent gastric cancer population that received no neo-adjuvant treatment. To
establish sample size we initially performed power calculations using the results of the test-
set. Based on these values we calculated 129 patients to be sufficient to obtain significan-
ce with an alpha-level of 0.05 and 90% power. Because of expected difficulties in retrospec-
tively analyzing (on average) 12 year old tissue blocks, we added 40% extra patients to
account for patients of which no results could be generated. To obtain a homogenous study
group we requested blocks of patients without postoperative mortality and that received
R0 resection (resection margin microscopically free of tumor). These patients are more like-
ly to be node-negative. An unbiased selection was performed to assure sufficient events for
survival analysis. This resulted in that 37% of patients analyzed were node-negative in the
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Figure 4. Kaplan-Meier analysis of survival for gastric cancer patients with primary tumors assessed for
methylation status of cyclooxygenase-2 (COX-2). Among 40 fluorouracil, doxorubicin, and metho-
trexate (FAMTX) trial patients, those with methylated primary tumors had a significantly improved
(A) overall survival and (B) longer time to recurrence for 35 patients that could be evaluated for
this outcome parameter. (C, D) Represent Kaplan-Meier analysis of 137 D1D2 trial gastric cancer
patients. 
111
Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer
COX-2 Trial Patients 
FAMTX (n=40) D1D2 (n=137) 
Variable Meth Unmeth P* Meth Unmeth P* 
No. of patients 9 31 38 99
Sex
Female 5 15 .84 19 47 .79 
Male 4 16 19 52
Age, years 
Mean 61.7 60.1 .58† 66.9 67.2 .85† 
SD 6.6 9.9 8.7 8.2
Randomization assignment 
FAMTX  surgery/D1 resection 4 15 .84 24 54 .36
Surgery alone/D2 resection 5 16 14 45
Lauren classification 
Intestinal 6 17 .59 33 73 .34 
Diffuse 3 14 4 23
Mixed — — 1 3
UICC pathologic stage 
IA 2 2 .43‡ 15 14 .008‡ 
IB 2 5 8 23
II 2 15 7 30
IIIA 3 4 5 21
IIIB 0 1 1 6
IV 0 4 2 5
UICC nodal status 
N0 4 12 .71‡ 23 28 .006‡
N1 (1-6 positive) 5 15 9 52
N2 (7-15 positive) 0 3 4 16 
N3 (16 positive) 0 1 2 3
Tumor invasion 
T1 2 2 .68‡ 15 24 .02‡
T2 4 19 20 52
T3 3 10 3 21
T4 — — 0 2
Curative resection 
Yes 8 27 .89 — — —
No 1 4 — — 
Table 1. Association Among COX-2 Methylation and Clinicopathologic Variables 
Abbreviations: COX-2, cyclooxygenase-2; FAMTX, fluorouracil, doxorubicin, and methotrexate; Meth, methylated COX-2
promoter; Unmeth, nonmethylated COX-2 promoter; UICC, International Union Against Cancer; SD, standard deviation. 
































































































































































































































































































































































































































































































































































































































































validation group (similar as in the test-set). Finally, 178 blocks were processed. Molecular data
could be generated of 137 patients. The patients in analysis were than assessed for differen-
ces from the non-analyzed patients (table 3). As expected, the selected study group showed
significant higher proportion of node-positive patients. Older gastric cancer patients are more
likely to be node-positive at time of surgery and this explained the higher age of the 137 ana-
lyzed patients. Thirty-eight (28%) patients were classified as COX-2methylated using the pilot
study cut-off (MI=0.24). Mean MI was 0.71 (S.D. 0.29, range 0.26-1.00) in methylated
tumors and 0.01 (S.D. 0.04, range 0-0.19) in unmethylated primaries. In this validation
group, significant correlation was observed for COX-2 methylated tumors with lower TNM-
stage, node negativity, and lower T-stage (table 2). The predictive value of methylation status
was confirmed in univariate and multivariate analysis for OS and TTR (figure 4, table 2). 
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Patients Receiving R0 Resection Without 




Factor No. % No. % P
Sex 
Female 189 43 66 48 .31 
Male 260 57 71 52 
Age, years 
Median 63 66 
SE 0.6 0.7 .001 
Random assignment 
D1 resection 247 54 78 57 .54 
D2 resection 211 46 59 43 
T stage 
T0 5 1 0 0 .49 
T1 131 28 39 28 
T2 213 47 74 53 
T3 99 22 22 17 
T4 10 2 2 2 
N stage 
N0 229 50 51 37 .05 
N1 (1-6) 163 36 61 44 
N2 (7-15) 47 10 20 15 
N3 (16) 19 4 5 4 
Table 3. Comparison of Clinical Characteristics Between Selected and Non- Selected Cases From Curatively
Resected Patients of the D1D2 Trial
*Calculated by Mann-Whitney U test. 
Nodal involvement was the strongest prognostic variable and was present in all patients with
methylated COX-2 that relapsed within 1.8 years following surgery. Patients with COX-2 methy-
lation had improved TTR when only node-negative patients were analyzed (P=0.03). Lauren
type, showing borderline significance in the FAMTX-trial, was selected as an independent fac-
tor in the larger study group. T-stage was not a prognostic factor and this may be due to the
tight assocation with nodal status (P<0.0001). Because of this dependence, TNM-stage was
not a significant factor either in multivariate analysis. Trial randomization to extended or limi-
ted nodal dissection had no predictive value as shown in the initial trial analyses24. 
Discussion
In gastrointestinal cancers, the role of COX-2 in tumor-promotion has been shown34,35.
Numerous stimulatory factors, such as growth factors and cytokines, have been reported
to cause overexpression of COX-2 in cancer34,36-38. Studies have suggested methylation as
a regulatory mechanism of COX-2 expression in gastric cancer in vitro and in primary
tumors19,33,39-41. Recently it was reported that C/EBPbeta (CCAAT/enhancer-binding pro-
tein beta) transcription factor regulates the expression of endogenous COX-2 in a gastric
cancer line model, based on its methylation status42. The COX-2 methylated status may
abolish the effect of factors, such as C/EBPbeta, growth factors, or cytokines, due to the
inactivation of binding elements at the promoter region. Furthermore, COX-2 methylation
status in our study was independent in multivariate analyses of nodal status which is a high-
ly important predictor of disease recurrence. This independence may be explained by some
tumor-enhancing processes intrinsic to gastric adenocarcinoma that increased COX-2
expression is reported to be associated with. Examples of such processes are angiogenesis,
reduced apoptosis and increased inflammation. Also, our data suggests that COX-2 to be
involved in Lauren’s histologic classification. In the pilot study, intestinal type tumors cor-
related to decreased IHC staining intensity (P=0.03), and absence of COX-2 expression in
the intestinal tumor type has been previously reported20. In the D1D2 trial patient group
diffuse type tumors had a significantly decreased MI compared to intestinal type tumors
(P=0.03). Together, methylation of COX-2 may cause gastric tumor cells to maintain a more
differentiated, intestinal organization, and subsequently these tumors may constitute a cli-
nically less aggressive tumor type.
The outcome of both trials, for which patient specimens were used in this study, was
negative. The FAMTX trial did not show improved resectability rate of gastric cancer by
preoperative chemotherapy, and extended D2 nodal dissection did not reduce recurrence
rates, indicating the problem of managing gastric cancer disease. Development of molecu-
lar biomarkers for primary gastric cancer tumors may allow for better management strate-
gies. Long-term analyses of the D1D2 trial suggested that node-positive gastric cancer
patients may benefit from more extensive nodal dissection at primary tumor surgery24, and
two large randomized trials have now shown the benefit of (neo-)adjuvant treatment for
gastric cancer3,4. Our study confirms that presence of nodal involvement remains the sin-
gle most important factor to base treatment decisions upon postoperatively. However, the
D1D2 trial data showed that 20% of node negative patients show disease recurrence wit-
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hin 3 years after surgery. Biomarkers to select poor-prognosis, node-negative patients that
could be potentially useful for stratification in patients receiving adjuvant or neoadjuvant
therapy. COX-2 methylated tumors did show significantly less recurrence in univariate ana-
lysis in node-negative patients only, however, our study was underpowered to show inde-
pendence of COX-2 methylation status as a predictor of poor prognosis in node-negative
patients. The actual advantage of our study for clinical applicability lies in that COX-2
methylation status is a primary tumor characteristic and therefore can be assessed in stan-
dard performed diagnostic tumor biopsy. Primary tumor COX-2 methylation status therefo-
re may be used as a preoperatively assessable biomarker to tailor more aggressive treatment
modalities at time of surgery to gastric cancer patients with poorer prognosis. To date no
such biomarkers are preoperatively available in gastric cancer.
DNA is much more stabile in archived tissues as compared to proteins. Our approach
to assess gene COX-2 methylation instead of protein expression by IHC analysis may be
more promising as a biomarker in assessment of archival specimens. Furthermore, our
study is the first in gastric cancer to show that DNA methylation is an independent prog-
nostic factor predicting a favorable effect on patient outcome by down-regulating the
expression of a known tumor-enhancing protein. Our results shift the paradigm that tumor
acquired DNA methylation of promoter regions results in adverse outcome in gastric
tumors.
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Abstract
Introduction: There are no accurate prognostic biomarkers specific for rectal cancer.
Epigenetic aberrations, in the form of DNA methylation, accumulate early during rectal
tumor formation. In a preliminary study, we investigated absolute quantitative methylation
changes associated with tumor progression of rectal tissue at multiple genomic methylated-
in-tumor (MINT) loci sequences. We then explored in a different clinical patient group whe-
ther these epigenetic changes could be correlated with clinical outcome.
Methods: Absolute quantitative assessment of methylated alleles (AQAMA) was used to
assay methylation changes at MINT1, 2, 3, 12, 17, 25, and 31 in sets of normal, adeno-
matous and malignant tissues from 46 patients with rectal cancer. Methylation levels of
these biomarkers were then assessed in operative specimens of 251 patients who under-
went total mesorectal excision (TME) without neoadjuvant radiotherapy in a multicenter
clinical trial. 
Results:Methylation at MINT 2, 3, and 31 increased 11-fold (P=0.005), 15-fold (P<0.001),
and 2-fold (P=0.02), respectively, during adenomatous transformation in normal rectal epi-
thelium. Unsupervised grouping analyses of quantitative MINT methylation data of TME
trial patients demonstrated two prognostic subclasses. In multivariate analysis of node-nega-
tive patients, this subclassification was the only predictor for distant recurrence (HR:4.17,
95%CI:1.72-10.10, P=0.002), cancer-specific survival (HR:3.74, 95%CI:1.48-9.43,
P=0.003) and overall survival (HR:2.68, 95%CI:1.41-5.11, P=0.005). 
Conclusion: Methylation levels of specific MINT loci can be used as prognostic variables in
patients with AJCC stage I and II rectal cancer. Quantitative epigenetic classification of rec-




Rectal cancer is the second most common cancer of the digestive system in the U.S.A.1
Neoadjuvant therapy has improved local control of rectal cancer in patients undergoing
total mesorectal excision (TME)2-4, but distant recurrence remains the major cause of disea-
se mortality. Although tumor involvement of regional nodes is the most important predic-
tor of metastasis, 20% of node-negative patients will recur at distant sites. This suggests that
even early stages of tumors have potential for systemic metastasis and, therefore, molecu-
lar subclassification may be clinically relevant. Development of prognostic molecular bio-
markers for rectal cancer would improve management and potential treatment stratificati-
on. Colon and rectal cancers are often assessed together in the analysis of molecular/genetic
biomarkers. This is often due to the limited availability of tumor for analysis, or specimens
are not procured from a specific clinical trial. We now know both cancers are different in
etiology and treatment, as well as (epi)genetics5. In this study, we have focused specifical-
ly on epigenetic changes of rectal cancers from a clinical trial. 
Epigenetic instability, such as changes in genomic DNA methylation status, is an early
event during gastrointestinal tumor development and encompasses both hyper- and hypo-
methylation changes6-8. The majority of the studies assessing epigenetic changes and asso-
ciation with clinical outcome focus on hypermethylation of specific genomic loci and use
non-quantitative measures. Consequently, methylation status is mostly analyzed in a dicho-
tomous manner, categorizing specimens as methylated or unmethylated. Absolute quanti-
tative interpretation of methylation data would improve analysis of epigenetic events9.
Recently, we developed an assay for absolute quantitative assessment of methylated alleles
(AQAMA) and showed quantitative methylation events to be associated with colorectal
tumor progression10. AQAMA measures the amount of methylated and unmethylated copy
numbers simultaneously in a single reaction. The assay has excellent linearity in assessing
DNA methylation levels and can be used on paraffin-embedded archival tissue (PEAT) sec-
tions treated with the on-slide (in situ) sodium bisulfite modification (SBM) technique that
allows microdissected histology-oriented assessment of small (1-2mm2) lesions11,12. This
allows efficient comparison of precursor adenoma and normal cells adjacent to tumor cells.
Methylation levels of methylated-in-tumor (MINT) loci have not been specifically tes-
ted for prognostic utility in rectal cancer. MINT loci are CpG-dinucleotide-rich regions loca-
ted in non-protein-encoding DNA regions, and have been reported to become methylated
in a tumor- and adenoma-specific manner in gastric and colon cancer13-17. In a preliminary
study, we quantified methylation levels of seven MINT loci at different stages of rectal
tumor formation comparing paired normal-adenoma and adenoma-cancer tissues, and sub-
sequently analyzed whether methylation level changes related to rectal tumor progression.
Our developed hypothesis was that methylation levels at MINT loci have prognostic signi-
ficance for early rectal cancer progression. We then assessed the potential prognostic utili-
ty of MINT loci in primary tumor tissues from patients enrolled in a multicenter, randomi-
zed, surgical clinical trial. In this translational study analysis, unsupervised cluster analysis
identified a subclass of patients whose quantitative methylation data were independently
prognostic of progression to distant disease. 
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Materials and Methods
Tissue Specimens
In the preliminary study, patients operated on for rectal cancer with histopathologic confir-
med adenocarcinoma were identified from the cancer registry database at SJHC. Only
patients operated after 1995 were evaluated because of possible DNA degradation. Further
selection of specimens was based on pathology-documented presence of tumor, as well as
adenoma cells on the same tissue section.
For the clinical correlation studies, primary tumor PEAT specimens were obtained from
322 non-irradiated patients enrolled in the multi-center, randomized, quality-controlled
TME trial coordinated by the Dutch Colorectal Cancer Group3. The trial investigated whe-
ther neoadjuvant radiotherapy (5x5Gy) before TME improved local control compared to
TME surgery alone in patients with all stages of rectal cancer. Trial eligibility criteria and
follow-up protocols have been described previously3,18,19. All TME trial patients enrolled at
the Dutch multicenter study sites were eligible further adhering to the following criteria:
non-irradiated, TNM-stage I-III, with no evidence of disease (NED) after surgery. We opted
to analyze the treatment arm because potential effects of radiation on genomic methylati-
on are not known. Research protocols for the methylation studies on PEAT were approved
by SJHC/JWCI and Leiden University Medical Center IRBs.
DNA preparation from PEAT specimens for preliminary and clinical studies 
From the preliminary study specimens, two consecutive sections (4 and 7 µm) of each PEAT
block were cut and placed on adhesive-coated slides. The 4 µm section was stained with
H&E and mounted. Tissue areas with normal epithelial, classic adenomatous, and invasive
cancer cells were identified and marked off by an expert surgical pathologist (R.R.T). The tis-
sue categories were histopathology identified. Cancer cells were only taken from areas with
nuclear atypia and signs of invasion of tissue architectural boundaries, the hallmark of can-
cer. Adenomatous cells were only taken from areas with classic villous and/or tubular ade-
nomatous dysplasia. We did not include adenomatous tissue in the analysis with highly-dys-
plastic features without signs of invasion The 7 µm section was treated by on-slide SBM as
described previously11. Target tissue areas were identified and microdissected under a light
microscope. Isolated cells were digested and 1 l of the lysate was used for PCR.
From the clinical study TME trial patient specimens, tissue sections (7 µm) were cut
from PEAT specimens and mounted on non-adhesive glass slides. Tumor-representative
areas on H&E stained sections were marked by a surgical pathologist specializing in rectal
cancer (JHJMvK). Two sections per patient were deparaffinized, and the marked tissue was
carefully microdissected. DNA was isolated and modified by sodium bisulfite, as previou-
sly described20. Salmon sperm DNA was added as a carrier21. DsDNA and ssDNA were
quantified before and after SBM by PicoGreen and OliGreen assays (Molecular Probes), res-
pectively. Sufficient input DNA for AQAMA was determined as described10. A salmon
sperm DNA sample without tumor DNA was included in triplicate to assess background
signal. Tissue blocks and isolated DNA were coded to prevent any bias. 
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AQAMA MINT locus methylation level assessment
Absolute quantitative assessment of methylated alleles at MINT loci 1, 2, 12, and 31 has
been described previously10. Unpublished primer and probe sets for the remaining three
MINT loci were: MINT3, 5’-TGATGGTGTATGTGATTTTGTGTT-3’(forward), 5’-ACCC-
CACCCCTCACAAAC-3’(reverse), 5’-ACCTACGAACGAACAC-3’(methylated probe), 5’-
TACCTACAAACAAACAC-3’(unmethylated probe); MINT17, 5’-AGGGGTTAGGTT-
GAGGTTGTT-3’ (forward), 5’-TCTACCTCTTCCCAAATTCCA-3’(reverse), 5’-TTG-
GATGGATCGCGG-3’ (methylated probe), 5’-TATTTTGGATGGATTGTGG-3’(unmethyla-
ted probe); MINT25, 5’-GGGGATAGGAAGATGGTTT-3’(forward), 5’-CCCCCATCCCATA-
CAACC-3’(reverse), 5’-TTTGTTTCGTAGCGGAGT-3’(methylated probe), 5’-GATTTT-
GTTTTGTAGTGGAG-3’ (unmethylated probe). DNA samples were run in 384-well
microplates in triplicate, and each plate contained individual marker cDNA standards with
known copy numbers, allowing assessment of absolute methylated and unmethylated copy
number. Controls for specificity of AQAMA for methylated and unmethylated sequences,
as well as controls for non-specific amplification, were included10,22. Final analysis outco-
me was the methylation index (MI), calculated as: [copy numbermethylated alleles/(copy num-
bermethylated alleles+copy numberunmethylated alleles)].
Profiling by Unsupervised Random Forest Clustering
For identification of patient clusters with similar MINT locus methylation profiles, we
employed unsupervised random forest (RF) clustering23, as it has been successfully applied
in comparable data sets (supplemental appendix 1)24,25. 
Results
MINT Locus Methylation Levels During Rectal Cancer Development
Sets of normal, adenomatous, and malignant PEAT tissues from 46 patients with rectal can-
cer were examined by AQAMA of MINT loci known to be differentially methylated in colo-
rectal cancer12. The H&E-stained sections cut from the tissue blocks that, according to the
diagnostic pathology report, contained adenoma as well as cancer tissue, were histopatho-
logy-evaluated by an expert pathologist (R.R.T). In the 46 tissue sections, 19, 46, and 35
areas of normal epithelium, adenoma, and cancer tissue, respectively, were identified. This
resulted into paired analyses of 19 normal-adenoma sets and 35 adenoma-cancer sets.
Figure 1 shows scatterplots of the MI values in the three histopathology categories for each
MINT locus. MINT loci 2, 3, and 31 underwent a significant increase in absolute mean
methylation level during adenomatous transformation. There were no significant MINT
methylation changes for any MINT locus during progression from adenoma to cancer.
Subsequently, the significant increases were early events associated with dysplastic change
of normal rectal epithelium. Because three MINT loci (2, 3, 31) showed significant increa-
se in methylation levels and the normal distribution of the quantitative methylation data
sets in healthy rectal epithelium changes to non-normal in adenoma in four other loci (1,
12, 17, 25) (supplemental appendix 2), all seven MINT loci were considered to have
potential utility to identify epigenetic subclasses in the clinical study patient group.
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Sample size calculations
To establish the sample size for the clinical study, we performed power calculations using
methylation results of the preliminary study and recurrence rates of the TME trial. It was
calculated that 250 patients were sufficient to obtain significance for predicting distantre-
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Figure 1. Scatterplots of measured methylation indices in normal rectal epithelium, rectal adenoma tissue, and
rectal cancer tissue for the 7 MINT loci studied. MINT, methylated in tumor; ns, not significant. 
currence with an alpha-level of 0.05 and 90% power. Because the available patient speci-
mens from the trial were primary tumor PEAT blocks from various hospital sites, we allo-
wed for 30% loss of cases due to availability and quality of tissue and DNA. We therefore
required 72 additional cases, and the final sample size was set at 325 cases. 672 patients
fulfilled our study criteria (see Material and Methods). Finally, of 314 cases, DNA was iso-
lated (in 11 cases, tumor cell number was insufficient). Subsequently, of the 314 DNA iso-
lations, after processing and bisulfite treatment, only 251 had sufficient input DNA for
AQAMA. Characteristics of the 251 patients finally analyzed were not significantly diffe-
rent in prognostic factors and characteristics from the original trial population 
(supplemental appendix 3).
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Figure 2. Methylated in tumor (MINT) locus methylation subclass identification. (A) multidimensional sca-
ling [MDS] plot displaying the level of dissimilarity between all patients (MDS plot axes represent
arbitrary units, and are therefore dimensionless). (B) Three-dimensional plot representing expec-
tation maximization algorithm with a mixture of Gaussians analysis of the MDS plot coordinates
showing Gaussian distribution (bell-shaped) of the two identified clusters. (C) MDS plot showing
final cluster allocations for the patient population. (D) Box plots comparing the differences in
methylation levels (MI) between cluster 1 and 2 for all MINT loci. 
MINT Locus Methylation Profile Identification
To investigate whether rectal cancer can be grouped by methylation level at specific MINT
loci, we performed unsupervised RF clustering on the quantitative methylation level results
of patients from the TME trial. As an outcome, a MDS plot indicated the mutual distance
between the cases based on methylation level of all seven MINT loci (figure 2A). Inspection
of the MDS plot indicated two groups of rectal cancer cases. To identify which patients
belonged to which group, we performed an EM-MoG analysis based on the Gaussian shape
of patient clusters (figure 2B,C). The EM-MoG algorithm allocated the patients based on
the likelihood to fall under the normal (Gaussian) distribution of one of the two clusters.
Subsequently, variable importance and the methylation patterns matching the identified
clusters were analyzed (figure 2D, table 1A). The 89 patients (35%) allocated to cluster
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All Patients Node-Negative Patients
(n=251) (n=145) 
MINT Gini Cluster 1 Cluster 2 P- Value* Cluster 1 Cluster 2 P-Value*
locus Index (n=89) (n=162) (n=55) (n=90)
Median† Median† Median† Median†
MINT1 11.6 0.00 0.01 <0.001 0.00 0.00 0.006
(0.00-0.01) (0.00-0.09) (0.00-0.02) (0.00-0.09)
MINT2 10.8 0.08 0.00 0.07 0.00 0.00 0.51
(0.00-0.02) (0.00-0.12) (0.00-0.03) (0.00-0.10)
MINT3 20.2 0.87 0.50 <0.001 0.84 0.49 <0.001
(0.79-0.99) (0.06-0.65) (0.79-0.99) (0.06-0.65)
MINT12 13.5 0.03 0.02 0.01 0.02 0.02 0.22
(0.00-0.02) (0.01-0.05) (0.00-0.02) (0.00-0.05)
MINT17 20.7 0.08 0.21 <0.001 0.09 0.20 0.005
(0.04-0.13) (0.08-0.30) (0.05-0.15) (0.12-0.24)
MINT25 12.1 0.00 0.00 0.21 0.00 0.00 0.81
(0.00-0.04) (0.00-0.08) (0.00-0.05) (0.00-0.09)
MINT31 6.0 0.00 0.00 0.90 0.00 0.00 0.82
(0.00-0.00) (0.00-0.00) (0.00-0.00) (0.00-0.00)
† Interquartile range
* Calculated by Mann-Whitney’s u-test
Table 1A: Variable Importance by Gini Index and Comparison of Mean MINT Locus MI Values Between 
Identified Clusters
1 had significantly increased methylation at MINT3 and significantly decreased methylati-
on at MINT1, 12, and 17 as compared with patients in cluster 2. The unsupervised clus-
tering results showed that subclasses of rectal cancers can be identified by differences in
DNA methylation level of tested MINT loci. The Gini-index indicated that MINT3 and
MINT17 were the most important variables in forming the clusters. 
Clinicopathological correlation and distant recurrence analyses 
There were no significant associations observed in epigenetic subclasses of rectal cancer to
any of the investigated standard clinical or tumor-pathological factors (table 1B). The pre-
liminary results demonstrated that methylation level differences at the specific MINT loci
develop early during tumor formation. There was no significant relation between cluster
allocation and clinico-pathological factors in node-negative tumors (table 1B). Because
identification of stage I and II patients at risk for distant metastasis is highly clinically rele-
vant and there was no dependence of the identified patient clusters to nodal status we
excluded stage III patients from distant disease recurrence analyses. We assessed the pro-
bability of distant disease recurrence, cancer-specific, and overall survival (OS). Because
EM-MoG analysis is a probability-based cluster assignment algorithm, we performed mul-
tiple imputation analysis to correct for cases that have a small difference in probability to
be assigned to either one of the clusters. In node-negative patients, cluster 1 patients had
significant increased risk for distant recurrence (P=0.01), shorter cancer-specific survival
(P=0.02), and shorter OS (P=0.05, figure 3A-C). At the time of the analyses, median dura-
tion of follow-up was 7.1 years (range 2.5–9.8 years). 
Multivariate Analyses
Multivariate analyses were performed to assess whether the observed prognostic value of
the clusters was independent from standard prognostic variables for the complete patient
group and for node-positive and negative patients (table 2). T-stage, N-stage, circumferen-
tial margin status, distance of the tumor to the anal verge, and tumor differentiation were
considered in a Cox’s regression analysis. In node-negative patients, the quantitative MINT
locus methylation profile was, of the considered variables, the only selected predictive fac-
tor for distant disease recurrence and cancer-specific survival. OS was also affected by T-
stage in patients without nodal involvement. Circumferential margin involvement of the
tumor and short (<5 cm) distance of the tumor from the anal verge increased the risk of
distant recurrence and decreased cancer-specific survival and OS in node-positive rectal
cancer patients. Possible dependence of the results on any of the 42 different study sites
was evaluated in the published clinical trial report26 and ruled out (data not shown) also in
our analyses. The multivariate results show that the identified subclass of rectal cancers is
independently predictive of distant recurrence.
MINT3 and MINT17
The Gini-index indicating variable importance in RF clustering shown in table 1A demon-
strated MINT3 and MINT17 to hold the most information to form the two clusters com-
pared to the other five MINT loci. We continued to assess whether methylation levels at
MINT3 and MINT17 have prognostic value as a separate marker set. The quantitative
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Clinical and Tumor All Patients P-value Node-negative P-value
Pathology Factors (n=251) Patients (145)
Cluster 1 Cluster 2 Cluster 1 Cluster 2
n=89 n=162 n=55 n=90
Sex
Male 64 (39) 98 (61) 0.08 38 (40) 56 (60) 0.40
Female 25 (28) 64 (72) 17 (33) 34 (67)
Age
Mean (SE) 64.8 (1.2) 62.5 (0.9) 0.15 65.4 (1.7) 63.4 (1.2) 0.33
TNM-stage
I 29 (41) 41 (59) 0.22 29 (41) 41 (59) 0.40
II 26 (35) 49 (65) 26 (35) 49 (65)
III 34 (32) 72 (68) - -
N-status
N0 (≥12 examined) 12 (35) 22 (65) 0.53 12 (35) 22 (65) 0.84
N0/NX (<12 examined) 44 (39) 68 (61) 43 (39) 68 (61)
N1 (1-3 positive) 21 (34) 40 (66) - -
N2 (≥4 positive) 12 (27) 32 (73) - -
Differentiation
Well 5 (28) 13 (72) 0.78 3 (33) 6 (67) 0.99
Moderately 66 (37) 110 (63) 44 (39) 70 (61)
Poor 18 (32) 39 (68) 8 (36) 14 (64)
Location distant recurrences
Liver 11 (41) 16 (59) 0.62 4 (50) 4 (50) 0.37
Non-liver 20 (49) 21 (51) 11 (73) 4 (27)
Resection type
Low anterior 54 (32) 113 (68) 0.26 32 (34)  62 (66) 0.35
Abdominoperineal 33 (43) 44 (57) 21 (47) 24 (53)
Hartmann 2 (29) 5 (71) 2 (33) 4 (67)
Circumferential margin
Negative 72 (35) 131 (65) 0.39 52 (39) 81 (61) 0.54
Positive 17 (35) 31 (65) 3 (25) 9 (75)
Table 1B: Comparison of Clinical and Tumor Pathology Factors and MINT Locus Clusters
methylation data of MINT3 and MINT17 were entered into the RF algorithm and the resul-
ting MDS plot is given in figure 4A. Four clearly separate clusters are formed and the corres-
ponding methylation level differences between the clusters are plotted in figure 4B. Cluster
3 containing 67 patients (27%) corresponds to the previously identified high-risk cluster 1 as
average MINT3 methylation index are relatively high and MINT17 methylation index is rela-
tively low. In KM analysis, cluster 3 patients are shown to be at significantly increased risk for
distant metastasis in node-negative patients compared to the other three clusters (figure 4C).
In multivariate analysis the results showed that the high-risk cluster 3 was selected as the only
independent factor among the variables analyzed predicting in node-negative patients distant
recurrence probability (HR:2.84, 95%CI:1,22-6,62, P=0.02), cancer-specific (HR:3,29,
95%CI:1,33-8,12, P=0.01) and overall survival (HR: 2,21, 95%CI:1,13-4,29, P=0.02). It was
concluded that patients at increased risk for distant metastasis can be defined as having tumors
with a MINT3 methylation level > 0.72 and MINT17 methylation level < 0.14. The analy-
sis also demonstrated that the specific combination of increased methylation at MINT3 and
decreased methylation at MINT17 is required for the prognostic information.
Discussion
Most studies of biomarkers in large bowel adenocarcinoma include colon, as well as rectum,
even though rectal and colon cancers are treated differently. Moreover, right-sided and left-
sided bowel adenocarcinomas have different molecular patterns; microsatellite instability and
methylator phenotype are rarely seen in the rectum27. Our data represents one of the largest
clinical analyses of methylation biomarkers in rectal cancer specifically, and also demonstrates
the first quantitative correlation between MINT methylation levels and disease progression. 
The preliminary study demonstrated a progressive increase in methylation levels of spe-
cific MINT loci comparing normal and adenomatous rectal tissue. No significant change in
methylation level at any MINT locus was detected comparing adenomatous and malignant
rectal tissue. A correlation between methylation of MINT loci and development of adeno-
matous dysplasia has been reported17. Our data are unique, as we used paired normal-ade-
noma-cancer specimens, quantitative techniques, and analyzed rectal cancers only. The
results of our clinical study identified two prognostic categories of rectal cancer based strict-
ly on the absolute quantitative differences in methylation level. Our data show that methy-
lation levels at multiple and two specific identified MINT loci are related to rectal tumor
formation, and that they may be seen as surrogate markers of distant rectal cancer disease
recurrence and disease survival. The role of non-coding regions have been of much inte-
rest in that they may be influential in gene encoding regions28-30. Especially interesting is
that the chromosomal location (1p36) of the MINT3 locus, which undergoes methylation
in most rectal adenomas, contains many cancer-related genes. Methylation of MINT loci 1,
2, 12, and 31 is often studied in relation to the CpG island methylator phenotype (CIMP)
that forms a subclass of right colon tumors closely associated with microsatellite instability
(MSI)31. In our study, the unsupervised clustering analyses did not identify a CIMP associ-
ated with hypermethylation in the selected MINT loci (data not shown). Interestingly, a
combination of relative hyper- as well as hypomethylation was observed in the identified
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All patients Node-negative Node-positive
n=251 n=145 n=106
Variable HR P-value HR P-value HR P-value
(95%CI) (95%CI)
Distant recurrence
T-stage (3/4) 1.70 0.09 1.19 0.70 2.91 0.05
(0.92-3.16) (0.49-2.93) (1.01-8.37)
Nodal status (+) 2.47 0.001 - - - ns
(1.44-4.23)
Circumferential  1.87 0.03 2.40 0.21 1.77 0.08
margin (+) (1.07-3.28) (0.62-9.39) (0.94-3.33)
Distance from anal 0.71 0.19 1.50 0.40 0.50 0.03
verge >5 cm (0.43-1.18) (0.59-3.85) (0.27-0.92)
Poor differentiation 1.39 0.23 1.24 0.71 1.59 0.16
(0.81-2.38) (0.40-3.89) (0.84-3.01)
MINT locus profile 1.68 0.04 4.17 0.002 1.11 0.75
(cluster 1) (1.03-2.73) (1.72-10.10) (0.59-2.09)
Cancer-specific survival
T-stage (3/4) 2.12 0.03 1.88 0.21 2.85 0.05
(1.07-4.19) (0.70-5.04) (0.98-8.26)
Nodal status (+) 2.47 0.002 - - - ns
(1.41-4.35)
Circumferential  1.93  0.02 2.28 0.23 1.88 0.05
margin (+) (1.09-3.41) (0.59-8.81) (0.99-3.56)
Distance from anal  0.59 0.05  1.46 0.46 0.40  0.004
verge >5 cm  (0.35-0.99) (0.53-4.03)  (0.22-0.75)
Poor differentiation 1.56 0.11 1.28 0.67 1.70 0.12
(0.91-2.70)  (0.41-4.06) (0.88-3.29)
MINT locus profile  1.47 0.15 3.74  0.005 0.99 0.98
(cluster 1) (0.88-2.45) (1.48-9.43) (0.51-1.93)
Overall survival
T-stage (3/4) 1.92 0.01 2.12 0.04 1.98 0.10
(1.14-3.23) (1.05-4.29) (0.87-4.50) 
Nodal status (+) 1.88 0.004 - ns - ns
(1.22-2.92)
Circumferential  1.66 0.04 1.65 0.33 1.66 0.08
margin (+) (1.02-2.69) (0.60-4.53)  (0.95-2.91)
Distance from anal 0.69 0.09 0.96 0.92 0.55 0.03
verge >5 cm (0.45-1.06) (0.49-1.90) (0.32-0.95)
Poor differentiation 1.33 0.22 1.06 0.90 1.37 0.28
(0.84-2.09) (0.45-2.47) (0.77-2.44)
MINT locus profile  1.48 0.06 2.68 0.003 1.00 1.00
(cluster 1) (0.98-2.24) (1.41-5.11) (0.57-1.77)
Table 2: Multivariate Analysis Results of All Patients and Node-negative Patients
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Figure 3. (A) Kaplan-Meier plots grouping analy-
zed node-negative total mesorectal exci-
sion trial patients into clusters 1 and 2
and comparing postoperative distant
recurrence free survival probability. (B)
Cancer-specific and (C) overall survival
are plotted. 
Figure 4. Random forest analyses using only
MINT3 and 17 quantitative methylation
data as input. (A) Multidimensional sca-
ling plot showing the four clusters. (B)
Box plots comparing the differences in
methylation levels (MI) between the four
clusters. (C) Kaplan-Meier plot illustra-
tes the distant recurrence probability
between high-risk cluster 3 and the com-
bined clusters 1, 2, and 4. 
subclasses. This specific combination was even required to show prognostic value on rec-
tal cancer distant recurrence rates. This corroborates that CIMP does not occur in the rec-
tum and that rectal cancer may have different epigenetic pathological changes compared
to proximal colon adenocarcinoma. Reported correlations between MINT 1, 2, 12, and 31
and clinico-pathological features overlap with the features of MSI(+) tumors (right-sided-
ness, poor differentiation, early stage) and therefore our results can not be compared27,32,33.
We previously showed relevance of the AQAMA technique testing methylation levels at
MINT 1, 2, 12, and 31 and increased methylation at this loci detected by the AQAMA
assay was significantly correlated to right-sided colon tumors10. 
Our preliminary study data indicates that methylation events at the measured MINT
loci are related to early dysplastic proliferation of subclasses of rectal premalignancies and
MINT loci may be a clinical biomarker. Subsequently, in a large rectal cancer patient group,
RF clustering was able to identify, in an unbiased manner, two groups of rectal cancer
patients that were naturally present within the quantitative methylation data. This demon-
strated that subclassification of rectal cancer patients can be made based on absolute quan-
titative methylation level differences.
There was no correlation between MINT methylation profile and nodal status; in node-
negative patients, the MINT profile was the only selected variable in multivariate analyses
for distant recurrence probability and, subsequently, for cancer-specific survival. Identifying
stage I and II patients at risk for distant disease recurrence, assessing primary tumors for
predictive genomic biomarkers would be important for stratifying adjuvant treatment.
Moreover, since accurate upstaging from stage II to III remains a difficult task34, we appro-
ached this by a quantitative analysis of a specific panel of epigenetic biomarkers. The advan-
tage of using genomic analysis is the stability of DNA as compared to mRNA in PEAT,
where, in the latter, there is a higher level of degradation with time. Further studies will
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Profiling by Unsupervised Random Forest Clustering
Each tree is trained on a bootstrap dataset, drawn with replacement from the original data-
set, and on a fixed number of randomly chosen predictors. Each tree, containing about two-
third of the original dataset, places a vote on bagged data points. Bagging eliminates the
need for a separate training and validation set in decision tree learning1. The multidimen-
sional distances are expressed in the resulting proximity matrix of the RF algorithm. A series
of 5000 trees were trained with 3 random variables per node. The random forest (RF) dis-
similarity algorithm used is based on individual decision tree predictors and automatically
dichotomizes the expressions into clusters in a data-driven approach. The groups were the-
refore not established by employing cut-offs. The Gini-index indicating individual MINT
loci variable importance was calculated2-4.
Cluster Assignment 
We used the proximity matrix obtained from the RF clustering algorithm (represented in a
multi-dimensional scaling (MDS)) plot to perform a cluster analysis.5 Cluster assignments
were obtained by performing an expectation maximization algorithm with a mixture of
Gaussians (EM-MoG) for two clusters on the scaled data. EM-MoG clustering is based on
a two-step approach to fit Gaussian probability models on the data, in order to estimate
most likely clusters. All analyses to identify the MINT locus profiles were performed using
MATLAB software (v7.3, MathWorks) and “R” (http://cran.r-project.org). The number of
clusters was established by inspection of the MDS-plot6,7. The posterior cluster probabili-
ties are subsequently used in a multiple imputation procedure to account for cluster mem-
bership uncertainty.
Further Statistical Analyses
In the preliminary study, differences between methylation levels of the normal, adenoma-
tous, and cancerous tissue from the same PEAT block were assessed by non-parametric,
Wilcoxon’s rank sum-test for paired samples. 
For the clinical study on TME trial patients, differences in survival, clinical and tumor-
pathological factors between patients assigned by RF clustering were analyzed. Specimens
that did not yield sufficient DNA quantity or quality for PCR were excluded. Chi-square
tests were used to compare proportions. Mann-Whitney or Kruskal-Wallis u-tests were used
to compare ordinal variables. Student’s t-test was used to assess differences in age. Survival
differences between groups were visualized by the Kaplan–Meier method and log-rank test
assessed significance. The Cox proportional hazards model was used for multivariate ana-
lysis of time-to-event endpoints. Results are presented as hazard ratios and 95% confiden-
ce intervals. Co-variables entered in the model included T-stage, N-stage, circumferential
margin status, distance of the tumor from the anal verge, and tumor differentiation. A two-
sided P-value of 0.05 or less indicated statistical significance. All clinical correlative analy-
ses with identified clusters were performed using SPSS statistical software (v12.0.1, SPSS
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Inc, Chicago). The day 0 point for the analyses of survival and recurrence was the day of
surgery. Data on patients who were alive or free of recurrence were censored at the time
of the last follow-up. Uncertainty in RF cluster membership assignment was taken into
account using multiple imputation8, where multiple (M=5) complete datasets were gene-
rated using the posterior cluster membership probabilities obtained from the EM-MoG algo-
rithm.
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The distribution of the methylation data for each MINT locus for each tissue category was
characterized by Kurtosis and Kolmogorov-Smirnov (K-S) analysis testing adherence to the
normal distribution assumption. We have previously used this approach in the context of
quantitative methylation data1. Kurtosis indicates the size of a distribution’s tail. The hig-
her the Kurtosis, the more likely it is that the outlier MI values differ substantially from
values around the mean (Kurtosis>5 is considered significant for a sample size n<50)2. K-
S analysis was used to test coherence of the data-set to the normal distribution assumpti-
on3, 4. Significance indicates that the tested data-set is not normally distributed and values
higher than the “most extreme positive difference” do significantly differ from the mean.
table 1 shows the distribution parameters of the measured methylation indices for each
MINT locus and for each tissue category. MINT1, 12, and 25 methylation data distributi-
on demonstrates high Kurtosis in adenomatous tissue while Kurtosis is lower than five in
normal epithelium. K-S test becomes significant during adenomatous transformation for
MINT1, 12, 17 and 251-4. 
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MINT1 Kurtosis 1.6 31.4 34.8
K-S analysis Mean 0.01 0.02 0.01
Most extreme positive difference 0.21 0.45 0.35
P-Value 0.31 <0.001 <0.001
MINT2 Kurtosis 20.9 3.9 3.4
K-S analysis Mean 0.01 0.10 0.05
Most extreme positive difference 0.49 0.35 0.38
P-Value <0.001 <0.001 <0.001
MINT3 Kurtosis 1.3 1.4 1.2
K-S analysis Mean 0.04 0.49 0.53
Most extreme positive difference 0.31 0.14 0.09
P-Value 0.03 0.36 0.92
MINT12 Kurtosis 0.7 21.8 25.7
K-S analysis Mean 0.03 0.04 0.04
Most extreme positive difference 0.21 0.33 0.35
P-Value 0.26 <0.001 <0.001
MINT17 Kurtosis 1.7 0.5 0.6
K-S analysis Mean 0.25 0.24 0.25
Most extreme positive difference 0.26 0.24 0.19
P-Value 0.12 0.01 0.04
MINT25 Kurtosis n.a. 20.4 36.9
K-S analysis Mean 0.00 0.01 0.01
Most extreme positive difference 0.00 0.48 0.50
P-Value n.a. <0.001 <0.001
MINT31 Kurtosis 19.6 14.1 12.6
K-S analysis Mean 0.00 0.02 0.00
Most extreme positive difference 0.53 0.45 0.40
P-Value <0.001 <0.001 0.002
*Kurtosis, Kolmogorov-Smirnov (K-S) Analysis
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Characteristic Cases in TME Cases eligible Selected cases Non-selected
trial for current for current cases for
(n=1805) study study (n=251) current study
(n=672) (n=421)
Age Category*
Median 65 64 63 64
Range 23-92 23-92 27-85 23-92
Sex*
Male 1151 (64) 419 (62) 162 (65) 257 (61)
Female 654 (36) 253 (38) 89 (35) 164 (39)
Type of Resection*
None 45 (2) - - -
Low anterior 1183 (66) 442 (66) 167 (66) 275 (65)
Abdominoperineal 485 (27) 206 (31) 77 (31) 129 (31)
Hartmann 90 (5) 24 (3) 7 (3) 17 (4)
Unknown 2 (<1) - - -
TNM stage*
0 28 (2) 11 (2) - 11 (3)
I 509 (28) 203 (30) 70 (28) 133 (32)
II 497 (28) 186 (28) 75 (30) 111 (26)
III 624 (35) 272 (40) 106 (42) 166 (39)
IV 122 (7) - - -
Unknown or no resection 25 (1) - - -
Circumferential Margin*
Negative 1494 (83) 552 (82) 207 (82) 345 (82)
Positive 301 (17) 120 (18) 44 (18) 76 (18)
Unknown 10 (<1) - - -
* P-value not significant; patients in current study were not significantly different from the original trial popula-
tion. 
Table 1: Comparison of Patient Characteristics of the TME Trial and Selected Cases 
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Abstract 
Purpose: Risk assessment for loco-regional disease recurrence would be highly valuable in
preoperative treatment planning for patients undergoing primary rectal tumor resection.
Epigenetic aberrations such as DNA methylation have been shown to be significant prog-
nostic biomarkers of disease outcome. In this study, we evaluated the significance of a quan-
titative epigenetic multimarker panel analysis of primary tumors to predict local recurren-
ce in rectal cancer patients from a retrospective multicenter clinical trial. 
Experimental Design: Primary tumors were studied from patients enrolled in the trial
that underwent total mesorectal excision (TME) for rectal cancer (n=325). Methylation
levels of seven methylated-in-tumor (MINT) loci were assessed by absolute quantitative
assessment of methylated alleles (AQAMA). Unsupervised random forest clustering of quan-
titative MINT methylation data was used to show subclassification into groups with mat-
ching methylation profiles. 
Results: Variable importance parameters (Gini-Index, GI) of the clustering algorithm indi-
cated MINT 3 and 17 (GI=20.2 and 20.7, respectively) to be informative for patient grou-
ping compared to the other MINT loci (highest GI 12.2). When using this two-biomarker
panel, four different patient clusters were identified. One cluster containing 73% (184/251)
of the patients was at significantly increased risk of local recurrence (hazard ratio 10.23,
95% CI 1.38-75.91) in multivariate analysis, corrected for standard prognostic factors of
rectal cancer. This group showed a significant higher local recurrence probability than
patients receiving preoperative radiation (P<0.0001). 
Conclusion: Quantitative epigenetic subclassification of rectal cancers has clinical utility
in distinguishing tumors with increased risk for local recurrence and may help tailor treat-




Rectal cancer is the second most common cancer of the digestive system in the USA1.
Worldwide, colorectal cancer has the second highest incidence2, with rectal tumors consti-
tuting 33% of large bowel tumors3. An important clinical feature of rectal cancer is its close
anatomical relation to the small pelvis which makes it prone to local recurrence after sur-
gical removal even at early stage disease. Loco-regional recurrence occurs in approximate-
ly 10% of rectal cancer patients after total mesorectal excision (TME) surgery with curati-
ve intent4, 5. However, loco-regional recurrence is difficult to treat with a very poor overall
survival prognosis.
Fixation in the small pelvis makes malignancies of the rectum suitable for external
beam radiation therapy. The Dutch multicenter TME clinical trial demonstrated significant
reduction of local recurrence by adding short course (5 x 5Gy) preoperative radiation the-
rapy to TME6. The multidisciplinary treatment of rectal cancer is a subject of many clinical
trials randomizing patients to regimens that include various neoadjuvant therapies combi-
ned with radical surgery7-10.
(Neo)adjuvant regimens aim at two clinical outcome parameters: improvement of local
control and/or to reduce distant recurrence, the latter occurring in approximately 25% of
patients after radical primary tumor resection4. The improved local control shown by the
TME clinical trial has not translated into an overall survival benefit in the trial analyses after
6 years of follow-up and the data show that overall survival is determined predominantly
by distant recurrence4. The trial data further show that only 25% of non-irradiated tumors
with distant spread also recur locally, whereas 60% of the locally recurrent tumors show
distant disease spread4, 6. The distant-spreading, non-locally recurring tumor may therefo-
re constitute a separate subclass of rectal cancer. 
Allocation of patients to neoadjuvant therapies might lead to overtreatment; since 10%
of rectal cancer patients will develop local recurrence, 90% of patients may be overtreated.
Neoadjuvant therapies used in the treatment of rectal cancer have their specific morbidi-
ties, as has been shown for both radiotherapy11 and combined chemoradiotherapy12. It is
therefore of great importance to define biomarkers that can categorize tumors into local
and distant spreading type preoperatively to target the multimodality treatment regimens
towards a more systemic or local approach. 
Molecular analysis of primary tumor tissues is an attractive form of preoperative dia-
gnostics since rectal primary tumors are easily accessible for biopsy, which is routinely per-
formed in the preoperative work-up. In contrast to colorectal cancer, to date few biomar-
kers have been described to be predictive or prognostic value specifically in rectal cancer.
It is important especially in multivariate analyses to distinguish rectal cancer from other
bowel adenocarcinomas or colon cancer. Specific factors need to be taken into account for
rectal cancer as compared to colon cancer, such as circumferential margin involvement,
type of surgical procedure or distance of the tumor to the anal verge13.
Epigenetic changes, such as changes in DNA methylation status, are regarded as early
events contributing to carcinogenesis14. Methylation of cytosine residues in DNA is one of
the mechanisms regulating transcriptional activity15. In cancer, aberrant DNA hypermethy-
lation of specific regions as well as global hypomethylation is observed16. In this study, we
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investigated epigenetic changes in rectal cancer and specifically methylation of methylated-
in-tumor (MINT) loci. MINT loci are CpG dinucleotide-rich regions located in nonprotein-
encoding DNA regions and have been reported to become methylated in a tumor-specific
manner in (colo)rectal cancer17, 18, gastric cancer19 and recently malignant melanoma20. 
In a previous study, we have quantitatively studied methylation of MINT loci in pre-
malignant stages of rectal cancer and have shown that the MINT methylation index inc-
reases during adenomatous transformation of normal epithelium18. We also identified a
quantitative, two MINT methylation biomarker panel (MINT3 and MINT17) that is pre-
dictive of distant recurrence in early, node-negative rectal cancers patients18. In the present
study, we assessed the value of this panel to predict local recurrence of patients enrolled in
the multicenter, randomized, clinical TME trial. 
Materials and Methods
Tissue specimens
Primary paraffin-embedded archival tissue (PEAT) specimens were obtained from 325 non-
irradiated patients enrolled in the TME multicenter clinical trial4. Patients used in this study
fulfilled the following criteria: non-irradiated, TNM stage I-III, with no evidence of disease
after surgical resection. Using power calculations, a sample size of 250 patients was calcu-
lated to be sufficient to obtain statistical significance for predicting recurrence (with   = 0.05
and a power of 90%), as described previously18. Allowing for 30% loss of patient samples
due to availability and quality of PEAT and DNA, 75 additional PEAT specimens were col-
lected. In eleven patient PEAT blocks, tumor tissue was no longer present on the section.
DNA was isolated from 314 randomly selected patient specimens with sufficient tumor cell
numbers. After processing and sodium bisulfite treatment, samples of 251 patients yielded
sufficient amount of quality DNA for AQAMA. The selected group of patients analyzed in
our previous study18 did not differ from non-selected patients in the non-irradiated treat-
ment arm or from the complete trial population. Trial eligibility criteria and follow-up pro-
tocols have been described previously4, 21, 22. Non-irradiated patients were selected since
predictive value of the tested biomarkers for local recurrence probability should be tested
in patients who did not receive adjuvant therapy, as this affects local recurrence.
For external validation studies, 43 additional TME trial patients that adhered to the
same selection criteria were added. Further, 42 non-irradiated patients that participated in
the transanal endoscopic microsurgery (TEM)23 were added and these have been previou-
sly described24. DNA was extracted from adenomatous and cancer tissues. The adenomas
were subdivided into cases consisting of only adenoma tissue in the resection (A, n=21)
and adenoma fractions of cases with a carcinoma focus infiltrating at least in the submuco-
sa (A, C+, n=8). The carcinomas were subdivided into groups: tumor fractions consisting
of a mixture of adenoma and carcinoma tissue (C+A, n=6) and only carcinomas (C, n=7).
We further collected normal rectal epithelial tissue from the tumor specimen resection mar-




DNA preparation from PEAT specimens
From the TME trial patient’s primary tumor PEAT specimens, 7-µm tissue sections were
cut and mounted on non-adhesive glass slides. Tumor-representative areas on H&E-stained
sections were identified and marked by a surgical pathologist specializing in rectal cancer
(JHJMvK). Per patient, two tissues sections were deparaffinized. DNA was isolated from
microdissected tissue from the marked areas and modified by sodium bisulfite, as previou-
sly described25. Salmon sperm DNA was added as a carrier26. Before and after sodium bisul-
fite modification, double-stranded and single-stranded DNA were quantified using
PicoGreen and OliGreen assays (Molecular Probes; Invitrogen, Carlsbad, CA), respective-
ly. Sufficient input DNA for AQAMA was determined as described17. To assess background
signal, a salmon sperm DNA sample without tumor DNA was included in all assays in tri-
plicate. To prevent any bias, PEAT blocks and isolated DNA samples were coded.
AQAMA MINT locus methylation level assessment
Primary tumor methylation levels of methylated-in-tumor (MINT) loci 1,2,3,12,17,25 and
31 were assessed by AQAMA in triplicate17. Controls for specificity of AQAMA for both
methylated and unmethylated sequences, as well as controls for nonspecific amplification,
were included17, 27. As a final outcome of the analysis, a sample’s methylation index (MI)
was the mean value of three MI measurements that were calculated for each well as fol-
lows: [copy number methylated alleles / (copy number methylated alleles+ copy number unmethylated
alleles)]. Of these 3 measurements the standard deviation (SD) was calculated. Values with
a SD <0.1 were accepted and used in analysis. When the SD was larger than 0.1 this was
in most cases due to that 1 or 2 out of the 3 methylated or unmethylated measurements
was undetermined. These cases were identified and the MI was than calculated as mean
methylated copy number / (mean methylated copy number + mean unmethylated copy
number). If 1 out of 3 methylated or unmethylated measurements could not be determi-
ned this value was not incorporated in the calculation. If 2 or more out of 3 measurements
could not be determined the value was zero. Cases with 6 complete results and with an
SD > 0.1 were individually evaluated. When after omitting the most deviate MI value the
SD was still > 0.1 the sample was excluded from analysis. 
Statistical analysis
Differences in recurrence probability, survival and clinical and tumor pathologic factors
were analyzed between TME trial patients assigned by unsupervised random forest (RF)
clustering using MINT3 and MINT17 as described18. Unsupervised RF clustering dissimi-
larity algorithms are based on individual–decision tree predictors and it automatically dicho-
tomizes the expressions into clusters in a data-driven approach28. Groups are therefore not
established by employing cutoffs. The internal validation of RF clustering further elimina-
tes the need for separate training and validation sets to test reproducibility of cluster forma-
tion. External validation of the data in an independent patient group is still required. The
GI29, 30 of each input variable (MINT locus) was given. This index measures the inequali-
ty of two distributions and is defined as the ratio between the area spanned by the obser-
ved cumulative distribution and the area of a uniform hypothetical cumulative distribution
for a non-discriminating variable. A higher GI shows increasing inequality and therefore
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higher discrimination of that input variable. 
Specimens yielding insufficient or low quality DNA for polymerase chain reaction were
excluded. To compare ordinal variables, Mann-Whitney and Kruskal-Wallis U tests were
performed. Differences in age were assessed using t tests. Cumulative incidences, accoun-
ting for death as a competing risk, were used to visualize survival differences31 and signifi-
cance was assessed by the log-rank test. For multivariate analysis the Cox proportional
hazards model was used, with results presented as hazard ratios and 95% confidence inter-
vals. Co-variables entered in the model included T stage, N stage, circumferential margin
status, distance of the tumor from the anal verge and tumor differentiation. All clinical cor-
relative analyses with identified clusters were performed using SPSS statistical software
(version 16.0.1, SPSS Inc, Chicago, IL). A two-sided P-value of 0.05 or less was conside-
red statistically significant. Data on patients alive or free of recurrence were censored at the
time of the last follow-up. 
Results
MINT locus methylation profiling 
In our previous study, methylation levels at the seven MINT loci were measured in nor-




1 2 3 4 1,2 and 4 P-Value 
(n=33) (n=83) (n=67) (n=68) (n=184) 
Mean MI Mean MI Mean MI Mean MI Mean MI Cluster 3 
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) vs. 
Clusters 1,2 and 4 
MINT1 0.09 0.14 0.04 0.07 0.11 <0.001
(0.04-0.15) (0.09-0.19) (0.00-0.07) (0.03-0.11) (0.07-0.13) 
MINT2 0.14 0.12 0.05 0.07 0.10 0.001 
(0.06-0.22) (0.07-0.16) (0.02-0.09) (0.03-0.10) (0.08-0.13) 
MINT3 0.85 0.37 0.88 0.38 0.46 <0.001 
(0.82-0.87) (0.32-0.43) (0.86-0.90) (0.31-0.45) (0.41-0.50) 
MINT12 0.04 0.07 0.03 0.03 0.05 0.07 
(0.02-0.06) (0.03-0.10) (0.01-0.04) (0.02-0.04) (0.03-0.06) 
MINT17 0.28 0.31 0.06 0.07 0.22 <0.001 
(0.24-0.33) (0.28-0.35) (0.05-0.07) (0.06-0.07) (0.19-0.24) 
MINT25 0.24 0.08 0.10 0.07 0.11 0.04 
(0.12-0.37) (0.05-0.12) (0.04-0.16) (0.03-0.11) (0.08-0.14) 
MINT31 0.09 0.05 0.02 0.04 0.05 0.10 
(0.02-0.17) (0.02-0.08) (0.00-0.03) (0.01-0.07) (0.03-0.08) 
MI: methylation index.  CI: confidence interval. 
Supplemental Table 1: Methylation Index Values for Individual  Cluster and Combined 
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Figure 1. Methylation index plots of MINT3 and MINT17 for individual patients. Representation of MINT3
(X-axis) and MINT17 (Y-axis) methylation indices for TME trial patients using all seven and using
only MINT3 and 17 in the random forest algorithm in Figures 1a and 1b, respectively. The hori-
zontal and vertical reference lines represent cut-offs to separate the groups. 
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M3 & M17 M3 & M17 
Node Negative P- Node Positive P-
(n=145) value (n=106) value
Clinical parameters Cluster Cluster Clusters Cluster 
1,2 & 4 3  1,2 & 4 3
n=108 n=37  n=76 n=30
Sex       
Male 70 (75) 24 (25) 1 46 (68) 22 (32) 0.22 
Female 38 (75) 13 (25)  30 (79) 8 (21)  
Age       
Mean (SE) 63.9  64.9 (2.0) 0.67 61.0 (1.4) 65.2 (1.9) 0.10 
(1.1)       
TNM-stage       
I 51 (73) 19 (27) 0.66 - - - 
II 57 (76) 18 (24)  - -  
III - -  76 (72) 30 (28)  
N-status       
N0 (≥12 examined)  27 (79) 7 (21) 0.51 - - 0.95 
N0/NX (<12 examined) 81 (73) 30 (27)  - -  
N1 (1-3 positive) - -  44 (71) 18 (29)  
N2 (≥4 positive) - -  32 (73) 12 (27)  
Differentiation       
Well 7 (78) 2 (22) 0.88 7 (78) 2 (22) 0.91 
Moderately 84 (74) 30 (26)  44 (71) 18 (29)  
Poor 17 (77) 5 (23)  25 (71) 10 (29)  
Location distant recurrences       
Liver 6 (75) 2 (25) 0.20 13 (68) 6 (32) 0.83 
Non-liver 7 (47) 8 (53)  17 (65) 9 (35)  
Resection type       
Low anterior 72 (77) 22 (23) 0.55 53 (73) 20 (27) 0.76 
Abdominoperineal 31 (69) 14 (31)  22 (69) 10 (31)  
Hartmann 5 (83) 1 (17)  1 (100) 0 (0)  
Circumferential margin       
Negative 98 (74) 35 (26) 0.73 54 (73) 20 (27) 0.66 
Positive 10 (83) 2 (17)  22 (69) 10 (31)  
Supplemental Table 2: Comparison of clinical and tumor pathology factors between two MINT loci
clusters in node-negative and node-positive patients.
MINT loci, except for MINT17, were mostly unmethylated. Significantly higher methyla-
tion of MINT2, 3 and 31 was detected in adenoma and cancer tissue compared to normal
tissue. Further analysis of the quantitative data showed non-parametric distributions indi-
cating presence of subgroups for MINT1, 2, 12, 17, 25 and 31 in adenoma and cancer tis-
sue. Based on these findings, we concluded that all seven MINT loci had potential to sub-
classify rectal cancer patient groups with corresponding methylation level patterns.
Quantitative methylation data of the seven MINT loci were then used to perform unsuper-
vised RF clustering analysis. An important aspect of RF clustering is that it eliminates a vali-
dation-training approach because of its internal validation quality. External validation of the
data is still required. The multidimensional scaling (MDS) plot as an outcome of using all
seven MINT loci in the RF clustering algorithm suggested presence of two clusters18. The
GI of the RF-analysis, indicating variable importance, appointed MINT3 and MINT17 as
the two MINT loci that carried the most information to form the clusters18. Being a mea-
sure of inequality, the higher the GI, the more the clusters can be considered different based
on that specific biomarker. MINT3 and MINT17 were shown to have the highest GI (20.2
and 20.7, respectively), compared to the five other MINT loci (range 6.0 - 13.5)18. The
MDS plot of the RF clustering using only these two biomarkers showed four clearly sepa-
rate groups18. Methylation level differences at the seven studied MINT loci between the
four clusters are given in supplemental table 1. For a more simplified representation, indi-
vidual patient MI values of MINT3 and were rendered in XY-plots. In figure 1A the
patients are labeled according to the outcome of the RF analysis using seven MINT loci that
showed presence of two clusters. In figure 1b the patients are labeled according to the
outcome of the RF analysis using only MINT3 and MINT17 that showed presence of four
clusters. figure 1B further shows that the groups can be divided by a cut-off of MI=0.73
for MINT3 and MI=0.14 for MINT17 with almost no miss-classification. This is important
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Figure 2. Cumulative incidence plots displaying local recurrence incidence for the four allocated clusters.
Cumulative incidence plots showing differences in local recurrence rates between the four sepa-
rate clusters in A and distant in B for cluster 3 patients compared to patients in the combined clus-





1,2 & 4 3
n=184 n=67
Sex
Male 116 (72) 46 (28) 0.41
Female 68 (76) 21 (24)
Age
Mean (SE) 62.7 (0.9) 65.0 (1.4) 0.17
TNM-stage
I 51 (73) 19 (27) 0.78
II 57 (76) 18 (24)
III 76 (72) 30 (28)
N-status
N0 (≥12 examined) 27 (79) 7 (21) 0.67
N0/NX (<12 examined) 82 (73) 30 (27)
N1 (1-3 positive) 44 (72) 17 (28)
N2 (≥4 positive) 32 (73) 12 (27)
Differentiation
Well 14 (78) 4 (22) 0.90
Moderately 128 (73) 48 (27)
Poor 42 (74) 15 (26)
Location distant recurrences
Liver 19 (70) 8 (30) 0.44
Non-liver 24 (59) 17 (41)
Resection type
Low anterior 125 (75) 42 (25) 0.46
Abdominoperineal 53 (69) 24 (31)
Hartmann 6 (86) 1 (14)
Circumferential margin
Negative 152 (73) 55 (27) 1
Positive 32 (73) 12 (27)
Table 1: Comparison of clinical and tumor pathology factors between identified two MINT locus clusters
in all patients
because such a two dimensional cut-off algorithm can be used for validation experiments
(see below). The two-biomarker cluster allocation of figure 1B was continued to be use for
the clinical correlation studies. 
Univariate analysis of clinicopathological parameters
Next, we were interested in comparing probability of loco-regional recurrence between the
four clusters. As shown in figure 2A, the incidence of loco-regional recurrence was lowest
for patients in cluster 3. The quantitative methylation pattern of cluster 3 patients was that
the tumors showed significantly higher methylation at MINT3 and lower methylation at
MINT17. This pattern corresponds with the clinically relevant rectal cancer patient cluster
at high-risk for distant recurrence and decreased cancer-specific and overall survival that
we previously identified18. Clusters 1, 2 and 4 showed similar probability outcomes. The
difference in local recurrence probability became more evident and reached statistical sig-
nificance after combining clusters 1, 2 and 4 (P = 0.03; figure 2B). This result shows that
the specific combination of increased methylation at MINT3 and decreased methylation at
MINT17 is predictive of reduced local recurrence probability. From this data it was demon-
strated that quantitative methylation assessment of MINT3 and MINT17 identifies a patient
group with an inversed risk incidence for distant recurrence and local recurrence.  
Significance of MI differences between the cluster 3 and the combined clusters 1, 2
and 4 are given in supplemental table 1. It is demonstrated that the 95% confidence
intervals of MINT3 and MINT17 do not overlap indicating that the rectal cancer patient
groups’ epigenetic classification is very distinct. The results also show that MINT1 and
MINT2 can be helpful as discerning biomarkers for both patient groups.
Using univariate analysis, standard clinicopathological parameters including sex, age,
TNM stage, N-status, tumor differentiation, location of distant recurrences, resection type
and circumferential margin status were compared between cluster 3 and the combined
group of clusters 1, 2 and 4. These parameters did not significantly differ between the two
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Local Recurrence
Variable HR (95%CI) P Value
T-Stage(3-4) 1.16 (0.44-3.08) 0.76
Node (+) 3.40 (1.39-8.33) 0.007
Circumferential Margin (+) 2.27 (0.93-5.53) 0.07
Distance from Anal Verge <5cm 1.40 (0.62-3.18) 0.42
Poor Differentiation 0.98 (0.40-2.41) 0.96
MINT Locus Profile* 10.23 (1.38-75.91) 0.02
HR: hazard ratio, CI: confidence interval. *: “Cluster 3” is null-hypothesis
Table 2: Multivariate Analyses in All Analyzed Patients 
patient groups identified based on methylation levels of MINT3 and MINT17 (table 1). In
addition, no significant difference was observed for these standard clinicopathological fac-
tors between the patient groups when nodal status was taken into account (supplemen-
tal table 2). 
Multivariate analyses
To assess whether the observed prognostic value of the clusters was independent of stan-
dard prognostic variables, we performed multivariate analyses. The Cox regression method
was used to analyze standard prognostic factors of rectal cancer; T stage, N stage, circum-
ferential margin status, distance of the tumor from the anal verge and tumor differentiati-
on (table 2). Based on the epigenetic subclassification, the multivariate analysis showed
patients of clusters 1, 2 or 4 to be at significant, over 10-fold, increased risk of local recur-
rence compared to cluster 3 patients. Nodal involvement was further significantly associa-
ted with increased local recurrence incidence and tumor involvement of the circumferen-
tial resection margin showed borderline significance. 
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Figure 3. Cumulative incidence plots displaying local recurrence incidence differences between irradiated
and non-irradiated patients. Cumulative incidence plot showing significant local recurrence inci-
dence differences between patients that received preoperative radiation and patients belonging to
the identified high-risk cluster for local recurrence.
Comparison with preoperatively irradiated tumors
Because we found the non-irradiated cluster 3 patients to be at reduced risk for local recur-
rence, we were interested to see how recurrence probability rates of this group compared
to those of preoperatively irradiated patients from the TME trial (figure 3). The irradiated
patients were selected using the same clinical parameters that did not differ significantly from
the non-irradiated selected patients (data not shown). The difference in loco-regional recur-
rence rate in cluster 3 patients was 3% versus 4.7% in patients who receive 5x5Gy before
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Figure 4. Two dimensional cut-off validation experiment results. Representation of MINT3 (X-axis) and
MINT17 (Y-axis) methylation indices for patients of the TME trial, TEM study and 19 normal rec-
tal mucosa samples. The horizontal and vertical reference lines represent the previously suggested
cut-offs to separate the groups. For the TEM series, the following specimens were assessed: (A)
adenoma with no carcinoma cells; (A, C+) adenoma with carcinoma cells; (C+A) carcinoma mixed
with adenoma cells; and (C) carcinoma.
surgery (P=0.43). Patients of high-risk clusters 1, 2 or 4 had significantly higher recurrence
probability over time postoperatively compared to irradiated patients (P<0.0001). These
results indicate that patients with TME alone identified by the quantitative two marker
MINT profile have at least comparable, loco-regional recurrence rate compared to irradiated
patients. This group will likely not be disadvantaged when preoperative radiotherapy before
TME is not given and can be spared from unnecessary treatment morbidity.
External validation experiments
To test reproducibility of cluster allocation by the cut-offs established in figure 1B we mea-
sured MINT3 and MINT17 methylation levels in primary tumor tissues of 43 additional
TME trial patients, and an independent group of 42 patients consisting of rectal adenoma-
tous and cancer tissue from patients treated by TEM. In figure 4 the results are given and
show that 19%8/43 of TME and 19% of TEM patients were allocated to the prognostic clus-
ter 3. The suggested cut-offs therefore show allocation of an independent group of rectal
cancer patients, including patients with adenomas and very early disease stage, consistent
in size and comparable to the size of the test group patients (27%). In the additional TME
patient group there was only one event for local recurrence (which did occur in the high-
risk cluster). The TEM group was treated differently and also contained premalignant sta-
ges and therefore not comparable. Further external validation of these clinical findings in
future studies is needed. 
To show the MI of the two biomarkers in normal rectal mucosa we added those data
of 19 specimens to figure 1B. The results of the normal rectal tissue analysis shows that
these are well separable from a cluster 3 patient which is important as these patients may
be selected for treatment of their rectal tumor by surgery alone. 
Discussion
Although recurrence rates have decreased to about 10% after the introduction of TME sur-
gery, locally recurrent cancer remains an important clinical problem1. In a previous study18,
MINT methylation was shown to increase early during tumor progression, indicating that
methylation of MINT loci is a factor acquired early during rectal tumorigenesis, and there-
fore can be used to subclassify early disease. Preoperative molecular profiling of the prima-
ry tumor could potentially be of great value to identify patients at high risk of developing
local recurrence. This study shows that based on absolute quantitative methylation levels
of the MINT3 and MINT17 loci, rectal cancers with a high-risk of local recurrence can be
identified.
The MINT3 locus CpG island is localized on chromosome 1p34-35 just downstream
of RBBP4 (retinoblastoma-binding protein 4)32, SYNC1 (encoding the syncoilin protein
involved in cell cytoskeleton and extracellular matrix proteins)33, YARS (tyrosyl-tRNA syn-
thetase, involved in angiogenesis)34, 35 and s100p-binding protein (s100p is overexpressed
in many solid tumors)36, 37. MINT17 is localized on the long arm of chromosome 12, just
upstream of the Harakiri (HRK) gene which is a member of the BCL2 gene family, which
encodes apoptosis regulatory proteins and its expression in GI cancers is known to be regu-
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lated by promoter region methylation38. A regulatory or functional relation between the
MINT3 and MINT17 CpG islands and the above mentioned genes has not been establish-
ed. MINT locus methylation may therefore be seen as a surrogate biomarker. In the litera-
ture, several studies have shown clinical utility of the MINT loci methylation as predictive
biomarkers in colon and gastric cancer, melanoma and renal cell carcinoma18, 39-42. Our
large-scale study adds novel findings that MINT locus methylation levels may have utility
in rectal cancer local recurrence prediction. Importantly, in this study we propose an algo-
rithm using only two MINT biomarkers with a simple cut-off and demonstrated validation
of the algorithm to have excellent clustering capacity, even in early stage disease and that
it separates cases well from normal rectal tissue. 
This is the second study specific for rectal cancer from our group that shows clinical
utility of MINT3 and MINT17 methylation levels. Strong probability differences between
the two patient groups could be shown for local recurrence, with cluster 3 patients having
an over 10-fold increased risk of developing local recurrences than patients allocated to the
other clusters. Local recurrence rates of cluster 3 patients were comparable to those of irra-
diated rectal cancer patients and this shows that leaving out preoperative radiation can be
done safely with the advantage of reducing treatment morbidity. This molecular stratifica-
tion approach needs to be further investigated in a randomized multicenter trial to be vali-
dated.
Subdivision according to nodal status (data not shown) showed that patients in cluster
3 with a positive nodal status were at significant increased risk of local recurrence. Node
negative patients in cluster 3, however, showed a significantly decreased cancer-specific and
overall survival compared to the other clusters in our previous study18. This is explained
by the fact that these node negative patients were found to be at significantly increased risk
of distant recurrence in our previous study18. Early metastasizing of rectal cancer, in absen-
ce of evident nodal spread, may occur via the hematogenic route. This is supported by our
group that circulating tumor cells can be detected in peripheral blood of early stage I/II
colorectal cancer patients which has prognostic clinical utility43. Our findings are in accor-
dance with data from the TME trial showing that survival is determined predominantly by
distant and not by loco-regional recurrence4. This suggests that non-locally recurrent and
distantly spreading rectal cancer constitutes a separate subclass of rectal cancers which can
be identified by our two-biomarker MINT methylation profile.
The TME trial showed reduction of rectal cancer local recurrence rates by adding pre-
operative radiotherapy7. A reduction of distant recurrence of rectal cancer, as well as impro-
ved disease-free and overall survival, has been shown in several randomized controlled tri-
als, either alone or in combination with radiotherapy44-46 using adjuvant chemotherapy.
This is the first study to demonstrate that loco-regional recurrence patterns of AJCC stage
I, II and III rectal cancers can be distinguished using preoperatively assessable, quantitati-
ve epigenetic subclassification of primary rectal tumor tissue. Our previous study showed
the methylation status of the described MINT loci to have utility in predicting distant recur-
rence probability in stage I and II disease. Therefore, a new treatment stratification appro-
ach for rectal cancer can be suggested as follows: after preoperative assessment of primary
tumor biopsy specimens of MINT3 and MINT17 methylation levels, about 30% of patients
could be spared from preoperative radiation therapy, but might benefit from systemic tre-
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atment. The other 70% should receive preoperative radiotherapy, and if node-positive, post-
operatively systemic treatment can be considered. The identification of patients who do not
need pre-operative radiotherapy would likely reduce long-term morbidity and improve qua-
lity of life47. The results of our study should be further evaluated in order to improve plan-
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Background: Microsatellite instability (MSI) and genomic hypermethylation of methyla-
ted-in-tumor (MINT) loci are known strong prognostic indicators of a subgroup of sporadic
colorectal cancer (CRC) patients. A study was designed to determine whether methylation
of MINT loci during adenoma progression to CRC is related to MSI in CRC. 
Methodology: Methylation index (MI) was assessed by absolute quantitative assessment
of methylated alleles (AQAMA) at seven MINT loci in CRC and contiguous adenomatous
and normal tissues of 115 patients using in situ histopathology analysis. Results were then
validated in primary tumor tissue from an independent group of 54 CRC patients. 
Results: Increased methylation levels of MINT loci 1 and 31 were significantly associated
with MSI and shown to be adenoma-specific. The total MI and number of methylated loci
were 3-fold (P=0.02) and 5-fold (P=0.004) higher, respectively, in adenomas associated
with microsatellite stable (MSS) versus MSI-High primary CRC. MINT methylation levels
correlated with mismatch repair protein expression, MSI, B-RAF(V600E) mutation status,
human mut-L homologue 1 (hMHL1) methylation status and CRC survival in an indepen-
dent patient group. 
Significance: Methylation levels of specific MINT loci were prognostic indicators of colo-
rectal adenomas that will develop into sporadic microsatellite instable CRCs. The study
indicates that increased MINT locus methylation precedes MSI in absence of malignant




Epigenetic changes in epithelial cells, such as DNA methylation of CpG islands, have been
related to the genesis and progression of some gastrointestinal (GI) cancers1, 2. Aberrations
in DNA methylation are considered to be as important as genetic alterations in GI tumor
initiation and progression. In colorectal cancer (CRC), both hypomethylation and hyperme-
thylation of promoter-region related CpG islands have been correlated with clinical and
pathology parameters3, 4. A number of tumor-related gene promoter regions have been
demonstrated to be methylated in early dysplastic stages of the colonic malignant pathway
such as in hyperplastic polyps5, aberrant crypt foci6, 7 and adenomas8-10. Progressive geno-
mic and epigenomic aberrations may be linked in CRC11. For instance it has been reported
that widely increased methylation in sporadic CRCs overlaps with microsatellite instability
(MSI)12-15. Studies have been performed to pinpoint the onset of MSI in hereditary nonpo-
lyposis colorectal cancers (HNPCC) that show germline mutations (mt) in mismatch repair
(MMR) genes13, 14, 16, 17, but as yet no study has examined this process in sporadic CRC.
Further, the relation between genomic instability and epigenomic aberrations during spora-
dic CRC progression is not clear. 
We recently described on-slide sodium bisulfite modification (SBM) technique for gene
methylation analysis in small (1-2 mm2) tissue areas isolated from a single section of paraf-
fin-embedded archival tissue (PEAT)18. On-slide SBM allows comparison of gene methyla-
tion in the primary CRC and a contiguous adenoma lesion within the same tissue section.
Genomic aberrations such as MSI and epigenomic changes can be tested at the same time
from the same microdissected tumor lesion. Simultaneous assessment of CRC, precursor
and normal tissues in the same PEAT section would provide valuable information that has
not been available in the past.
In a previous study, our group assessed methylated-in-tumor (MINT) loci 1, 2, 12 and
31 and demonstrated technical feasibility of detecting methylation level differences between
different colorectal tissue areas within the same tissue section using these loci8. MINT loci
are conservative human genomic sequences that adhere to the CpG island definition,19, 20
found in non-coding genomic regions, and gene regulatory or other functional attributes to
date are unknown. We have previously shown the clinical utility of methylation levels of
specific MINT loci in rectal cancer20 and melanoma4 and other groups have studied MINT
locus methylation in colorectal20-22 and gastric cancers23, 24. Methylation of MINT loci has
also linked to MSI in CRC25, 26; however this event has not been studied in adenomas.
Therefore, we examined the methylation level of seven MINT markers in cancer, precan-
cer, and normal tissue. 
The objective was to identify if MINT locus hypermethylation influences MMR during
early stages of CRC development. Methylation at MINT loci was quantified using the on-
slide SBM technique combined with AQAMA. We further assessed MSI status, K-RAS mt
at codons 12 and 13, B-RAF V600E mt, and methylation status of the MMR gene, MutL
homolog 1 (hMLH1), in primary CRC as well as the contiguous precursor lesion in order
to rigorously assess whether these events occur at early stages of CRC development. Our
hypothesis was that adenoma tissue adjacent to MSI-high (MSI-H) invasive CRC tissue has
increased MINT locus methylation levels, methylation of the hMLH1 promoter region, and
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MSI in comparison to precursor cancer lesions adjacent to microsatellite stable (MSS) can-
cers. We then validated in an independent patient group that MINT methylation levels posi-
tively correlated to hMLH1 methylation index (MI), MSI-status, B-RAF V600E mt, MMR
protein expression, and disease survival. 
Materials and Methods
Patient Specimens
For the first phase of the study, we searched the cancer registry database at Saint John’s
Health Center (SJHC) to identify patients whose resected CRC specimen contained histop-
athologically confirmed areas of adenoma as well as invasive cancer. Excluded were any
cases without available PEAT specimens. Consecutive patients were identified in reverse
chronological order until an adequate sample size was reached. The final cohort of 115
patients underwent surgical resection of CRC between 1996 and 2009.
A single H&E section was prepared and mounted and 7-µm sections were consecuti-
vely cut and mounted on silane-coated glass slides for DNA studies. Areas of adenoma (ser-
rated and non-serrated), carcinoma and normal tissue as well as the adenoma type were
identified by a surgical oncology pathologist (R.R.T.) with expertise in CRC pathology8, 27. 
Archived CRC primary tumor tissue PEAT blocks collected from a cohort of 54 patients
that underwent surgical tumor resection at the Leiden University Medical Center (LUMC)
between 1990 and 2001 were used for the validation study. All patients had been previou-
sly analyzed for MMR sufficiency at LUMC’s pathology department. From each PEAT block,
a single section was cut for HE staining, and 7-µm sections were consecutively cut on coat-
ed slides for on-slide SBM. Tumor areas were identified and marked by an expert CRC
pathologist (H.M.). Study protocols were approved by the institutional review boards at the
LUMC and at Saint John’s Health Center.
AQAMA and hMLH1 Methylation Assessment 
DNA from PEAT was modified in situ by sodium bisulfite according to our previously repor-
ted protocol18. AQAMA of MINT loci 1, 2, 3, 12, 17, 25 and 31 was performed and data
analyzed as previously described8, 28. hMLH1 methylation status was analyzed by capilla-
ry-array-electrophoresis methylation-specific PCR (CAE-MSP)27, 29, 30. Primer sequences
were those whose correlation with hMLH1 protein expression had been validated in pre-
viously reported studies31-35.
MSI, K-RAS and B-RAF mt Analysis
For MSI assessment in the first phase study, an additional tissue section from each of the spe-
cimens was deparaffinized and stained with hematoxylin to identify tumor cells for DNA iso-
lation, as previously described8. Normal epithelial cells were harvested either from a separa-
te tissue block of the same specimen (i.e. from uninvolved resection margins). As markers
for MSI assessment, we used three quasi-monomorphic mononucleotide repeats BAT25,
BAT26 and BAT40 and two microsatellite, dinucleotide repeats D2S123 and D5S346 accor-
ding to the revised Bethesda guidelines36. Forward primers (supplementary table S1) were
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dye-labeled for automated high-throughput multiplex detection by CAE37 (CEQ 8000XL,
Beckman Coulter, Fullerton, CA). PCR product fragment length differences among diffe-
rent tissue categories were visualized by the CEQ software (Beckman Coulter). PCR pro-
ducts from the five amplified microsatellite regions in adenoma and cancer were compared
to the reference normal epithelium. K-RAS (codons 12 and 13) and B-RAF (V600E) mt were
assessed by a peptide nucleic acid (PNA) clamp– and locked nucleic acid (LNA) probe–based
quantitative real-time PCR assay as previously described38, 39. These assays were performed
in triplicate and carried out at least twice to confirm accuracy. A gene in a specimen was
considered mutated when results were uniformly positive in the triplicates under the opti-
mal conditions. Respective normal and positive PEAT and cell lines controls were run in
each assay. 
Second Patient Group MMR and mt Status Analysis
The diagnostic techniques used by the LUMC’s pathology department for MSI status and
MMR protein expression assessment were as described40. Briefly, MSI-status was assessed
by MSI Analysis System (Promega Corp.; five mononucleotide and two pentanucleotide
repeats)41. Immunostaining of MMR proteins was performed with anti-MLH1 (clone G168-
728; 1:50; BD Biosciences, NJ) and anti-PMS2 (clone A16-4; 1:50; BD Biosciences). IHC
staining was performed on 4-µm-thick, PEAT sections from tissue microarray (TMA). IHC
staining patterns of these MMR proteins were evaluated using normal epithelial, stromal,
or inflammatory cells, or the centers of lymphoid follicles as internal controls as previously
published42. TMAs contained three cores punched from each case’s primary tumor.
Individual cores of the TMA were scored as either positive (showing nuclear staining in at
least some tumor cells) or negative. Patients were considered positive if at least one TMA
tissue core showed nuclear staining and negative otherwise. Cases in which both tumor
and internal control stained negative were not included in the study. Cases were scored by
two independent reviewers (H.M. and N.F.C.C. de M.) and in case of a tie, both reviewers
reassessed the slides for consensus. K-RAS43 and B-RAF44 mt were detected by means of
sequencing as previously described. 
Biostatistical Analyses
Significance of changes in MI at individual MINT loci and total MI was evaluated with non-
parametric tests for related and independent sample sets (Wilcoxon’s rank-sum test, Mann-
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Whitney’s u-test). Fisher’s exact test (two-tailed) was used to assess significance of differen-
ces between hMLH1 methylation prevalence among groups.
Spearman's rank correlation coefficient between quantitative MINT MI and hMLH1
MI was assessed as a non-parametric measure of correlation. Correlations with clinical para-
meters were tested with Pearson’s c-square and in case of ordinal variables with Mann-
Whitney’s or Kruskal-Wallis’ u-tests. Postoperative distant recurrence probability disease-
free and overall survival over time were visualized with Kaplan-Meier plots and significance
was assessed with the log-rank test. Cox’s regression models considered the following vari-
ables that were entered in a stepwise manner: age, N-stage, MSI status, tumor differentia-
tion. P<0.05 (two-sided) was considered significant. SPSS (SPSS Inc., Chicago, IL) statisti-
cal software version 16.0.1 was used for all analyses.
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Total Patient Patients with Micro- Micro- P-value
Group Cancer Tissues satellite satellite




Male 45 (39%) 35 (44%) 3 (33%) 33 (47%) 0.44
Female 70 (61%) 44 (56%) 6 (66%) 37 (53%)
Age
Mean (SE) 76.1 (1.2) 75.0 (1.0) 81.4 (7.3) 76.1 (10.6) 0.15
Tumor Location
Cecum 24 (21%) 16 (20%) 3 (33%) 14 (20%) 0.03
Colon Ascendens 15 (13%) 9 (11%) 4 (44%) 5 (7%)
Hepatic Flexure 6 (5%) 4 (5%) 0 4 (6%)
Colon Transversum 17 (15%) 12 (13%) 2 (22%) 9 (13%)
Colon Descendens 4 (4%) 3 (4%) 0 3 (4%)
Sigmoid Colon 13 (11%) 9 (11%) 0 8 (11%)
Rectosigmoid 12 (10%) 9 (10%) 0 9 (13%)
Rectum 24 (21%) 17 (22%) 0 18 (26%)
Adenoma Type
Sessile Serrated 9 (8%) 5 (6%) 2 (22%) 3 (4%) 0.10*
Classic: 106 (92%) 74 (94%) 7 (88%) 67 (96%)
-Villoglandular 7 (6%) 4 (5%) 0 4 (6%)
-Tubular 11 (10%) 8 (10%) 2 (22%) 6 (9%)
-Tubulovillous 15 (13%) 10 (13%) 1 (11%) 9 (13%)
-Villous 73 (63%) 52 (66%) 4 (44%) 48 (68%)
*Fisher’s exact test evaluating differences of MSI status in sessile vs classic adenoma in patients with adenoma
as well as carcinoma available for analysis (n=72)
Table 1: Patient and tumor characteristics.
Results
MINT Locus Methylation Status and MSI during CRC Development
In the first phase of the study, we assessed operative specimens from 115 patients who
underwent open resection of CRC whose specimen, according to the pathology report con-
tained adenoma as well as cancer (see table 1 for patient characteristics). We first revie-
wed the newly cut sections for our study. Adenoma cases with high-grade dysplasia were
not selected to obtain good separation between the adenoma and carcinoma category, and
only carcinoma tissue with evidence of at least submucosal invasion was selected.
Subsequently, 27 specimens were deleted. Of the remaining 88 specimens that contained
low- or medium-grade adenomatous dysplasia, 79 also had invasive carcinoma tissue. 50
of these specimens had normal tissue present.
MSI status was analyzed using five established genomic markers36 in normal and can-
cer tissue of 79 patients. Nine patients (11%) showed instability in ≥4 biomarkers and were
classified as MSI-H. Sixty-five patients (83%) did not show a shift in any of the markers,
and five (6%) patients had a single dinucleotide repeat affected. These 70 patients with ≤1
aberrant MSI-marker were classified as MSS. The median age of MSI-H patients was 81.4
yrs (range 69-91). figures 1 and 2 show a representative PCR product analyses of AQAMA
and CAE.
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Figure 1: Representative examples of molecular analyses in normal (A), adenoma (B) and cancer (C) tissue.
AQAMA (MINT31) real-time PCR results showing results in triplicate of exponential amplification
of methylated (M) and unmethylated (U) dye probe signal. Y-axis represents signal intensity, X-axis
represents PCR cycle number.
We compared MIs of the three tissue categories (normal, adenoma, cancer) for each
individual MINT locus and divided the cases into MSI-H and MSS (figure 3). Methylation
levels of MINT loci 1, 2, 3, 12 and 31 were significantly higher in CRC than in normal epi-
thelium. Methylation levels of MINT loci 1, 2, 12 and 31 were significantly higher in MSI-
H CRC compared to MSS CRC. Methylation levels of MINT loci 1 and 31 were significant-
ly higher in adenomas contiguous to MSI-H CRC than in adenoma contiguous to MSS CRC.
The total MI of tumor-specific, MSI-related MINT loci 1, 2, 12 and 31 was 4.5 times hig-
her in adenomatous tissue paired to MSI-H tumors (P=0.02, figure 4). The average num-
ber of tumor-specific MSI-related MINT loci showing MI>0.1 was 1.5 (SD±1.4) in MSI-H
related adenomas versus 0.3 (SD±0.6) in MSS related adenomas (P=0.004, figure 4).
MINT17 MI was MSI-related in CRC but was also present in normal tissue. MSI status was
significantly correlated to right-sided tumor location and not to serrated polyp type (table 1).
MI was significantly higher in the serrated adenomas only at MINT1 and MINT31 (P=0.002
and P=0.02, respectively) compared to non-serrated adenomas. There were no significant
MINT methylation level differences between carcinoma tissue contiguous to serrated ade-
nomas versus carcinoma tissue contiguous to classic adenoma. Methylation levels of the
two serrated/MSI-H adenoma were relatively low compared to the non-serrated/MSI-H
adenoma.
From this we conclude that increased methylation levels of MINT loci 1, 2, 12, 17 and
31 are markers of MSI-H sporadic CRCs and except MINT 17 these are tumor-specific
events. Increased methylation of MINT 1 and 31 were identified as adenoma/MSI-speci-
fic events and these loci are differentially methylated in sessile serrated adenomas compa-
red to non-serrated adenomas. The MSI-H precursor lesions identified by MINT loci methy-
lation analysis did not show any distinct histopathologic features. The total MIs and number
of affected biomarkers of the cancer/MSI-specific MINT loci show significant differences
and are indicators of colorectal adenomas that will become a microsatellite instable CRC.
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Figure 2: Representative examples of molecular analyses in normal (A), adenoma (B) and cancer (C) tissue.
CAE results of amplified dye-labeled PCR products of 5 MSI biomarkers and hMLH1 methylation-
specific (M, in blue) and unmethylated-specific sequence (U, in green) primer sets. Red peaks
represent the DNA ladder signal. The horizontal axis represents size of the PCR product in base-
pairs (bp). The vertical axis represents arbitrary units of signal intensity of detected amplicons. 
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Figure 3: Box plots summarizing MI values for normal, adenoma and cancer tissue separated into MSS and
MSI-H tumors for each individual MINT locus.  
hMLH1 methylation status and MSI during CRC development
Subsequently we determined whether the relation between MINT methylation levels and
MSI in colorectal precursor lesions can be explained by a relation to methylation of the
hMLH1 MMR gene. Therefore, hMLH1 methylation status was assessed in normal, adeno-
matous and cancer tissues of the nine MSI-H patients and in a control group of 13 MSS
patients of which normal, adenomatous and cancer tissues were available of the first phase
study. All nine MSI-H patients’ tumors showed methylation of hMLH1 compared to 2 of
13 of the MSS controls (P<0.001). Six of 9 MSI-H adenomas showed methylation of
hMLH1 compared to 2 of 13 adenomas paired to the MSS controls (P=0.02). In 6 MSI-H
patients with high tumor MI (≥0.88), instability of at least four MSI-biomarkers could be
shown in only three of six (50%) of the associated adenomas. The paired adenoma tissue
of these six patients did show increased MI at the MSI-specific MINT loci (≥0.56) compa-
red to their paired normal epithelium Together, MI of MINT1, 2, 12 and 31 and collateral
methylation of hMLH1 constitute specific biomarkers of adenomatous colorectal tissue that
shows MSI or will develop into a sporadic MSI-H CRC. The results further demonstrated
that MINT locus methylation along with hMLH1 methylation precede MSI in the sequen-
ce of CRC development before histopathology signs of cancerous invasiveness are present.
B-RAF and K-RAS mt during CRC development
Studies in CRC have shown correlations between increased methylation of important tumor-
related genes and mt of B-RAF (V600E) and K-RAS (codons 12 and 13), often in combination
with MSI-H15, 19, 45, 46. The significance is not clearly understood, however it has been sugge-
sted that these events synergistically induce a high-risk phenotype that results in a clinically dis-
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Figure 4: Box plots representing normal, adenoma and cancer tissue separated into MSS and MSI-H tumors.
(A)Y-axis represent total MI of 4 MSI-related MINT loci (MINT1, 2, 12 and 31). (B) the Y-axis repre-
sents the number of MSI-related MINT loci with MI>0.1.
tinct subtype of CRC. We determined B-RAF V600E and K-RAS mt in the same group used for
hMLH1 methylation status analysis (9 MSI-H cases and 13 MSS cases): the mt incidence was
46% and 18% for K-RAS and B-RAF, respectively. B-RAF mt was shown in 44% of the MSI-H
carcinomas and in 63% of the contiguous adenomas. By comparison, none of the MSS adeno-
mas and carcinomas had B-RAF mt (P=0.003 and P=0.02, respectively). K-RAS mt was more
frequent in MSS adenomas and carcinomas (54% and 62% respectively), compared with MSI-
H lesions (13% and 22%, respectively), although this did not reach statistical significance
(P>0.09). These results were as expected based on previous reports. Total methylation levels
at MINT loci 1, 2, 12 and 31 were significantly increased in B-RAF mt adenomas (P=0.03) as
well as B-RAF mt carcinomas (P=0.002). None of the MINT loci were differentially methyla-
ted in K-RAS mt versus wild-type adenomas or carcinomas. This assessment demonstrated that
genetic and epigenetic events synergize in the earliest phase of CRC development.
Quantitative Methylation and Mismatch Repair
The methylation levels of five MINT loci dispersed were related to methylation of hMLH1
and to MSI. These findings were validated using a second independent cohort of CRC
patients whose hMLH1 expression was known. We first corroborated whether increased
MINT MI linearly correlates to hMLH1 MI, and subsequently whether it affects MMR at the
protein level. MIs at the MSI-associated MINT loci (1, 2, 12, 17, 31) and hMLH1 MI were
measured in 54 CRC specimens that were previously analyzed for MMR sufficiency. Two
outcome parameters were analyzed: total MI (defined by the sum of MIs of MINT loci 1, 2,
12, 17 and 31) and number of methylated MINT loci. The number of methylated MINT loci
in a specimen was determined as the number of MINT loci (1, 2, 12, 17 and 31) that exceed-
ed the MSI-H related MI cut-off. The avarage MI + 1SD of MSS CRC specimens from the
first phase study determined this cut-off for MSI-related methylation. Correlation analysis
showed that both outcome parameters were significantly associated with hMLH1 MI with
a correlation coefficient of  r=0.43 (P=0.002) and  =0.400 (P<0.001) for total MI and num-
ber of methylated MINT loci, respectively. Furthermore, in Table 2 the results for the asso-
ciation of hMLH1 protein expression in relation to MI are given. hMLH1 underexpression
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hMLH1
Number Average P IHC non- P
of Methylation expressing* 
Patients Index (SD) (%) 
Number of MINT 0 32 0.14 (0.22) 0.007 5 (16) 0.002
loci methylated 1 7 0.08 (0.10) 2 (29)
2 4 0.01 (0.01) 1 (25)
3 5 0.72 (0.34) 1 (20)
4 2 0.42 (0.25) 2 (100)
5 4 0.43 (0.37) 4 (100)
* Confirmed by underexpression of PMS2
Table 2: Relation of Methylated Loci and MI to hMLH1 Methylation Status and Protein Expression
was corroborated by underexpression of its co-protein PMS2 in all cases47. Examples of IHC
and CEA-MSP results are given in figure 5. Subsequently all MMR protein deficient cases
showed MSI by PCR analysis. Again we analyzed two outcome parameters: number of affec-
ted MINT loci and total MI. These results demonstrated a linear relation of quantitative
MINT methylation to hMLH1 down regulation and subsequent MMR deficiency, and impor-
tance of both the number of loci involved as well as total MI.
B-RAF and K-RAS mt were also assessed in this patient group. B-RAF mt cases (n=11,
20%) were significantly associated with MSI-H (P=0.003) and under expression of hMLH1
(P=0.003). K-RAS mt tumors (n=14, 26%) did not show any significant associations with
mismatch repair parameters. B-RAF mt tumors had significantly increased methylation at
MINT1, 2, 12, 17 and 31 (P<0.001, P<0.001, P=0.001, P<0.001 and P=0.003, respecti-
vely). None of the B-RAF mt tumors had K-RAS mt. Methylation levels did not differ signi-
ficantly between K-RAS mt tumors and K-RAS wild-type tumors. 
Clinical outcome in our validation group was analyzed with respect to the number of
MINT loci that showed MSI-related methylation. The result (figure 6) confirmed previous
reports of a direct correlation between methylation levels recurrence-free survival.
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Figure 5: Representative IHC staining of hMLH1 and PMS2 proteins. In A and B examples of hMLH1 and
PMS2, respectively, expressing CRC with their corresponding CAE-MSP results for hMLH1 sho-
wing unmethylated signal only. In C, an example of a CRC showing methylation of the hMLH1
promoter region with corresponding absence of nuclear staining of hMLH1 which is confirmed by
underexpression of PMS2. 
Multivariate analysis showed that number of methylated, MSI-related MINT loci was an
independent predictor of distant recurrence-free survival (HR 0.20, 95% CI 0.04 - 0.96,
P=0.02), disease-free survival (HR 0.33, 95%CI 0.12 - 0.87, P=0.04) and overall survival
(HR 0.38, 95%CI 0.14 - 1.00, P=0.05) along with nodal stage, and patient age. 
Discussion
Epigenetic silencing of hMLH1 has been identified as the causative mechanism for MSI in
non-hereditary CRC by several groups13-15, 48. Our study adds important findings in geno-
mic and epigenomic events at an early stage of CRC development. We could demonstrate
that the relation between MSI and methylation is present at the premalignant stage in colo-
rectal tissue without cancer histopathology. MI as well as the number of MINT loci methy-
lated was significantly increased in MSI-H versus MSS CRC tumors and importantly, this
was also found in their precursor lesions. In adenomas associated with MSI-H tumors there
was subsequently significantly more hypermethylation of hMLH1 detected. This suggests
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Figure 6: Kaplan Meier curves for distant recurrence probability stratified into patients 0, 1-2 or 3-5 MINT
loci with MSI-related methylation.
that CRC precursor lesions with a higher MI at MINT loci may be more likely to have the
hMLH1 MMR gene methylated as well. This has not been reported to date. We were able
to demonstrate this by combining on-slide SBM and AQAMA techniques on PEAT which
allowed accurate comparison of MIs between CRC tissues and contiguous adenoma tissu-
es. Previous approaches reported were not capable of accurate analysis based on compara-
ble synchronous histopathology and depended on comparison of specimens of different sta-
ges of CRC formation from different patients. The study’s results demonstrate significant
changes in epigenetic and genetic markers at the origin of the development of a subset of
CRC tumors. 
The relation between degree of MINT methylation and MSI was further validated on
the MMR protein level in a second independent patient group. MINT MI linearly correla-
ted with hMLH1 MI, and subsequently resulted in underexpression of hMLH1 protein and
MSI. This suggests that deregulation of a CRC’s MMR system causing sporadic MSI results
from the increased likelihood of methylation of hMLH1 in a tumor with increased MIs at
MINT loci. This demonstrated the level of DNA methylation to be an underlying mecha-
nism of sporadic MSI and that this accumulation of DNA methylation affects the MMR sys-
tem early during CRC development. We corroborated the validity of the quantitative MINT
methylation AQAMA assay further by reproducing prognostic value which previous studies
have shown in colorectal and gastric cancer49-51. 
Recently some studies on DNA hypermethylation in CRC include B-RAF and K-RAS mt
analyses. B-RAF mt is more frequently found in sporadic CRCs showing MSI-H (approxi-
mately 50%), CIMP+ and hMLH1 methylation52, 53 and are possibly associated with adver-
se disease survival51. Specific single-nucleotide mt of K-RAS have predictive value in stage
III/IV CRC, likely related to systemic treatment response54-56. However, as yet no study has
demonstrated a functional relation between MMR impairment and the reduced cell signa-
ling properties of K-RAS or B-RAF mutant CRCs. Our results confirm the association of the
V600E B-RAF mt to MINT locus hypermethylation and add that this ensemble of events
initiates early in CRC development in non-serrated adenomas with only low or intermedi-
ate dysplasia. 
Early identification of patients at risk for developing MSI-H phenotype sporadic cancers
by AQAMA of MINT loci may be of clinicopathology utility. An approach that may be use-
ful in the future would be to examine whether other polyps collected during subsequent
colonoscopies from the same patient have similar DNA methylation results on repetitive
samplings; this may identify a high-risk predisposition to CRC development. The polyp
recurrence probability of patients with adenomas with high MINT locus methylation could
be studied and the frequency of follow-up colonoscopies may be adjusted for such patients.
Our results further show that MINT loci methylation levels can discriminate normal from
adenomatous tissue. The MINT biomarkers could also be a part of a screening panel tested
on fecal DNA to identify patients that should undergo colonoscopy. Not only MSI-H pre-
cursor lesions may be identified by MINT biomarkers 1, 2, 12 and 31 but also MSS lesions
may be identified by MINT3 methylation. Furthermore, it is known that MSI-H cancers res-
pond differentially to common chemotherapeutics. For instance, irinotecan is suggested to
be more effective than 5-FU in these tumors. With the development of new targeted drugs,
preventive treatment regimens may be indicated for high-risk patients with adenomas that
176
Chapter 8
show high MINT locus methylation. Also there is increasing evidence for MSI-induced
generation of novel tumor-specific carboxy-terminal frameshift peptides (FSPs) in MSI-H
cancers57. Patients who have polyps with high MINT locus methylation may become a stra-
tified target patient group for vaccination trials of FSP-based approaches.
This is the first study to demonstrate a correlation between MSI and MINT hyperme-
thylation in CRC precursor lesions, and this may be attributed to suppression of the MMR
system by progressive epigenetic events. Therefore, the degree of genomic hypermethyla-
tion in CRC precursors is implicated as a potential causative factor of sporadic MSI CRC.
Specific MINT locus methylation identification may have utility in early identification of
colorectal polyps that will develop into sporadic MSI-H cancers. 
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General Discussion
The treatment of GI cancers and in particular that of gastric, colon and rectal cancer is mul-
tidisciplinary and requires close collaboration between surgeons, gastroenterologists, radi-
ologists, pathologists, radiation therapists, medical oncologists, oncologic nurses and psy-
chologists. Surgical tumor removal is the mainstay of GI cancer treatment. The surgeon
therefore plays a central role in coordinating the various treatment options after the initial
diagnosis. Biomarkers may improve guiding of such treatment decisions. Postoperatively,
after complete pathologic disease staging, the current markers in GI cancer (i.e. pTNM
stage, CT/PET-imaging) are adequate and remain our best tools in the shed. Patient disea-
se recurrence and survival data, however, indicate that there is much room for improve-
ment in GI cancer staging, especially for early disease patients1-3. Also, there is a need for
biomarkers that can guide preoperative treatment. One must keep in mind that TNM-sta-
ging is an observer-dependent, anatomical and therefore surrogate marker of cancer that
does not include primary cancer cell properties. Hence, there is a need for a new category
of GI cancer biomarkers. Primary tumor cell molecular features, assessed in preoperative
biopsy material, are a very attractive tool which is currently under investigation. Molecular
oncologic scientists are increasingly appreciating the role of epigenetic factors in GI carci-
nogenesis. Epigenetic primary tumor biomarkers, such as DNA methylation therefore merit
evaluation to assess their possible utility to aid GI cancer treatment4-6. This thesis studies
aimed at two goals: to further develop analytical techniques for DNA methylation assess-
ment, and secondly, to validate DNA methylation markers in retrospective studies using
primary GI tumor tissue. The epigenetic biomarkers´ value was tested for predicting disea-
se outcome parameters that are of specific use in GI cancer treatment.
Section 1: Technical Advances
In chapter one a method is presented that helps to control methylation-specific PCR (MSP)
analysis of DNA samples. As a basic principle in scientific experiments, each performed assay
needs to be positively and negatively controlled to allow proper, undisputed interpretation
of a tested sample’s result. To obtain positive controls in MSP assays means that in each expe-
riment a sample should be amplified which contains DNA verified to have the target sequen-
ce fully methylated. Such DNA can be obtained by incubating whole genome human DNA
with SssI (Spiroplasma sp. Strain MQ1) methyltransferase in the presence of S-adenosylme-
thionine (SAM) as a methyl-group donor7. To obtain negative controls for MSP experiments
verified to have the target sequence unmethylated is very time-consuming and sometimes
impossible. Mostly, DNA from peripheral blood lymphocytes is used in which usually genes
of interest in cancer research show to be unmethylated. However, some genes are methyla-
ted in the healthy human genome. The first section describes a protocol to synthesize large
quantities of completely unmethylated genomic DNA that can be used as a negative control
in any methylation experiment, a so-called universal unmethylated control. The method is
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based on that phi-29 DNA polymerase, an enzyme used for whole genome amplification
does not transfer methylation patterns to its synthesized copies8,9. After several rounds of
amplification the amount of possibly methylated start material DNA becomes undetectable
for PCR and completely unmethylated DNA is obtained. This method is cheap, useful and
can be performed in any standard equipped laboratory.
In chapter two, a protocol for DNA preparation for methylation analysis is presented
that is well suitable for tissue resources such as formalin fixed, paraffin-embedded (FFPE) tis-
sue blocks derived from pathology department’s archives. Although suboptimal for DNA eva-
luation, this specimen resource is highly valuable for initial retrospective assessment of bio-
markers as these tissue blocks are abundantly available and long term follow up data of the
patient’s disease outcomes can be retrieved. Also, hematoxylin-eosin stained sections cut
from FFPE tissue blocks provide excellent assessment of tumor tissue histopathology and is
the golden standard. Some basic limitations have to be taken into account when working
with DNA derived from FFPE tissue compared to more optimal DNA resources, i.e. from
fresh frozen tissue. The formalin incubation the tumor tissue before fixation in paraffin cau-
ses DNA cleavage which results into a reduced average DNA strand length that hampers
PCR amplification depending on the chosen amplicon length. Protocols to purify DNA for
PCR preparation target to lose contaminating, PCR inhibiting proteins and salts. However,
during purification there is much collateral loss of sample DNA. The further needed bisulfi-
te modification (SBM) treatment again reduces and degrades the amount of sample DNA as
it is incubated at 60 degrees for three hours at a pH of 510. After SBM, several steps are need-
ed to purify the DNA from the sodium bisulfite salts that will interfere with reaction buffers
and hamper Taq-polymerase activity. chapter two describes the on-slide SBM protocol that
was designed to reduce the number of steps needed to work up DNA for methylation sta-
tus assessment. The protocol was adapted from a study by Nuovo et al11. After deparaffini-
zation, the tissue section on a glass slide is directly incubated in bisulfite solution with the
DNA remaining in-situ, in the cell’s nucleus  (see figure 1). Our study at first compared this
method with the classic used methods for bisulfite modification and shows that on-slide SBM
converts DNA as efficiently as the standard protocols while harvesting significantly higher
amounts of DNA. The on-slide modification dramatically reduces DNA loss as it eliminates
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Figure 1: Schematic representation of the on-slide SBM procedure 
purification steps as the DNA remains in-situ. Subsequently, on-slide SBM enables a high
MSP success rate of tissue areas as small as 1-2 square millimeters of 7 µm tissue sections.
Other studies ensure a sufficient yield of modified sample DNA for PCR by increasing the
amount of start sample. Sometimes this is achieved by putting in several whole paraffin tis-
sue sections or lysis of complete fresh tumor tissue cubes. These methods compromise on
accuracy as input DNA is not controlled for actual tumor cell content. 
In the diagnostic work-up of the pathologist, usually the invasive margins of a tumor are
assessed for T-stage and often in these transitional areas cells of the precursor lesion can be
identified and also normal mucosa. An application of on-slide SBM is that DNA methylation
status can be compared between malignant and adjacent pre-malignant and normal tissue
within the same tissue section with paired analysis statistics. This is important as in other
studies comparisons are often made between non-paired groups of cancer and adenoma spe-
cimens. The potential to develop into an invasive lesion is unsure when using adenoma tis-
sue from a polyp harvested by colonoscopy. On-slide SBM therefore ensures that the adeno-
ma represents a precursor lesion that has a proven progression into invasive carcinoma. To
exemplify application, it was demonstrated in colorectal cancer that promoter region hyper-
methylation of the important tumor-related genes RASSF1a 12,13 and p16(INK4a) 14-16 occurs
in the cancer stage and not in the adenoma stage. When applied in breast cancer i.e. ductal
carcinoma in-situ (DCIS) areas can be compared with invasive ductal carcinoma, in cervical
cancer i.e. cervical intraepithelial neoplasia (CIN) can be compared with squamous cell car-
cinoma. On-slide SBM can increase our knowledge of DNA methylation differences between
cancers and their precursor lesions with optimal tissue histopathologic control. It may help
to elucidate the changes that are specific for the transition between benign adenoma to inva-
sive carcinoma which is the key step in malignant tumor formation. 
For DNA methylation analysis our group uses capillary array electrophoresis MSP (CAE-
MSP) as a standard technique for methylation analysis. CAE-MSP has several advantages over
the classic MSP assay that uses agarose gel electrophoresis for PCR product detection. Gel
electrophoresis is operator dependent and often requires nested PCR to obtain detectable
bands which may induce non-specific amplification results. In CAE-MSP, a single round of
PCR is performed with color-labeled, automatically detectable oligonucleotides with different
colors for the methylation specific and unmethylation specific reaction. This enables sensitive
amplicon detection in a high through-put capillary automated detection system using 96-well
plates followed by automated software fragment analysis. The procedure also allows semi-
quantitative interpretation of the data and confirms with each sample the predicted amplicon
size length with high precision. As mentioned, CAE-MSP has excellent qualities, however, it
is not a fully quantitative assay. In chapter three, absolute quantitative assessment of methy-
lated alleles (AQAMA) is introduced for accurate assessment of a sample’s DNA methylation
level instead of methylation status. The AQAMA PCR principle was derived from QAMA des-
cribed by Zegschnik et al. and is based on real-time PCR techniques. In AQAMA, two fluo-
rescent minor-groove binding (MGB) probes, one methylation-specific and one unmethylati-
on-specific are used to detect the amount of methylated and unmethylated alleles present in
sample DNA. Important features of AQAMA that enhance reliable quantification are: 1. The
use of minor groove binding (MGB) probes ensures the required high specificity to discrimi-
187
General Discussion and Future Perspectives
nate between CT (unmethylated) and CG (methylated) SBM modified sequences17-19. 2.
Quantification is performed in a single PCR reaction while other methods use separate methy-
lation specific and unmethylation specific reactions with different reaction kinetics. 3. The use
of standard curves of dilution series of cDNA synthesized in E.Coli vectors enables absolute
copy number assessment of methylated and unmethylated alleles with highly specific positi-
ve and negative control of the quantification. 4. The assay can be performed in a 384 wells
system that further reduces inter-assay variability when dealing with large sample sizes as our
studies intend. In chapter three the quantitative accuracy and linearity of AQAMA is demon-
strated and its application by combining AQAMA with on-slide SBM. Tissue areas with diffe-
rent histopathology could be quantitatively compared for differences in methylation level
instead of dichotomous comparison of methylated versus unmethylated. As an example sig-
nificant differences in level of MINT locus methylation (a known specific marker for colorec-
tal cancer) were detected between adenoma and cancer colorectal tissue. AQAMA combined
with on-slide SBM can provide further quantitative detail of epigenetic events during colorec-
tal or other solid tumor formation.
The onslide-SBM technique majorly improves and simplifies DNA preparation for DNA
methylation analysis. As cells are harvested by needle scratch under a light microscope, it
is inevitable that the finally analyzed sample contains some normal cells such as tumor infil-
trating lymphocytes or stromal cells. To further reduce non-tumor cells sample content and
to strive for analyzed DNA to be derived from 100% tumor cells, on-cap SBM was develo-
ped as described in chapter four. The method integrates in-situ SBM with the laser cap-
ture microdissection platform20-22. The cells stick to a cap that can be lifted from the secti-
on and afterwards the cells can be treated, in-situ, with sodium bisulfite before cell digestion
and continued DNA isolation. We combined on-cap SBM with the AQAMA assay to mea-
sure global hypomethylation of colorectal cancers by targeting long interspersed nucleoti-
de element one (LINE-1), a DNA repeat that represents about 15% of the human genome.
On-cap SBM followed by AQAMA of LINE-1 allowed as a first to demonstrate stepwise
reduction of global hypomethylation in colorectal cancer with advanced disease stage. We
also showed necessity of employing target cell selection techniques, such as laser capture
microdissection, when analyzing LINE-1 in colorectal cancer. 
Section 2: Clinical application
These thesis projects were initiated because of an interest to test clinical utility of epigenetic
biomarkers using patient tissue of clinical databases from trials coordinated by the Leiden
University Medical Center Surgical Department. Two trials were selected: the first concerned
gastric cancer, the so-called D1D2 trial, and the other concerned rectal cancer, the so-called
total mesorectal excision or TME-trial. The studies were initiated by the Dutch Gastric Cancer
Group and the Dutch Colorectal Cancer Group, respectively. These collaborative scientists´
networks have a unique infrastructure covering almost every oncologic surgical clinic in the
Netherlands enabling a nation-wide cohort inclusion of GI cancer patients. As almost every
citizen in the Netherlands has a family physician, patients can easily be tracked after clinical
discharge which enhances complete long-term follow-up data. The clinical results of primary
endpoints of these trials have been published23,24 and primary tumor tissue blocks were col-
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lected from the different study sites pathology departments. As a consequence, the patients
of the study groups in this thesis were very well documented with prospectively collected fol-
low-up data. 
The D1D2 trial compared total or partial gastric resection with D1 lymph node dissection
to surgery with more extensive D2 lymph node dissection that is widely used in Asian countries
and is mostly promoted by the expert gastric cancer surgeons from Japan. Almost 1000 patients
were randomized in this study providing a unique patient group with a median of 14 years of
follow-up at the time of our biomarker data analysis. As discussed in this thesis introduction, the
multidisciplinary treatment of gastric cancer has long been frustrated by inability to show effect
of (neo)adjuvant chemotherapeutics25. A landmark study by McDonald et al. in 2001 was the
first to show benefit of postoperative chemoradiotherapy and again gave an impulse to put scien-
tific effort in improving treatment of gastric cancer26. In 2006, Cunningham et al. showed bene-
fit of perioperative chemotherapy over surgery alone27. These important studies have created a
need for biomarkers in gastric cancer to better allocate patients to the introduced aggressive tre-
atment regimens. Cyclo-oxygenase-2 (COX-2) is a well studied gene in many cancers and pre-
dominantly in GI cancer. The COX-2 enzyme is involved in production of prostaglandine PGE2
and to a lesser extent thromboxane, both implicated in angiogenesis, cell proliferation, cell sur-
vival, migration, invasion, and modulation of host immune cells28-30. Tumors overexpressing
COX-2 have been shown to behave more aggressively during clinical follow-up in gastric can-
cer as well as other cancers31,32. The epigenetic regulation of COX-2 has been described in gast-
ric cancer33-35. The methylation status of the COX-2 promoter region has not been tested to
have utility as a biomarker in gastric cancer. In chapter 5 it was demonstrated that a hyperme-
thylated status of the COX-2 promoter region indeed leads to underexpression of COX-2 pro-
tein and subsequently to improved disease survival. A strong aspect of this study was that the
predictive value was shown in two independent clinical trial populations which reduces the risk
of overfitting of the data. The predictive value was independent of the established clinical para-
meters and therefore may have value to further aid treatment decisions in gastric cancer. From
this study’s conclusion it can be derived that epigenetic silencing does not necessarily result into
more aggressive disease outcome of gastric cancer. DNA methylation research generated much
interest because it was novel way of shut-down of tumor suppressor genes as a cause of carci-
nogenesis. This has lead to a paradigm that DNA methylation is an unfavorable tumor event.
Since demethylating drugs are available there is an argument that they may be used to remove
those unwanted methyl-groups and make the tumor-suppressor genes function again. In chap-
ter 5 we demonstrate DNA methylation to have a favorable role in predicting disease outcome
and removal of this methylation by demethylating drugs may therefore worsen disease outco-
me. The data further suggest that specific gene promoter region hypermethylation may replace
gene protein expression as a biomarker. DNA methylation assays have some specific advantages
(i.e. non-receiver-operated, automated) and may be used instead of assessment of protein expres-
sion by immunohistochemistry when that gene is epigenetically regulated. 
The Dutch TME trial on rectal cancer was the second clinical study of interest to test
DNA methylation biomarker utility. The study showed improvement of the surgical treatment
of rectal cancer by reducing local recurrence rates by adding short course radiotherapy befo-
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re surgery23. An important quality of this trial was the standardization of the surgical proce-
dure using the total mesorectal excision technique described by Heald et al36. Participating
surgeons underwent a technical training program and were supervised during the first five
operations. Furthermore, standardization of the pathology assessment of the rectal specimens
controlled for completeness of the surgical treatment. The trial included 1861 patients in less
than 4 years from over 108 surgical clinics. To date, epigenetic biomarkers have not been tes-
ted in rectal cancer specifically. For the study described in chapters 6 and 7, we established
research objectives that are of specific use for rectal cancer treatment such as prediction of
local recurrence and distant recurrence in early disease. In the experiments testing AQAMA
and on-slide SBM we obtained encouraging data that methylation levels may have potential
to subclassify rectal cancers. The required sample size for showing prognostic value was esta-
blished by sample size calculations. The four MINT loci used in the AQAMA validation stu-
dies (MINT1, 2, 12 and 31) were used as markers and expanded by three more (MINT3, 17
and 25). To test if change in MINT methylation levels was related to tumor progression we
first analyzed normal, adenoma and cancer tissues (chapter 6). We used the assay combining
on-slide-SBM and AQAMA to study this. The data showed that MINT locus methylation esta-
blishes during adenomatous transformation of normal rectal epithelium and is maintained
during malignant transformation. Biomarkers in other studies often positively correlate to inc-
reasing TNM-stage meaning that only a small number of cases with early disease are positi-
ve. Such markers are therefore less likely to be of clinical use in early stage patients while this
group would benefit most from better subclassification. The clearly detectable and non-nor-
mally distributed MINT methylation levels in adenomas and early cancer were therefore pro-
mising to subclassify early stage disease. Then MINT locus methylation values were measu-
red in 314 non-irradiated patients´ tissues. Unsupervised random forest clustering of the data
was used to analyze whether specific methylation patterns could be discerned from the data.
This unconventional statistical method was opted for because of its capacity of internal vali-
dation, eliminating the need of a test-validation study set-up. Random forest (RF) clustering
does not make assumptions on data distribution which makes it suitable for analyzing the non-
normally distributed methylation data. Two methylation markers (MINT3 and MINT17) were
identified by RF clustering that could separate the patients into four groups. Importantly, the
separation was clear, with no overlap. Most biomarkers concern gene expression data with a
cut-off being the median expression value. Because gene expression data are usually normal-
ly distributed, separation by this cut-off is not clear. Interestingly, an inverse relation between
MINT3 and 17 methylation was present and this specific combination was required to have
predictive value for distant recurrence probability in early, node-negative disease. This predic-
tive value was not present in node-positive disease. Disease spread early by the hematogenic
route may explain this finding. There is evidence of systemic spread of colorectal cancer cells
in the circulation and bone marrow even in the earliest stages37-39. This indicates that very
early on, tumor cells can have the capacity to enter to bloodstream and therefore may metas-
tasize without signs of lymphatic spread. Our assay may have identified rectal tumors with
such early potential for hematogenic spread. Further studies are needed to support this. 
The MINT3 locus CpG island is localized on chromosome 1p34-35 just downstream of
RBBP4 (retinoblastoma-binding protein 445,46), SYNC1 (encoding syncoilin protein involved in
cell cytoskeleton and extracellular matrix proteins), YARS (tyrosyl-tRNA synthetase, involved
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in angiogenesis47,48) and s100p-binding protein (s100p is known to be overexpressed in many
solid tumors49,50). MINT17 is localized on the long arm of chromosome 12 upstream of the
Harakiri (HRK) gene which is a member of the BCL2 gene family that encodes apoptosis regu-
latory proteins and its expression is a known target of regulation by promoter region methyla-
tion51. A functional relation between MINT3 and 17 and the mentioned genes or their expres-
sed proteins has not been established but is an interesting subject of future studies.
5-Fluoro-uracil (5FU) -based adjuvant treatment for rectal cancer is given standard in the
United States and Asia for transmural (T3) and/or node-positive rectal cancer40,41 and the
SCRIPT trial (www.dccg.nl) currently investigates adjuvant treatment with capecitabine (an
oral form of 5FU) for this patient group in the Netherlands. The clinical utility of predicting dis-
tant recurrence in early stage rectal cancer patients becomes now important since clinicians
may be hesitant to consider node-negative patients for adjuvant therapy as it is known that only
15-20 percent of these patients will show distant recurrence. Together, our results were shown
in a large trial-derived patient group that was controlled for surgical and pathological quality
and that was established by sample size calculations. We used preselected markers with shown
potential for subclassification and obtained clearly distinct subgroups in an unbiased manner
by using unsupervised random forest clustering. The predictive value in early disease patients
may have utility in targeting systemic treatment after surgery due to identification of high risk
on distant disease spread despite the early detection.
Another important clinical issue in the rectal cancer specifically is the risk of local recur-
rence due to the close anatomical relation of the rectum to the pelvis. Rectal cancer patients
are therefore additionally treated with radiotherapy pre- and/or intraoperatively to improve
local control. Radiation therapy in addition to surgery comes with specific long term morbi-
dity such as more faecal incontinence, sexual dysfunction and a general reduced quality of
life42-44. Local recurrence rates after adequate TME surgery alone are around 10% meaning
that 90% will be overtreated when all rectal cancer patients undergo short-course preopera-
tive radiotherapy. Targeting radiation treatment to those patients who are likely to locally
recur could therefore be of benefit. In chapter 7 the predictive value of MINT3 and
MINT17 epigenetic biomarkers for local recurrence was evaluated. The specific combinati-
on of hypermethylation of MINT3 and decreased methylation of MINT17 was tested to be
predictive for this purpose. This patient group which was at high risk for distant recurrence
had significantly lower risk for local recurrence. In chapters 6 and 7 the identification of an
epigenetically distinct group of rectal cancer patients who early on in their disease formati-
on have increased potential metastasize systemically without local spread is reported. These
patients may benefit more from systemic chemotherapy and less from preoperative radiati-
on. It is important to notice that since MINT3 and MINT17 primary tumor tissue methyla-
tion levels as biomarkers can be assessed preoperatively on tumor biopsy material so it can
be considered in the preoperative multidisciplinary decision making process.
In chapter 8 the relation between quantitative MINT locus methylation and microsa-
tellite instability (MSI) is analyzed. MSI+ colorectal cancers are a firmly established gene-
tically distinct subgroup of sporadic colorectal cancers with mismatch repair system defec-
tiveness and clear guidelines exist for assays to identify MSI+ cases. Sporadic MSI occurs
in approximately 15% of colorectal cancers and 50% of right-sided colon cancers. Studies
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have repeatedly shown a relation between DNA methylation and MSI. It is now accepted
that sporadic MSI occurs through epigenetic silencing by DNA methylation of the impor-
tant mismatch repair protein hMLH1. This is observed in tumors with genome-wide, glo-
bal increased methylation at multiple CpG islands52. Still many issues remain unsolved. For
instance at what stage of tumor formation (normal, adenoma or cancer) the relation
between globally increased methylation, methylation of hMLH1 and MSI is initiated. Our
assay of on-slide-SBM combined with AQAMA is suitable to answer this specific question
as paired analysis of quantitative methylation and genetic MSI analysis can be performed
in different stages of CRC development. The results showed increased methylation of
MINT loci and hMLH1 in adenomatous precursors of MSI+ CRCs which showed to be
MSI+ in only 50% of the cases. The data indicate global hypermethylation to precede MSI
at the adenoma stage of tumor formation. Inconsistent results are published on whether
MSI+ CRCs have significant better disease survival. hMHL1 methylation is causative of spo-
radic MSI and this methylation is part of a global, genome-wide increased methylation of
which, according to our results, MINT loci are representative. Our results show that level
of MINT locus methylation has predictive value for disease outcome independent of MSI
status. This result is confirmed by other groups53-55. The assumed improved outcome of
MSI+ tumors may therefore be explained by increased MINT locus methylation levels.
How high MINT locus methylation levels improve disease survival or how low MINT locus
methylation enhance distant metastasis is a subject for future studies.
There are many studies that have suggested colorectal cancers with heavy methylati-
on at CpG islands to form a clearly distinguishable subgroup of colorectal cancers, even a
phenotype, the CpG island methylator phenotype (CIMP). Clinically, CIMP+ tumor featu-
res overlap with those of MSI+ tumors which are: mucinous aspect, proximal location in
the large bowel and poor differentiation55. Genetically, there is a close association with
BRAF V600E mutations and KRAS wild type52,56. How to define CIMP+ cases is not agreed
upon as is in MSI. Different groups use different markers and different assay techniques
(often non-quantitative53). The frequently used quantitative MethyLight technique56 some-
times does not measure unmethylated allele presence and normalizes the methylated alle-
le number to a total allele count which may lead to underestimation of the degree of methy-
lation since DNA methylation is known to be heterogeneous. Also, the quantitative data
are dichotomized by a cut-off into methylated or unmethylated and the actual methylation
level value is never used in clinical correlation studies. The cases showing hypermethylati-
on in chapter 8 likely overlap with CIMP+ patients. Our study ś objective, however, was
not to test whether CIMP exists, which has been established. We intended to study the
quantitative relation between methylation of MINT loci and MSI+ in normal, premalignant
and malignant colorectal tissue. 
Concluding Remarks and Future Perspectives
Techniques
In section one of this thesis, on-slide SBM, AQAMA and on-cap SBM are presented as tech-
niques for detailed quantitative epigenetic assessment of cancer specimens. These assays
are relatively simple to perform. On-slide SBM requires no more equipment than needed
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for standard immuhistochemical staining protocols. AQAMA requires a single PCR reacti-
on on an automated real-time PCR platform. We showed its quantitative quality, its appli-
cation and its potential clinical value. When interpreting results from other studies that eva-
luate epigenetic biomarkers consideration should be given to the techniques used.
Quantitative PCR analysis of primary tumor tissue has no role in GI cancer diagnostics yet.
The results of this thesis’ studies show promising prospects for clinical use of AQAMA in
GI cancer diagnostics. The quantitative detail of DNA methylation is yet to be further tes-
ted in other GI malignancies and solid tumors for clinical utility. 
The on-slide or on-cap technique combined with AQAMA has potential to elucidate the
relation of epigenetic and genetic events in the carcinogenic process of any solid tumor.
This thesis’ studies utilized the techniques in colorectal cancer, although the technique can
compare histologically different tissue areas within a single tissue section of any type of solid
tumor. The approach enabled to clarify that the relation between microsatellite instability
and DNA methylation is established in the earliest stages in the oncogenic pathway of colo-
rectal cancer. The epigenetic aspects of the histopathologically important steps in tumor for-
mation of premalignant transformation of normal cells and invasive transformation of pre-
malignant cells can be better studied with on-slide SBM. Applicable to any type of cancer,
the opportunities of new study subjects are numerous and likely to yield interesting results. 
Biomarkers
Epigenetics, like DNA methylation form a new category of molecular targets for biomarker
opportunities. This thesis’ studies aimed at testing DNA methylation to have utility in cli-
nically relevant subclassification of GI cancers. The data demonstrated that specific epige-
netic biomarkers in primary tumor tissue of gastric, colon and rectal cancer (the most com-
mon forms of GI cancer) can identify clearly separable subgroups of GI cancer patients and
to have potential aid in making preoperative treatment decisions guiding the multidiscipli-
nary treatment. To date, the TNM staging system is the best available tool to base treat-
ment decisions upon and will continue to do so in the future. We show that quantitative
epigenetic biomarkers can give valuable additional information in assessment of primary
tumor properties for stratification of disease aggressiveness.
COX-2 methylation status was identified in this thesis´ studies in gastric cancer to have
prognostic value independent from TNM-stage. Only recently, effective (neo)adjuvant tre-
atment regimens are being administered in gastric cancer. Further clinical studies have to
point out what subgroups of gastric cancer patients will benefit most by these aggressive
treatment regimens and biomarkers, like COX-2 methylation analysis, will likely be of addi-
tional value. Confirmative studies are needed to test COX-2 prognostic value in node-nega-
tive disease specifically. These analyses should be performed with a fully quantitative assay
as our studies were performed with semi-quantitative techniques. 
In rectal cancer we show that quantitative assessment of two MINT loci in primary
tumor tissue can be of aid in specific clinical problems. Preoperative treatment planning is
becoming more and more important since neoadjuvant strategies have been shown to be
effective. MINT locus methylation assessed by AQAMA can help select patients for preo-
perative radiation therapy and similar as in colon cancer can help identify early stage, high-
risk disease that may benefit from systemic treatment reducing distant metastasis. The fin-
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dings need to be validated in an independent prospectively collected patient group. If con-
firmed, the results may be used to design clinical trials that stratify non-locally advanced
patients into high-risk local / low-risk distant recurrence or low-risk local / high-risk dis-
tant recurrence and tailor treatment according (see figure 1). In the future rectal cancer
should be evaluated in biomarker studies as a separate group of large bowel cancers becau-
se it has specific treatment and specific clinical aspects to be taken into consideration.  
In colon cancer, there is much discussion how to improve the selection of high-risk node
negative patients for adjuvant chemotherapy. In node negative disease, primary tumor pro-
perties are becoming of clinical importance. The pathology report now additionally descri-
bes whether a tumor has signs of perineural/vascular/lymphatic invasion, however, these
assessments are not routinely and systematically performed. Our studies show that MINT
locus methylation is especially suitable in node-negative disease when it is detected in early
disease, even at the adenomatous stage. These epigenetic biomarkers may therefore be of
specific help in identifying high-risk, node-negative colon patients. Validation studies in inde-
pendent, prospectively collected patient groups are needed to further investigate this. 
Finally, this thesis is an example that shows the worth of close collaboration between
surgical oncologists and basic scientists and demonstrates that translational medicine is of
great value in cancer research to test clinical application of novel molecular targets and tech-
niques and subsequently bring the so-called “bench” and “bedside” closer to each other.   
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Figure 2: Suggested trial randomization schedule using MINT3 and MINT17 as biomarkers in non-locally
advanced rectal cancers. 
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English Summary
Inclusion as well as exclusion
This thesis reports on colon, rectal and gastric adenocarcinoma which are the most abun-
dant malignant tumors of the digestive system. They form a large health burden on socie-
ty and this burden will only grow the coming decades with the increasing life expectancy
of humans. The only chance for cure of these malignancies in most cases is radical
open/laparoscopic abdominal surgery which comes with morbidity and mortality, especial-
ly in older patients. Over the last years, treatment strategies have developed towards more
and more aggressive to improve survival rates. For instance, more extensive surgical resec-
tion of surrounding structures and nodal tissue or addition of systemic and local disease era-
dicating chemotherapeutic and radiotherapeutic modalities. We know from randomized
trial data that addition of radiotherapy and/or chemotherapy before (neoadjuvant) or after
(adjuvant) surgery improves the outcomes of all rectal and gastric cancers and advanced
stage colon cancers. The added morbidity of these treatments affects many patients and is
higher in the older patient. Neoadjuvant therapy also increases the risks of the surgical pro-
cedure and reduces the chance of a full recovery.
The clinical data demonstrate that a considerable percentage of patients will be cured
with surgery alone and therefore the additional therapy is an overshoot in many patients.
A better estimation of a tumor´s aggressiveness beyond the current standard staging
methods is an important subject to improve treatment allocation of patients. The potential
benefits of improved tumor risk assessment in addition to nodal status are two-fold. First,
it may allow to include more early stage patients at high risk of disease recurrence that
would benefit from aggressive therapy. Secondly, it appoints low risk, early or even advan-
ced stage patients to exclude them from undergoing unnecessary therapy. 
Since it is known that neoadjuvant regimens improve disease outcomes of rectal and
gastric cancer it is important to perform risk assessment preoperatively. The current dia-
gnostic imaging modalities (CT, MRI, PET/CT) are highly important in setting up the 
individual treatment plan. For instance to detect distant disease spread or assess T-stage in
rectal cancers. These findings are used in tailoring treatment regimens for different disease
stages. The imaging modalities are used to predict the TNM-stage as best as possible. Nodal
involvement remains the most important classic risk indicator for gastric and colorectal can-
cer survival. To determine N-stage reliably preoperatively is still not possible by imaging
techniques especially in gastric and colon cancer. Primary tumor features are an attractive
form of preoperative diagnostics as a tissue diagnosis obtained through gastroscopy / colo-
noscopy / proctoscopy is always required. Molecular primary tumor features on the DNA
level are attractive because a minimum of tissue is required and the techniques are auto-
mated, robust and highly sensitive. Furthermore, the DNA molecule is highly stable com-
pared with RNA or protein.
Epigenetics
The completion of the human genome project was a milestone in science, however, the
function of only 5-10% of the genome can be explained till now. The term completion was
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therefore misleading. For a long time, the other 90-95% has been called `junk DNA´, a term
introduced in 1972 by Susumu Ohno. The hidden complexity of the human genome has
become more evident since other genomes of life forms which are considered less complex
have been unraveled. For instance, a fruit fly (Drosophila melanogaster) has an estimated
27,463 encoding genes compared to 31,896 in homo sapiens. This relatively small diffe-
rence indicates that the less understood “junk DNA” may contain important functional ele-
ments that may discriminate the human and fruit fly life form. The relatively small diffe-
rence of less than 9% points out that the number of genes is of lesser importance. Activation,
interaction and modulation of gene expression is crucial for development of differentiated
cells and the interaction of these cell in and between organ systems. The developing field
of epigenetics has been shown to play a highly important role in gen regulation. The latest
definition of epigenetics is that these are heritable traits (over rounds of cell division and
sometimes transgenerationally) that do not involve changes to the underlying DNA sequence.
One important epigenetic, DNA regulatory element has been recognized in methyl-group
placement or DNA methylation. This mechanism has many important functions: specific
gene silencing, X-chromosome inactivation, cell differentiation. In cancer, DNA methylati-
on is known to be tremendously affected even more than the DNA itself. The clinical sig-
nificance of changes in DNA methylation in cancer are currently being studied. 
This thesis´ objective is to study the role of DNA methylation in gastric, colon and rectal
cancer. More specifically to explore whether these epigenetic features can be of clinical use
in making multidisciplinary treatment decisions, not only to include patients that will benefit
from more aggressive therapy but also to exclude patients from unnecessary therapy.
Dutch Trials
In The Netherlands an excellent infrastructure exists for the performance of multicentre
clinical studies in patients with cancer. In 1989, a collaborative network of surgical onco-
logists started a randomized trial on surgery for gastric cancer comparing two levels of
lymph node dissection. The successful surgical enterprise lead to the design of more stu-
dies and expansion of the network to multidisciplinary. Today, the Dutch Colorectal Cancer
Group (DCCG) is a nationwide collaboration between medical disciplines that are relevant
for the diagnosis and treatment of colorectal and gastric cancer (surgical oncology, radio-
therapy, medical oncology, pathology, radiology, gastroenterology). This thesis´ clinical stu-
dies were performed with primary tumor tissue derived from patients that participated in
two large trials conducted by the DCCG. First, the D1D2 gastric cancer trial (described
above) that enrolled over 700 patients is probably the largest prospectively collected
Western population of gastric cancer patients with long term follow up data up to a median
of 16 years postoperatively. Second, the TME trial for rectal cancer that compared total
mesorectal excision (TME) surgery with or without radiation therapy preoperatively. This
trial is one of the largest trials conducted in rectal cancer specifically in Europe that inclu-
ded protocols to control the surgical procedure as well as the pathologic diagnostic process.
The use of patient material to test clinical value of biomarkers in prospectively collected
patient´s tumor material is highly important and the two trials mentioned above provide
well described patient study groups for researchers to interpret the results. 
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Section I: Technical Improvements
The studies are divided in two sections. The first section reports on four studies that des-
cribe technical improvements for analysis of DNA methylation on paraffin embedded archi-
val tissue which was the specimen source available from the DCCG trial patients. In gene-
ral, an initial assessment of the value of biomarkers is usually performed on sections of
paraffin embedded tissue from pathology archives as this is an abundant tissue source and
relatively easily accessible. It further allows excellent linkage of the tissue analyzed with
histopathology. A problem in studying DNA methylation is that the most widely used tech-
nique requires treatment of the DNA with degrading chemicals such as sodium bisulfite
modification (SBM) which makes larger amounts of input DNA necessary. This means that
multiple sections of tissue or tissue punches are needed and this compromises the detail in
which DNA methylation can be studied i.e. comparison of small tissue areas of a single sec-
tion of HE stained tissue. We described two techniques in this section that enable such
detailed analyses and that they can even compare the DNA methylation status between
small groups of cells such as from early dysplastic cells in a colonic crypt with the differen-
tiated cells of the contiguous villus. 
Chapter one reports a useful protocol for researchers that perform methylation-speci-
fic polymerase chain reaction derived techniques. A protocol is described for synthesis of
completely unmethylated human genomic DNA which cannot be found in nature. This
DNA can be used as a negative control to include in PCR reactions that tests the DNA
methylation status of any region of interest. Chapter two shows that SBM of unpurified
DNA while it is still in the cell’s nucleus on the tissue section mounted on a glass slide has
an equivalent effect to treatment of DNA that is isolated and purified before SBM.
Application of this method shows that it can be used to analyze small (1-2 mm2) tissue areas
from a single section of PEAT and therefore one can compare DNA methylation features of
areas with different types of histopathology such as tumor precursor cells and cancer cells,
which was difficult to do before.
Chapter three continues with the introduction of absolute quantitative assessment of
methylated alleles (AQAMA), a real-time PCR technique for assessment of DNA methyla-
tion levels. Before AQAMA our research group used capillary array electrophoresis methy-
lation-specific PCR (CAE-MSP) which is semi-quantitative. It was shown that application of
AQAMA can be used in combination with the on-slide SBM method and levels of DNA
methylation can now be compared between histopathologically different tissue areas inste-
ad of two-way outcomes, methylated or unmethylated. Our data demonstrated differences
in levels of DNA methylation at methylated-in-tumor (MINT) loci in colorectal polyp cells
compared to contiguous cancer cells that invade the bowel wall isolated from the same tis-
sue section. Our findings indicate the importance of assessment of methylation level inste-
ad of methylation status. 
Chapter four reports on on-cap SBM which integrates the in situ SBM technique with
cell isolation by laser capture microscopy. This further enhances the details in which DNA
methylation can be studied. Application of on-cap SBM was demonstrated that methylation
levels measured by AQAMA could be compared of long-interspersed-nucleotide-elements
(LINE1) between cells isolated from the luminal side of the tumor and cells isolated from
the invasive front. The major advantage of on-cap SBM is that it minimizes the pick-up of
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normal cells such as fibroblasts and lymphocytes or other stromal components of a tumor.
Together these chapters demonstrate not only useful techniques but also the application of
these techniques that will create new possibilities of DNA methylation analysis. On-slide
SBM and AQAMA have excellent qualities for assessment of large patient groups from the
DCCG trials using only a few sections of paraffin embedded primary tumor tissue blocks.
Section II: clinical application
After developing robust and high-throughput techniques for processing primary tumor tis-
sue derived from paraffin blocks we started the analysis of the DCCG’s patients’ material. 
Over the last years more scientific effort is put in improvement of gastric cancer treat-
ment after MacDonald et al. in 2001 showed benefit from adjuvant treatment for the first
time. The recently reported improved survival rates with the addition of pre- or postopera-
tive radio- or chemotherapy have created a need for novel markers to further classify gast-
ric cancer patients to better tailor these newly developed regimens. Gastric cancer is known
for its infiltrative component in which enzymes expressed by the tumor cells mediating the
body’s reaction to the tumor may play an important role. From previous work, the expres-
sion of cyclooxygenase-2 (COX-2), which is known to play a key role in the inflammatory
process, has been shown to be regulated by DNA methylation of its promoter region in gast-
ric cancer in vitro. Other studies have demonstrated that patients with tumors highly
expressing COX-2 have worse disease outcome. In chapter 5, the hypothesis was tested
that the DNA methylation status of COX-2 is a predictor of gastric cancer disease survival.
We could show in the two independent trial patient groups both well described and with
follow up data over 12 years after surgery that COX-2 methylation is a predictor of disea-
se recurrence and survival independent of the current prognostic factors such as lymph
node involvement.
COX-2 activity in gastric cancer can be assessed by staining of the tumor tissue paraf-
fin sections with a specific antibody. This technique called immunohistochemistry is wide-
ly used in cancer diagnostics. A major problem of IHC in gastric cancer with its known dif-
ficult histopathology is the inter-individual variance of the operator that assesses the staining
intensity in individual cases. There may be derived from our study’s results that the expres-
sion of genes such as COX-2 which are regulated by DNA methylation can be assessed by
automated, operator independent methylation assays. 
Specific targeted drugs that inactivate the COX-2 enzyme are widely used as analge-
sics in rheumatic conditions. These drugs are also being tested in cancer and there are many
reported studies that show probable benefit of targeted COX-2 inhibition in gastrointesti-
nal cancers. Another finding of our study was that our COX-2 DNA methylation assay does
correlate to COX-2 protein expression in vivo which has not been shown before. This indi-
cates that the COX-2 methylation assay can also be used to select patients that will bene-
fit from these drugs. This is especially important since an increased risk of cardiovascular
events as a side-effect of specific COX-2 inhibitors has been reported.
In chapters six and seven the findings of two studies on the clinical application of
quantitative DNA methylation analysis in patients with rectal cancer are described. Rectal
cancer is a clinically distinct subtype of large bowel cancer. The most important difference
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lies in the close anatomical relation due to fixation of the rectum in the small pelvis com-
pared to the colon proximal of the sigmoid fold. This makes complete surgical resection
more challenging and increases the risk of local recurrence also in early stage disease, espe-
cially in tumors that lie closer to the anus. The fixation of the rectum enables directed exter-
nal beam radiotherapy whereas this would not be possible in the mobile colon. The previ-
ously mentioned DCCG trial for rectal cancer evaluated a surgical technique called total
mesorectal excision (TME) with or without a short course of radiotherapy before operati-
on. TME surgery entails rectal excision en block with the surrounding rectal fat using the
mesorectal fascia posterior of the fat as an anatomical border with sparing of the sacral ner-
ves. Previous to the introduction of TME surgery by Bill Heald in the early 1980s, blunt
dissection posterior of the rectum was performed that resulted into 20-25% local recurren-
ces. The TME trial showed major improvement of this important morbidity causing disea-
se parameter as recurrence rates were 10% after TME surgery alone and this was further
reduced to 4% with the addition of preoperative radiotherapy. Despite these important fin-
dings the overall survival of rectal cancer patients did not improve and trial data analysis
after five years of follow-up showed that distant disease spread determines the survival out-
come. 
AQAMA assays were designed to measure DNA methylation levels at seven different
MINT loci that are located on 7 different chromosomes. These MINT loci were detected
in a genome wide screening as differentially methylated comparing a colorectal cancer cell
line with healthy DNA. MINT loci do not express any protein and have no known other
function in the human genome. The MINT loci have been tested by various research groups
in gastric and colorectal cancer to be of clinical value. Initially, DNA methylation levels
were measured in tumor and contiguous adenoma and normal tissue. The results showed
that increases of MINT methylation levels are very early events in rectal cancer and most-
ly establish during adenoma formation as compared with cancerous progression of adeno-
mas. The distribution of the measured MINT methylation levels in adenoma and cancer tis-
sue were non-normal and this indicated that the markers have potential to group rectal
cancer patients. Then over 300 rectal cancer patients from the surgery-only TME trial arm
were assessed by the AQAMA assays and the methylation level values were analyzed direct-
ly by a unsupervised clustering algorithm. The grouping method recognizes patterns that
are present within the data in an unbiased manner. The result was that two of the MINT
markers (3 and 17) were inversely correlated and can divide the patients into clearly sepa-
rate groups with almost no overlap. In chapter six we report on the finding that this sub-
division identifies a group consisting of approximately 25% of the early stage, node-negati-
ve patients that have a significantly increased risk to develop distant recurrence and
subsequently reduced cancer-specific and overall survival. In chapter seven we report that
the same group of patients with a higher chance of developing liver metastasis have a sig-
nificantly lower chance of local recurrence. The DCCG previously demonstrated using the
TME trial data that the patients that received radiotherapy had more fecal incontinence,
sexual dysfunction, delayed wound healing and so a reduced quality of life after surgery.
The other group of approximately 75% of the rectal cancer patients was analyzed and had
a significantly higher incidence of local recurrence compared with irradiated patients. This
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suggests that leaving out the morbidity increasing preoperative radiation can be done wit-
hout disadvantaging these patients. The clustering method using only MINT3 and MINT17
was simplified using cut-offs and validated in an independent group of rectal cancer patients
in order to provide an algorithm to be used by other research groups. Together the two stu-
dies report on the identification of a group of rectal cancer patients that forms about 20-
25% of all patients that have a higher chance of developing liver metastasis and a lower
chance of developing local recurrence after curative resection. The cluster of patients was
identified by unbiased unsupervised clustering and had no overlap epigenetically with the
other patients. This is important because expression values of many markers have normal
distributions and often the median value is chosen as a cut-off. Most sample values are
around the median and therefore such a cut-offs result into poor separation. To our know-
ledge this is the first study that reports on quantitative epigenetic biomarkers for rectal can-
cer specifically with the potential to guide the multidisciplinary treatment controlling dis-
tant and local recurrence even in early stage patients. 
The final chapter 8 focuses on colorectal adenocarcinoma precursor lesions. It utili-
zes the techniques described in chapter two and three and shows the value of the enhan-
ced detail that this approach enables. About half of the right-sided colon cancers have a
defective DNA mismatch repair (MMR) system caused by epigenetic silencing of the human
Mut-L homologue (hMLH1) gene. The disruption of DNA repair results into shortening of
DNA repeat sequences called microsatellites and this can be detected by simple PCR tech-
niques. MMR defective tumors are therefore called highly microsatellite instable (MSI-H).
It is widely recognized that epigenetic silencing of the hMLH1 gene is part of a genome
wide increase of methylated CpG islands including the MINT loci. We hypothesized that
the quantitative AQAMA assay could detect that methylation levels at MINT loci are inc-
reased in precursor lesions of MSI-H tumors before MSI has established. The results show
that the AQAMA MINT assay can be used to identify adenomas that will developed into
MSI-H cancers. This finding is of biological interest as it shows that important epigenetic
changes initiate in the earliest phase of colorectal cancer formation with only the presence
of classic adenomatous tissue with low or intermediate dysplasia. These detectable changes
early on will later lead to a distinct phenotype of colorectal cancer. Early identification of
patients at risk for developing MSI-H phenotype sporadic cancers by AQAMA of MINT loci
may have clinical consequences. It would be interesting to examine whether other polyps
collected during colonoscopy from the same patient have similar DNA methylation featu-
res which may indicate a predisposition to colorectal cancer development. The polyp recur-
rence probability of patients with adenomas with high MINT locus methylation could be
studied and the frequency of follow-up colonoscopies may be adjusted for such patients.
Our results further show that MINT loci methylation levels can discriminate normal from
adenomatous tissue. The MINT markers may therefore be a part of a screening panel tes-
ted on fecal DNA to identify patients that should undergo colonoscopy. Not only MSI-H
precursor lesions may be identified by MINT markers 1, 2, 12 and 31 but also MSS lesions
may be identified by MINT3 methylation. Further, it is known that MSI-H cancers respond
differently to common chemotherapeutics. For instance, irinotecan is suggested to be more
effective than 5-FU in these tumors. With the development of better targeted and more
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patient friendly drugs, prevention strategies may be indicated for patients with polyps with
high MINT locus methylation. Also, there is increasing evidence that there is MSI-induced
generation of novel tumor-specific carboxy-terminal frameshift peptides (FSPs) in MSI-H
cancer patients. Development of FSP-based vaccination approaches is currently ongoing
and patients with polyps with high MINT locus methylation may become a target group for
such vaccination trials.
Future perspectives
All together this dissertation reports on improvement of molecular techniques for studying
DNA methylation and describes application of the techniques to identify biomarkers with
the potential to improve the treatment of gastric, colon and rectal cancer. The next step
was taken to further develop the clinical use of the described biomarkers. The prognostic
value of COX-2 methylation status as a biomarker in gastric cancer was shown in a second
independent, trial-derived patient group. Subsequently, a clinical trial could be suggested
that allocates patients with a methylated COX-2 promoter region to surgery alone leaving
out neoadjuvant therapy. The primary study objective would be to show that patients in
both trial arms have no significant differences in disease outcome. 
Future studies continuing the work on MINT3 and MINT17 as biomarkers in rectal
cancer would be to confirm the results of the predictive value for distant and local recur-
rence in an independent group of rectal cancer patients treated with and without preope-
rative radiotherapy. If confirmed, an interesting trial design can be proposed as follows.
MINT3 and MINT17 methylation index is measured in the preoperative tumor biopsy tis-
sue. The 20-25% of the specific risk cluster undergo TME surgery without preoperative
radiotherapy and do receive postoperative chemotherapy. The other 75-80% of the patients
receive 5x5Gy preoperative radiation and if node-positive or T3N0, postoperative chemo-
therapy can be considered. The latter consideration may be supported by the outcome of





Biomarkers: voor inclusie en exclusie
Dit proefschrift heeft als onderwerp maagkanker en dikke darmkanker. Dikke darmkanker
kan onderverdeeld worden in het colon carcinoom (vanaf de klep van Bauhin tot en met
de S-bocht) en het rectum carcinoom (endeldarmkanker). Deze maligniteiten ontaarden uit
de cellen van het bekledende slijmvlies van darm en maag en zijn de meest voorkomende
vormen van kanker van het spijsverteringsstelsel. Zij zorgen voor een aanzienlijk deel van
de kankersterfte, niet alleen in Nederland maar ook wereldwijd. Hiernaast vormen ze een
grote belasting voor de Nederlandse gezondheidszorg en met het stijgen van de levensver-
wachting zal dit alleen maar toenemen. De enige kans op overleving in het overgrote deel
van de gevallen bestaat uit het radicaal verwijderen middels open of laparoscopische buik-
chirurgie. Deze operaties kennen een niet gering risico op complicaties en sterfte. Deze risi-
co’s nemen toe bij oudere patiënten. Om de overlevingskansen van maag- en darmkanker-
patiënten te vergroten worden behandelstrategieën steeds agressiever. Men moet dan
bijvoorbeeld denken aan het wegnemen van meer omliggende structuren en klierweefsel
tijdens de operatie of het toevoegen van radiotherapie en/of chemotherapie voor en/of na
de operatie. Door middel van gerandomiseerde studies is aangetoond dat voorbehandelen
met chemotherapie de overleving verbetert in aanvulling op een radicale chirurgische ver-
wijdering van maagkanker. Zo ook resulteert het voorbestralen van rectum tumoren in
combinatie met het ruimer wegnemen van omgevend vet en bindweefsel tijdens de opera-
tie in een aanzienlijke afname van een recidief tumor locaal in het geopereerde gebied. De
toegevoegde morbiditeit van deze aanvullende behandelingen treffen veel patiënten en
komt wederom vaker voor bij de oudere patiënt. Voorbehandelen met chemo- en/of radi-
otherapie vergroot eveneens het risico op complicaties van de operatie en vermindert de
kans op een volledig herstel. De data van klinische studies die chirurgie in combinatie met
een aanvullende behandeling vergelijken met chirurgie alleen laten ook zien dat een aan-
zienlijk deel van de patiënten gebaat zouden zijn bij alleen een operatie. Dit wijst erop dat
deze nabehandeling, oftewel adjuvante therapie vaak een overbehandeling is. Een betere
inschatting van de agressiviteit van maag- en darmtumoren in aanvulling op de huidige sta-
diërings-methoden is daarom een belangrijk onderwerp om patiënten te kunnen selecteren
die ook daadwerkelijk baat hebben bij een agressievere behandeling. De huidige belangrijk-
ste voorspeller van overleving van maag- en dikke darmtumoren is het al dan niet vinden
van uitzaaiingen in de regionale lymfeklieren. De voordelen van verbeterde risico-inschat-
ting in aanvulling op deze parameter zijn tweeledig. Aan de ene kant zouden hoog-risico,
klier-negatieve patiënten geïncludeerd kunnen worden in trials om het nut van aanvullen-
de therapie te testen. Aan de andere kant zouden laag-risico, klier-negatieve en mogelijk
ook klier-positieve patiënten geëxcludeerd kunnen worden van morbiditeit- en mortaliteit
verhogende aanvullende therapie.
Het is bekend dat voorbehandelen (neoadjuvant) de uitkomst van ziekte van endel-
darmkanker en maagkanker na radicale chirurgie verbetert, is het dus ook van belang om
de risico-inschatting voorafgaand aan de operatie te kunnen doen. Beeldvormende technie-
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ken zoals CT-, MRI- en PET/CT-scans zijn van grote waarde bij het opstellen van een indi-
vidueel toegespitst behandelplan. Bijvoorbeeld voor metastaseringonderzoek of voor het
identificeren van “locally advanced, T3/4” rectum tumoren. Deze onderzoeken worden
gebruikt om zo goed mogelijk het TNM-stadium in te schatten vóór de operatie. De N-sta-
diëring die de belangrijkste voorspeller is, kan echter niet met 100% betrouwbaarheid wor-
den bepaald met de huidige beeldvorming en met name niet in het geval van maag- en
coloncarcinomen. Moleculaire kenmerken van de primaire tumor op DNA niveau zijn een
aantrekkelijk preoperatief diagnosticum omdat deze bepaald kunnen worden in tumorbi-
opten verkregen met scopisch onderzoek die horen bij het standaard diagnostisch proces.
DNA kenmerken zijn verder aantrekkelijk vanwege de chemische stabiliteit van het mole-
cuul waardoor slechts een minimale hoeveelheid weefsel nodig is.
Epigenetica
De voltooiing van het “human genome project” in 2003 dat de nucleotide-volgorde van
het menselijk genoom in kaart bracht was een mijlpaal in de wetenschap. Echter is de func-
tie van slechts 5-10% van het genoom bekend. De term “voltooiing” van dit project kan
daarom misleidend genoemd worden. De resterende 90-95% van het genoom is lange tijd
“junk DNA” genoemd, een term geïntroduceerd in 1972 door Susumu Ohno. De verbor-
gen complexiteit van het menselijk genoom werd nog eens benadrukt na de ontcijfering
van volledige genomen van andere levensvormen die gezien worden als minder complex.
Het genoom van een fruitvlieg (Drosophilia Melanogaster) heeft bijvoorbeeld een geschat
aantal van 27.463 coderende genen vergeleken met de 31.896 bij de mens (Homo Sapiens).
Dit relatief kleine verschil wijst er op dat in het onbegrepen deel “junk DNA” belangrijke
elementen verborgen moeten liggen die het verschil maken tussen een mens en een fruit-
vlieg. Het verschil van minder dan 9 percent laat dus zien dat het aantal genen van onder-
geschikt belang is. Activering, interactie en modulatie van expressie van genen is dan ook
cruciaal voor de vorming van gedifferentieerde cellen en de onderlinge communicatie tus-
sen gedifferentieerde celstructuren binnen en tussen orgaansystemen. Het zich ontwikke-
lende gebied van epigenetica heeft aangetoond een zeer belangrijke rol te hebben in gen
regulatie. De laatste definitie van epigenetica is dat dit overerfbare elementen zijn van cel
op cel, en soms van generatie op generatie, die geen betrekking hebben op veranderingen
in de onderliggende DNA volgorde. Een belangrijk DNA regulerend element is methyl-
groep plaatsing op cytosine-guanine dinucleotiden oftewel DNA methylering. Enkele
belangrijke fenomenen kunnen inmiddels verklaard worden door DNA methylering.
Bijvoorbeeld: X-chromosoom inactivatie, cel differentiatie, DNA stabilisatie en specifieke
gen inactivatie bij kanker. Veranderingen in DNA methylering worden meer/vaker gezien
in kankercellen in vergelijking met gezonde cellen. DNA methylering is zelfs meer afwij-
kend in kankercellen dan het DNA zelf. De klinische betekenis van veranderingen in DNA
methylering in kanker vormen een onderwerp van veel studies. 
Het doel van de studies beschreven in dit proefschrift is om de rol van DNA methyle-
ring te bestuderen in maag-, colon- en rectumcarcinomen. En meer specifiek om te explo-
reren of deze epigenetische elementen in de primaire tumor gebruikt kunnen worden als
markers om de multidisciplinaire therapie verder te kunnen sturen. Het gaat hierbij niet
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alleen om patiënten te kunnen includeren die baat zullen hebben van meer agressieve
behandeling, maar het gaat er ook om patiënten te kunnen excluderen van onnodig belas-
tende therapie.
De Nederlandse Trials
In Nederland bestaat een uitstekende infrastructuur om multicenter studies uit te kunnen
voeren bij kankerpatiënten. Een samenwerkingsverband van chirurgisch oncologen startte
in 1989 een gerandomiseerde trial naar chirurgie voor maagcarcinoom die twee niveaus
van lymfeklierdissectie met elkaar vergeleek. Deze succesvolle trial leidde tot meer studies
en multidisciplinaire uitbreiding van de samenwerking. Het resulteerde in de oprichting
van de “Dutch Colorectal Cancer Group” (DCCG). Vandaag de dag is de DCCG een lan-
delijk samenwerkingsverband tussen medische disciplines (o.a. chirurgen, radiotherapeu-
ten, internist-oncologen, pathologen, radiologen en gastro-enterologen) en is betrokken bij
de diagnose en behandeling van colorectale en maagtumoren. Dit proefschrift bevat enke-
le studies waarbij gebruik werd gemaakt van weefsel van primaire tumoren van patiënten
die deelnamen in twee grote trials gecoördineerd door de DCCG. Ten eerste, de zogenaam-
de D1D2 gerandomiseerde chirurgische trial voor patiënten met maagcarcinoom (zie hier-
boven) met meer dan 700 geïncludeerde patiënten. Deze trial is mogelijk de grootste pros-
pectief verzamelde Westerse populatie van patiënten met maagcarcinoom met follow-up
data gemiddeld tot 14 jaar postoperatief. Ten tweede, de zogenaamde TME trial voor
patiënten met rectum carcinoom die totale mesorectale excisie (TME) chirurgie met en
zonder vooraf radiotherapie vergeleek. Deze trial is één van de grootste studies specifiek
naar rectumcarcinoom met protocollen om de chirurgische procedure en het pathologisch
diagnostisch proces te controleren. De kwaliteit van studies die gebruik maken van humaan
materiaal om klinische waarde van biomarkers te evalueren staat of valt met de oorsprong
van de patiëntgroep. Prospectieve verzameling, uniforme behandeling, uniforme diagnos-
tiek en uniforme follow-up zijn van groot belang voor andere onderzoekers om de resulta-
ten te kunnen interpreteren. De kwaliteit en omvang van de D1D2 en TME trial heeft dus
in belangrijke mate bijgedragen aan de resultaten beschreven in dit proefschrift.
Sectie I: Technische verbeteringen.
Het proefschrift is verdeeld in twee secties. De eerste sectie behelst vier studies die gaan
over technische verbeteringen bij de analyse van DNA methylering in weefselcoupes
afkomstig van gearchiveerd, met paraffine gefixeerd tumor materiaal. Dit paraffine materi-
aal was de beschikbare bron van de DCCG trial patiënten. Gewoonlijk wordt voor een ini-
tiële bepaling van de waarde van biomarkers paraffine materiaal gebruikt. Simpelweg
omdat vele coupes van enkele micrometers dik gesneden kunnen worden en het weefsel
makkelijk toegankelijk ligt opgeslagen in de archieven van de patholoog. Verder geven
paraffine coupes het voordeel van direct visualisatie van de histopathologie. Een probleem
is dat de meest toegepaste techniek voor analyse van DNA methylering gebruikt maakt van
langdurige incubaties met DNA degraderende chemicaliën (sodium bisulfiet modificatie
oftewel SBM). Daarnaast resulteren DNA isolatie- en zuiveringsmethoden in verlies van
veel DNA. Veel studies beschrijven dan ook het gebruik van grote hoeveelheden startma-
teriaal bestaande uit multipele gehele coupes of zelfs blokjes tumorweefsel. Dit compromit-
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teert het detail van het startmateriaal en verhoogd de kans op contaminatie met gezond
weefsel. In sectie I worden twee technieken beschreven die het mogelijk maken om DNA
methylering te bepalen in een minimale hoeveelheid startmateriaal zoals 1-2 vierkante mil-
limeter van een 7 micrometer dikke weefselcoupe of van enkele duizenden cellen geïso-
leerd door middel van laser capture microscopie. Hiermee kan dus in potentie DNA methy-
lering vergeleken worden tussen vroege dysplastische cellen in een crypte van het colon
slijmvlies met de gezonde gedifferentieerde cellen van de aanliggende villus.
Hoofdstuk één beschrijft een nuttig protocol voor onderzoekers die methylering-spe-
cifieke polymerase chain reaction (PCR) technieken gebruiken of afgeleiden daarvan. Het
protocol behelst de synthese van compleet ongemethyleerd humaan genomisch materiaal
dat niet voorkomt in de natuur. Dit DNA kan gebruikt worden als een negatieve controle in
PCR reacties om de methyleringsstatus te testen van iedere gewenste regio van het genoom.
Hoofdstuk twee test de behandeling van coupes gedeparaffiniseerd weefsel op glaas-
jes direct met sodium bisulfiet, zogenaamd on-slide sodium bisulfiet modificatie (SBM).
Resultaten laten zien dat deze behandeling van het ruwe DNA, nog opgeslagen in de cel-
kern (in situ), dezelfde resultaten heeft als wanneer van geïsoleerd DNA opgelost in water
gebruik wordt gemaakt. Omdat de isolatie- en zuiveringstappen overgeslagen kunnen wor-
den resulteert onslide-SBM in een veel hogere DNA opbrengst voor verdere PCR analyse.
Als toepassing van deze bevinding wordt aangetoond dat DNA methylering van kleine stuk-
jes weefsel van 1-2 vierkante millimeters van één enkele coupe paraffine materiaal met
elkaar vergeleken kan worden. Als voorbeeld was in een colon tumor de promoter-regio van
een belangrijk tumor-gerelateerd gen gemethyleerd in carcinomateus weefsel en ongemethy-
leerd in het aanliggend weefsel met daarin benigne voorloper cellen. Dit soort analyses
waren voorheen moeilijk uitvoerbaar en onslide-SBM maakt dit aanzienlijk eenvoudiger.   
Hoofdstuk drie beschrijft een kwantitatieve PCR techniek genaamd AQAMA (abso-
lute quantitation of methylated alleles). Onze onderzoeksgroep gebruikte hiervoor klassie-
ke methylerings-specifieke PCR met capillaire array electroforetische analyse van de PCR
producten (CAE-MSP) die slechts semi-kwantitatief is. Als toepassing werd AQAMA gecom-
bineerd met in situ, on-slide SBM. DNA methylerings-gehaltes van specifieke genomische
loci kunnen nu vergeleken worden met histopathologisch verschillende weefselstukjes van
dezelfde paraffine coupe in plaats van met een dichotome uitkomst: gemethyleerd of onge-
methyleerd. De resultaten lieten significante verschillen zien in gehalte DNA methylering
van methylated-in-tumor (MINT) loci tussen colon adenomateus en carcinomateus weef-
sel. De bevindingen illustreren het belang van bepaling van het methylerings-gehalte in
plaats van methylerings-status.
Hoofdstuk vier gaat over de zogenaamde “on-cap SBM“ van DNA die de eerdere in
situ behandeling van een weefselcoupe op een glaasje (on-slide) integreert met laser-captu-
re microscopie. Met deze techniek kunnen individuele cellen of groepen cellen van een
paraffine coupes geïsoleerd worden. On-cap SBM verbetert dus het detail van DNA methy-
lering analyse van kleine stukjes weefsel van een paraffine coupe naar individuele cellen.
Als toepassing werd het methyleringsgehalte van DNA repetitieve elementen (long-inter-
spersed-nucleotide-elements oftewel LINE-1) gemeten met AQAMA en vergeleken met
colon kankercellen van de luminale zijde van een tumor en de kankercellen geïsoleerd van
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het invasieve front. Het belangrijkste voordeel van on-cap SBM is dat het contaminatie met
fibroblasten, lymfocyten en ander stromale componenten tot een minimum beperkt.
Bij elkaar beschrijven de studies van Sectie I niet alleen nuttige technieken maar ook hun
toepassing en dat ze nieuwe vormen van DNA methylering-analyses mogelijk maken. Daarbij
komt dat AQAMA gecombineerd met on-slide SBM een geschikte techniek is voor de analy-
se van het primaire tumor materiaal van grote patiëntengroepen van de DCCG trials.
Sectie II: Klinische toepassing
Na robuuste en “high-throughput” technieken te hebben ontwikkeld voor paraffine materi-
aal is er gestart met de analyse van tumor materiaal van patiënten van de D1D2 en TME trial.
De behandeling van maagkanker staat weer meer in de belangstelling omdat recent is
aangetoond dat chemotherapie voorafgaand aan chirurgie de overleving verbeterd. Deze
ontwikkeling schept een behoefte aan het ontwikkelen van voorspellende, preoperatief te
bepalen biomarkers, om risico-inschatting van patiënten met maagcarcinoom te verbeteren.
Zo kan wellicht de chemotherapie toegespitst worden op patiënten met een meer agressie-
ve ziekte. Het maagcarcinoom is bekend om zijn infiltrerende, infectieuze component
waarbij door de tumor tot expressie gebrachte enzymen, die de ontstekingsreactie van het
lichaam kunnen reguleren, mogelijk een belangrijke rol spelen. Eerdere studies laten zien
dat de expressie van cyclooxygenase 2 (COX-2), welke een sleutelrol speelt in het inflam-
matoire proces, wordt gereguleerd door DNA methylering van zijn promoter regio in maag-
carcinoom. Andere studies hebben laten zien dat patiënten met maagtumoren met een
hoge expressie van COX-2 een slechtere overleving hebben. 
Hoofdstuk vijf beschrijft de resultaten van een studie met als hypothese dat de pro-
moter regio DNA methylerings-status van COX-2 in primaire tumor cellen een voorspeller
is van de ziekteoverleving van maagkanker. In twee onafhankelijke trial patiënt groepen
met een mediane follow up van twaalf jaar na chirurgie kon worden aangetoond dat COX-
2 methylering een voorspeller van ziekte recidief en overleving is onafhankelijk van alle
bekende prognostische factoren zoals lymfeklier metastasen. COX-2 activiteit in maagkan-
ker kan worden bepaald met kleuring van tumorweefsel coupes met een specifiek antili-
chaam. Deze immunohistochemische techniek heeft als nadeel bij maagkanker (bekend om
zijn moeilijke histopathologie) dat er een inter-individuele bias ontstaat bij het scoren van
de mate van aankleuring onder de microscoop. De resultaten van de studie suggereren dus
dat bepaling van de eiwit expressie door middel van immunohistochemie van genen zoals
COX-2, die gereguleerd worden door DNA methylering, vervangen kan worden door een
geautomatiseerde, operatoronafhankelijke PCR test. Verder bestaan er geneesmiddelen die
specifiek COX-2 remmen en deze worden gebruikt als analgetica bij reumatische aandoe-
ningen. De toepassing van COX-2 remmers ter voorkoming van darmpoliepen is onder-
zocht en laat een gunstig effect zien. Onze resultaten toonden aan dat er een correlatie
bestaat tussen de COX-2 methylerings test en de COX-2 eiwit expressie. Mogelijke kan
deze test dus gebruikt worden om patiënten te selecteren die baat hebben bij een therapie
met COX-2 remmers. Dit is van belang omdat cardiovasculaire bijwerkingen in een klein
percentage van de behandelde patiënten is aangetoond.
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In de hoofdstukken zes en zeven worden de bevindingen beschreven van twee studies
naar de klinische toepassing van kwantitatieve DNA methyleringsanalyse bij patiënten met
rectumcarcinoom. Rectum tumoren vormen klinisch een aparte groep van dikke darm
tumoren. Het belangrijkste verschil is de nauwe anatomische relatie door de fixatie van het
rectum in het kleine bekken vergeleken met het colon proximaal van de omslagplooi. Dit
maakt een radicale chirurgische resectie tot een grotere uitdaging. Rectumtumoren hebben
dan ook een groter risico op locaal recidief, zelfs in vroege stadia. Dit risico neemt toe naar-
mate de tumoren dichter bij de anus gelokaliseerd zijn. De fixatie van het rectum in het
kleine bekken maakt het toepassen van externe radiotherapie mogelijk hetgeen niet moge-
lijk is in het mobiele colon. De hierboven genoemde DCCG trial voor rectumcarcinoom
evalueerde een chirurgische techniek genaamd Totale Mesorectale Excisie (TME) wel of
niet voorafgegaan door een korte kuur radiotherapie. TME chirurgie is een rectumextirpa-
tie met en-bloc resectie van het omliggende rectale vet welke gebruikt maakt van de meso-
rectale posterieure fascie als een anatomische scheidingsvlak met sparen van de sacrale
zenuwen. Voor de introductie van TME chirurgie door Bill Heald in de vroege jaren tach-
tig van de vorige eeuw was het stomp vrijprepareren posterieur van het rectum (vaak met
de hand) gebruikelijk. Deze techniek resulteerde in 20-25% locaal recidief. De TME trial
liet echter een forse afname zien van deze belangrijke morbiditeit veroorzakende parame-
ter van 10% locaal recidief na TME chirurgie alleen. En nog een significante verdere reduc-
tie naar 4% met de toevoeging van preoperatieve radiotherapie. Ondanks deze belangrijke
verbetering verschilde de algehele overleving 6 jaar na de operatie niet tussen de twee groe-
pen en lieten deze analyses zien dat overleving wordt bepaald door het optreden van uit-
zaaiingen op afstand.
AQAMA tests werden ontwikkeld om het methyleringsgehalte te bepalen van zeven
verschillende MINT loci in DNA gelokaliseerd op zeven verschillende chromosomen. Deze
MINT loci werden ontdekt als gehypermethyleerd in een genoom-wijde screen van een
bekende coloncarcinoom cellijn vergeleken met gezond DNA. MINT loci zijn zogenaamde
CpG eilanden van niet coderende gebieden DNA en hadden tot zover bekend geen func-
tie. MINT loci zijn echter door diverse onderzoeksgroepen bestudeerd in maag- en darm-
kanker en bleken wel van klinische waarde te zijn. In onze studie werd allereerst het DNA
methyleringsgehalte van de MINT loci onderzocht in tumorweefsel en aangrenzend ade-
nomateus en normaal weefsel. Dit liet zien dat toename van MINT methylering vroeg
optreedt in rectale carcinogenese, met de grootste toename tijdens adenomateuze veran-
dering van normaal weefsel in vergelijking met carcinomateuze verandering van adeno-
men. De distributie van de gemeten MINT methyleringsgehaltes in tumoren en adenomen
was niet normaal en dit wees erop dat de data gebruikt konden worden voor clusteranaly-
se. Vervolgens werd in primair tumorweefsel van meer dan 300 patiënten van de chirur-
gie arm van de TME trial methyleringsgehalte bepaald van de zeven MINT loci met
AQAMA. Deze data werden geanalyseerd met een ongesuperviseerde clustermethode om
patronen te identificeren zonder bias. De resultaten lieten zien dat MINT loci 3 en 17 een
sterke negatieve correlatie met elkaar hadden en op basis van deze twee biomarkers kon-




Hoofdstuk zes rapporteert de bevinding dat deze onderverdeling een groep van vroeg sta-
dium rectum carcinoom patiënten identificeert van ongeveer 25% van het totaal. Deze
patiënten hadden significant meer risico om levermetastasen te ontwikkelen en hadden een
kortere overlevingstijd na curatieve chirurgie. 
In hoofdstuk zeven wordt beschreven dat dezelfde groep patiënten met een hogere
kans op uitzaaiingen op afstand een significant lagere kans hadden op locaal recidief. De
DCCG heeft in publicaties met TME trial data laten zien dat patiënten die vooraf bestraald
werden meer kans hadden op fecale incontinentie, seksuele dysfunctie, vertraagde wond-
genezing en verminderd kwaliteit van leven na chirurgie. Het percentage locaal recidief van
de overige 75% van de patiënten was significant hoger vergeleken met bestraalde patiën-
ten uit de TME trial terwijl van de andere 25% dit iets lager was (niet significant). Dit sug-
gereert dat een kwart van de patiënten met rectumcarcinoom, geïdentificeerd door middel
van AQAMA van MINT 3 en 17, veilig geëxcludeerd kunnen worden van morbiditeit ver-
hogende preoperatieve bestraling. 
Bij elkaar beschrijven hoofdstuk zes en zeven de identificatie van een groep bestaande
uit ongeveer een kwart van de patiënten met rectumcarcinoom welke een significant hoger
risico heeft op het ontwikkelen van afstandsrecidief en een significant lager risico op het ont-
wikkelen van locaal recidief. In veel biomarker studies worden groepen gevormd door middel
van een afkappunt bij een mediane waarde van een normaal verdeling. Omdat de meeste waar-
des liggen rondom de mediaan leiden dit soort afkapmethoden tot een slechte scheiding van
de groepen. Een belangrijk gegeven is dat de groep in onze studie werd herkend door een onge-
superviseerde clustermethode zonder bias en dat de clusters geen overlap met elkaar hebben.
Onze studie is de eerste die laat zien dat kwantitatieve epigenetische biomarkers specifiek in
rectumcarcinomen de multidisciplinaire behandeling kunnen sturen in de richting van contro-
le op afstands- of locaal recidief, zelfs bij tumoren in een vroeg stadium. 
Het laatste hoofdstuk acht richt zich op voorloper laesies zoals poliepen en adenomen
van dikke darmkanker. Er wordt gebruik gemaakt van de technieken beschreven in hoofd-
stuk twee en drie (onslide SBM en AQAMA) en laat de meerwaarde zien van meer gede-
tailleerde analyses. Ongeveer de helft van de rechtzijdige coloncarcinomen hebben een aan-
getast DNA “mismatch repair (MMR)” systeem dat wordt veroorzaakt door epigenetische
afschakeling van het human mut-l-homologue (hMLH1) MMR gen door DNA methylering
van de promoter regio. Het falende MMR systeem resulteert in verkorting van zogenaamde
microsatelliet regio’s hetgeen eenvoudig bepaald kan worden door middel van PCR tech-
niek. MMR aangedane tumoren worden ook wel microsatelliet instabiel genoemd. Het is
aangetoond dat de epigenetische afschakeling van hMLH1 een onderdeel is van een genoom
wijd toegenomen methylering van promoter regio’s en ook van MINT loci. We onderzoch-
ten in hoofdstuk acht de hypothese dat methyleringsgehalte van MINT loci verhoogd is in
voorloper laesies van microsatelliet instabiele tumoren. De resultaten laten zien dat AQAMA
van specifieke MINT loci adenomen kunnen identificeren die zich zullen ontwikkelen tot
een microsatelliet instabiel colon carcinoom. Deze bevinding is biologisch relevant omdat
het laat zien dat epigenetische veranderingen ontstaan in de vroegste fase van colorectale
tumorvorming waarin histopathologisch slechts polypeus weefsel met laag tot gemiddelde
dysplasie is te zien. Deze veranderingen leiden veel later tot een apart fenotype darmkanker.
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Een mogelijke klinische toepassing is dat sommige MINT markers gebruikt kunnen worden
als onderdeel van een panel om fecaal DNA te screenen om patiënten te selecteren voor
colonoscopie. Verder is bekend dat microsatelliet instabiele tumoren anders reageren op che-
motherapie. Het veel gebruikte 5-fluorouracil is bijvoorbeeld minder effectief in deze tumo-
ren, echter reageren ze beter op bijvoorbeeld irinotecan. Preventieve specifieke behandels-
trategieën zijn dan ook denkbaar bij patiënten bij wie met colonoscopie veel poliepen met hoge
MINT locus DNA methylering worden gevonden. Verder is bekend dat bij patiënten met
microsatelliet instabiele tumoren zogenaamde frameshift peptiden detecteerbaar zijn. Deze
peptiden kunnen middels antilichamen een immuunreactie van het lichaam tegen de tumor-
cellen opwekken. Poliepvormende patiënten met hoge DNA MINT locus methylering in hun
adenomen kunnen dan ook mogelijk baat hebben van vaccinatie studies.
De toekomst
Dit proefschrift beschrijft verbeteringen van moleculaire technieken voor bestudering van
DNA methylering en beschrijft toepassingen van deze technieken om biomarkers te iden-
tificeren die potentieel de behandeling verbeteren van patiënten met maag-, colon- en rec-
tumcarcinoom. Bij de studie naar COX-2 methyleringsstatus als prognostische marker bij
maagcarcinoom werd ook de volgende stap gezet, namelijk validatie in een tweede onaf-
hankelijke groep patiënten eveneens afkomstig van een gerandomiseerde klinische studie.
Het is nu mogelijk een klinische trial te ontwerpen waarbij als volgt kan worden gerando-
miseerd: patiënten waarvan het preoperatief tumor biopt een gemethyleerd COX-2 gen laat
zien worden direct geopereerd zonder perioperatieve therapie terwijl de patiënten met een
ongemethyleerd COX-2 gen neoadjuvant behandeld zullen worden. Aan de hand van de
resultaten van de CRITICS trial kan dan worden besloten om COX-2 ongemethyleerde
en/of klier positieve tumoren dan adjuvant te behandelen met chemo-radiotherapie. De
primaire uitkomstmaat van de studie zou moeten zijn dat klier-negatieve, COX-2 gemethy-
leerde tumoren behandeld met chirurgie alleen een niet significant verschillende overle-
ving hebben vergeleken met de wel aanvullend behandelde patiënten. 
Toekomstige studies die verder gaan met MINT3 en MINT17 als biomarkers in rec-
tumcarcinoom dienen zich allereerst te richten op de validatie in een onafhankelijke groep
patiënten behandeld met en zonder preoperatieve radiotherapie. Indien de voorspellende
waarde voor afstands- en locaal recidief kan worden bevestigd dan kan de volgende trial
worden ontworpen; Allereerst wordt de MINT3 and MINT17 methylerings index bepaald
in weefsel van het preoperatieve tumorbiopt. Indien er sprake is van een non-locally advan-
ced tumor zoals bepaald per MRI onderzoek ondergaat ongeveerd 25 procent van de
patiënten van het specifiek risicocluster TME chirurgie zonder voorbestraling maar wel met
postoperatieve systemische chemotherapie. Alle locally advanced tumoren ondergaan de
meer uitgebreide neoadjuvante behandeling en afhankelijk van de MINT3 en MINT17
methyleringsstatus al dan niet adjuvante therapie. De andere 75% van de non-locally advan-
ced patiënten ondergaan 5x5Gy preoperatieve radiotherapie gevolgd door TME chirurgie.
De uitkomsten van de SCRIPT trial kunnen verder bepalen of patiënten met lymfeklierme-
tastasen of zonder lymfekliermetastasen waarvan de tumor door de hele darmwand groeit
nog verder baat zullen hebben van nabehandeling met het goed verdraagbare oraal in te
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Color Figures chapter 1
Figure 3. (A) SBM direct sequencing result at p16 promoter region on UUC in reverse direction. It is shown
that all the cytosines of CpG dinucleotides in UUC were converted to uracils (shown as A in rever-
se sequence with *), representing that there was no methylation on CpG dinucleotides. (B)
Methylated- and unmethylated-specific MSP for p16, RASSF1A, hMLH1, TWIST, ID4, ESR1, 14-3-
3d, and MGMT on SBM UUC. Unmethylatedspecific peaks were observed in unmethylated-speci-
fic MSP in upper figures (U), but no peaks were observed in methylated-specific MSP in lower figu-
res (M). The vertical axis represents the fluorescent intensity indicating the amount of PCR
amplicon and the horizontal axis represents the PCR amplicon size.
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Color Figures chapter 2
Figure 1 Microscopic photographs
of three tissue sections
after on-slide SBM treat-
ment and hematoxylin
staining. Magnification,
100 (A1, B1, and C1) and
200 (A2, B2, and C2).
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Color Figures chapter 3
Figure 1. Schematic representation of the AQAMA assay. A universal primer set amplifies a target sequen-
ce. A. A methylation-specific probe with FAM-labeled reporter, BHQ, and MGB molecule recogni-
zes sample DNA showing hypermethylation. B. An unmethylated-specific probe with VIC-labeled
reporter, BHQ, and MGB molecule recognizes unmethylated sample DNA.
Figure 4 Schematic representation of histology-oriented tissue isolation followed by AQAMA. Left, AQAMA
PCR plot. The adenomatous tissue component (bottom marked area) shows only unmethylated
fluorescent signal (triplicate results), whereas the cancerous component (top marked area) shows
both unmethylated and methylated fluorescent signal. Both signals are visualized here; however,
in the raw data analysis, the CT is analyzed separately. 
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Figure 2. Representative cyclooxygenase-2 (COX-2) immunohistochemistry (IHC) results of primary gastric
tumors with respective capillary array electrophoresis methylation–specific polymerase chain reac-
tion (CAE-MSP) outcomes. x-axis of the CAE-MSP represents the fluorescent intensity (M, methy-
lated product; U, nonmethylated product) indicating polymerase chain reaction amplicon. y-axis
represents the product base pairs. (A, C) Nonmethylated primary gastric tumor. Strong cytoplas-
mic COX-2 protein staining in tumor cells. (B, D) Methylated primary gastric tumors show weak
diffuse IHC staining. 
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Figure 2. Methylated in tumor (MINT) locus methylation subclass identification. (A) multidimensional sca-
ling [MDS] plot displaying the level of dissimilarity between all patients (MDS plot axes represent
arbitrary units, and are therefore dimensionless). (B) Three-dimensional plot representing expec-
tation maximization algorithm with a mixture of Gaussians analysis of the MDS plot coordinates
showing Gaussian distribution (bell-shaped) of the two identified clusters. (C) MDS plot showing
final cluster allocations for the patient population. (D) Box plots comparing the differences in
methylation levels (MI) between cluster 1 and 2 for all MINT loci. 
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Color Figures chapter 6
Figure 3. (A) Kaplan-Meier plots grouping analy-
zed node-negative total mesorectal exci-
sion trial patients into clusters 1 and 2
and comparing postoperative distant
recurrence free survival probability. (B)
Cancer-specific and (C) overall survival
are plotted. 
Figure 4. Random forest analyses using only
MINT3 and 17 quantitative methylation
data as input. (A) Multidimensional sca-
ling plot showing the four clusters. (B)
Box plots comparing the differences in
methylation levels (MI) between the four
clusters. (C) Kaplan-Meier plot illustra-
tes the distant recurrence probability
between high-risk cluster 3 and the com-
bined clusters 1, 2, and 4. 
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Figure 4. Two dimensional cut-off validation experiment results. Representation of MINT3 (X-axis) and
MINT17 (Y-axis) methylation indices for patients of the TME trial, TEM study and 19 normal rec-
tal mucosa samples. The horizontal and vertical reference lines represent the previously suggested
cut-offs to separate the groups. For the TEM series, the following specimens were assessed: (A)
adenoma with no carcinoma cells; (A, C+) adenoma with carcinoma cells; (C+A) carcinoma mixed
with adenoma cells; and (C) carcinoma.
229
Color Figures chapter 8
Figure 1: Representative examples of molecular analyses in normal (A), adenoma (B) and cancer (C) tissue.
AQAMA (MINT31) real-time PCR results showing results in triplicate of exponential amplification
of methylated (M) and unmethylated (U) dye probe signal. Y-axis represents signal intensity, X-axis
represents PCR cycle number.
Figure 2: Representative examples of molecular analyses in normal (A), adenoma (B) and cancer (C) tissue.
CAE results of amplified dye-labeled PCR products of 5 MSI biomarkers and hMLH1 methylation-
specific (M, in blue) and unmethylated-specific sequence (U, in green) primer sets. Red peaks
represent the DNA ladder signal. The horizontal axis represents size of the PCR product in base-
pairs (bp). The vertical axis represents arbitrary units of signal intensity of detected amplicons. 
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Figure 5: Representative IHC staining of hMLH1 and PMS2 proteins. In A and B examples of hMLH1 and
PMS2, respectively, expressing CRC with their corresponding CAE-MSP results for hMLH1 sho-
wing unmethylated signal only. In C, an example of a CRC showing methylation of the hMLH1
promoter region with corresponding absence of nuclear staining of hMLH1 which is confirmed by
underexpression of PMS2. 
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Color Figures General discussion and Future Perspectives
Figure 1: Schematic representation of the on-slide SBM procedure 
